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THE IMPACT OF DRUG AND ALCOHOL USE ON 
THE COURSE OF ILLNESS IN PSYCHIATRIC PATIENTS: 
A PROSPECTIVE FOLLOW-UP STUDY 
Drug and alcohol abuse has been cited as one of the most 
pernicious and widespread problems in contemporary American 
society. The majority of substance users are young adults. 
A particularly vulnerable subset of these substance using 
young adults are the mentally ill. Several studies have 
reported that the substance abuse rate among young adult 
psychiatric patients approaches or exceeds 50%. 
Despite the fact that substance use is quite common among 
young psychiatric patients, relatively little is known about 
the impact of such use on the course and outcome of mental 
illnesses. Nevertheless, major theorists have proposed that 
substance use is likely to interfere with the user's 
psychological, social and work adaptation, an adaptation 
that may already be somewhat precarious in mentally ill 
patients. 
The present study examined the clinical course and long-
term outcome of 267 young adult, early phase psychiatric 
patients, including 55 schizophrenics, 81 other psychotics, 
78 nonpsychotic depressives, and 36 other nonpsychotics. 
All of the patients were prospectively assessed at index 
hospitalization and then reassessed in two follow-up 
interviews two years and four to five years after hospital 
discharge. Adjustment in the areas of work, social 
functioning, rehospitalization and symptoms were assessed at 
each follow-up, as was level of substance use. 
The results indicated that 67.4% of the patients in this 
young adult psychiatric sample were substance users. 
Furthermore, substance use at the index hospitalization was 
associated with continued substance use at both the first 
(r=.36, R <.001) and second (r=.30, R< .001) follow-ups. 
For schizophrenics, substance use was significantly related 
to increased symptomatology (E(6,94)=2.29, R=.04), and 
predicted poorer overall outcome {E(3,51)=2.74, R=.05). For 
the depressives, substance use was related to better 
concurrent functioning, E(6,144)=2.74, R=.015, and predicted 
better overall functioning at the second follow-up, 
E(2,76)=4.10, R=.02. These findings indicate that substance 
use is not unequivocally associated with poorer outcome for 
all kinds of psychiatric patients. Rather, the effects of 
substance use appear to be diagnosis-specific. 
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CHAPTER I 
INTRODUCTION 
Drug and alcohol abuse has been cited as one of the 
most pernicious and widespread problems in contemporary 
American society. A recent investigation indicated that 
between 16 and 22% of the population is likely to abuse 
alcohol or drugs at some time in the course of their 
lifespan (Robins et al., 1984). This compulsive substance 
use diminishes the quality of life of vast numbers of 
people in this country. Health impairments, psychological 
turmoil, loss of social networks, economic hardships, and 
criminal involvement are among the more common and 
damaging consequences of sustained drug or alcohol use. 
Not simply a problem that affects individual users, 
substance abuse creates a negative spiral that touches 
entire families and communities. 
The majority of substance users are young adults. A 
particularly vulnerable subset of these substance using 
young adults are the mentally ill. Young adult 
psychiatric patients find themselves struggling with the 
same kinds of social problems and pressures encountered by 
other young adults. Although they have typical reasons to 
use drugs and alcohol, they may also have atypical 
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reactions to such use (Bergman & Harris, 1985). Substance 
abuse is as least as frequent, and probably more frequent, 
among young psychiatric patients than it is in the general 
population of young adults. Indeed, several studies have 
reported that the substance abuse rate among young adult 
psychiatric patients approaches or exceeds 50% (Bergman & 
Harris, 1985; McLellan, MacGahan, & Oruley, 1978; Pepper 
& Ryglewicz, 1984; Safer, 1987; Test, Knoedler, Allness & 
Burke, 1985). 
Although no conclusive evidence exists regarding the 
impact of drug and alcohol use and abuse in young adult 
mentally ill patients, there are many reasons to suspect 
that psychoactive substances would have particularly 
harmful effects on these individuals. First, substance 
use is likely to interfere with the user's adaptation to 
family and community life, an adaptation which may already 
be somewhat precarious in psychiatrically ill patients. 
Thus, patients who are vulnerable to difficulties in 
psychological and social functioning may develop even 
greater difficulties if they begin to use drugs or 
alcohol. 
Second, the use and abuse of illicit drugs and 
alcohol greatly complicates diagnosis. For instance, drug 
induced psychosis can be very difficult to differentiate 
from a schizophrenic or affective psychosis. Thus, these 
individuals are at risk for being misdiagnosed and given 
ineffective or iatrogenic treatments. 
Third, substance use often 
psychological and medical treatments, 
treatment planning decisions. There 
3 
interferes with 
and complicates 
is a dearth of 
information on treatment considerations involving the dual 
problems of mental illness and substance use and abuse 
(Alterman, 1985; Brown & Backer, 1988; Brown, Ridgely, 
Pepper, Levine, & Ryglewicz, 1989; Karwarth, 1990). In 
the case of pharmacological treatment, various forms of 
illicit drugs and alcohol can interact with prescribed 
medications in harmful, and even lethal ways (Blumberg, 
Cohen, Heaton, & Klein, 1971). Illicit substance use is 
probably also associated with reduced treatment 
compliance. 
Fourth, there is evidence that substance use 
contributes to relapse and the need for rehospitalization 
in psychiatric patients (Alterman, Erdlen, LaPorte, & 
Erdlen, 1982; Bergman & Harris, 1885; Cohen & Klein, 1974; 
Hall, Popkin, Devaul, & Stickney, 1975; Tsuang, Simpson, 
& Kronfol, 1982). In commenting on the seriousness of this 
risk, particularly for psychotic patients, Bergman and 
Harris (1985) have asserted that "drug use potentiates 
already serious impairments for these patients, and 
subsequent rehospitalization or reinstitutionalization 
further decreases their capacity to live productive lives. 
There is a high price to pay for each psychotic episode; 
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rarely does the chronic patient return to a pre-morbid 
level of functioning" {p.53). 
Given the widespread use of drugs and alcohol among 
young adult patients, and the likely negative consequences 
of such use, several writers have argued that there is a 
tremendous need for research to elucidate the effects of 
substance use on the lives of mentally ill patients (e.g., 
Alterman, 1985; Brown, et al., 1989; Kesselman, Solomon, 
Beaudett, & Thornton, 1982; Schneier & Siris, 1987). 
The present study attempts to contribute to 
clinicians' and researchers' knowledge about the impact of 
substance use on psychiatric patients by examining the 
clinical course and long-term outcome of patients who are 
users of psychoactive substances. Patients with similar 
diagnoses who do not use alcohol or drugs serve as the 
comparison group. The sample consists of young, 
nonchronic patients who were diagnosed according to 
Research Diagnostic Criteria {RDC; Spitzer, Endicott, & 
Robins, 1973) while in the hospital, and then studied 
longitudinally in two successive follow-ups over a period 
of approximately five years. 
The general aim of the study is to examine the 
relation between psychiatric illness and substance abuse 
in young psychiatric patients. The major hypothesis is 
that drug and/ or alcohol use is associated with poorer 
prognosis in terms of a number of indices of outcome 
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including work or school functioning, social functioning, 
psychotic symptoms, affective symptoms, rehospitalization, 
suicide, and overall outcome. 
This research addresses several issues which have 
been largely overlooked in the previous research, and 
which have important ramifications for understanding the 
relation between substance use and psychiatric illness. 
The first limitation is that minimal information exists 
regarding the clinical course and long-term outcome of 
psychiatric patients who use drugs and alcohol. In a 
March, 1989 article (Brown, et al.) in the American 
Psychologist entitled, "The Dual Crisis: Mental Illness 
and Substance Abuse. Present and Future Directions," the 
authors advanced an agenda for future research that would 
include studies which would "help illuminate the etiology 
and course of substance abuse in chronically mentally ill 
young adults" (p. 566). In line with this agenda, the 
present study employs a longitudinal design in order to 
examine the clinical course and long-term outcome of young 
adult psychiatric patients. 
The second limitation of many previous studies is 
that they have not examined the impact of substance use 
within particular diagnostic groups. It has been well 
established that psychiatric diagnosis has a major bearing 
on clinical course and outcome (e.g., Grossman, Harrow, 
Lechert-Fudala, & Meltzer, 1984). Furthermore, it has 
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been argued that inadequate diagnostic procedures have 
produced questionable findings in much of the addiction 
literature (Nathan & Lansky, 1978). Consequently, the 
impact of substance use is addressed with regard to a 
number of diagnostic groups. All diagnoses were based on 
ratings given by a trained diagnostic team using RDC 
criteria. Specifically, patients in the following 
diagnostic groups were examined: (1) depressives, (2) 
other nonpsychotics, (3) schizophrenics, (4) other 
psychotics. 
A third limitation (Nathan & Lansky, 1978) of the 
existing research on the addictions is that the criteria 
employed to assess substance use are often vague and 
imprecise. Therefore, the present study utilizes specific 
criteria to assess the degree of drug and alcohol use. 
These criteria were based on a modified version of the 
measure of multi-drug use developed by Cohen & Klein 
(1971). 
A fourth limitation of many of the previous studies 
in this area is that it they have not employed multiple 
measures of outcome. The present study utilizes extensive 
interviews and batteries of questionnaires administered at 
approximately 2 1/2 years and 5 years post-hospitalization 
to assess numerous areas of functioning including social 
functioning, work performance, psychotic, neurotic, and 
affective symptoms, and incidence of rehospitalization. 
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A fifth limitation is that many studies have examined 
only certain kinds of drugs, or alcohol. It is likely, 
however, that any psychoactive substance can have a 
significant impact on an individual's functioning. 
consequently, omitting mention of any of these substances 
may obscure the results. For instance, in a study of 
drug-users and nondrug-users, some of the nondrug-users 
may be alcohol abusers. Combining individuals who abstain 
from all psychoactive substances and alcohol abusers in a 
"control" group would be likely to confound the results. 
Therefore, the present study employs information on the 
use of all drugs and alcohol. 
CHAPTER II 
REVIEW OF THE RELEVANT LITERATURE 
For the sake of clarity, the literature review is 
divided into four separate sections, despite the fact that 
there is a great deal of overlap between some of these 
sections. The first section involves studies of drug and 
alcohol use that have specifically focused on young adult 
psychiatric patients. Most of these studies considered 
patients between the ages of 16 and 35 to be young adults. 
The next section describes studies of drug and alcohol use 
among schizophrenic patients. The third section describes 
studies of substance use in patients with affective 
disorders. The fourth section describes studies of 
substance use among samples of general psychiatric 
patients. 
Substance Use in Young Adult Psychiatric Patients 
studies of substance use in young adult psychiatric 
patients are, perhaps, the most relevant to the present 
investigation. However, unlike the present research, most 
of these studies have examined substance use and its 
impact at one point in time, rather than examining the 
course of substance use. In one such study of 41 young 
8 
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course of substance use. In one such study of 41 young 
psychiatric patients known to a community mental health 
center (Safer, 1987), 44% acknowledged current 
recreational substance use, 49% had a history of substance 
use, and 27% had little or no substance use involvement. 
Presence of substance use was assessed by reviewing charts 
and consulting with treating clinicians. The major 
finding was that young adult patients with ongoing 
substance abuse had an annual rate of hospitalizations 
that was 2 1/2 times the rate of each of the other 
comparison groups. It was also found that drug abuse was 
highly associated with alcohol abuse and with law 
violations. Additionally, 70% of the substance users were 
using psychoactive substances around the time of at least 
one of their psychiatric admissions. Moreover, most of 
these patients denied their recent substance use during 
their psychiatric admission interviews. 
A second study investigated vulnerability to 
prolonged psychosis associated with hallucinogen use in a 
sample of 95 psychiatric patients under the age of 30 
(Bowers & swigar, 1987). These patients were consecutive 
admissions to a psychiatric inpatient unit over a three 
year period who received an initial diagnosis of acute 
psychosis. Patients who reported using hallucinogenic 
drugs (such as marijuana, LSD, amphetamines, and cocaine) 
within three years prior to admission comprised the drug 
group (n=60) . 
10 
Psychotic patients who had had no drug 
involvement for the past three years comprised the control 
group (n=35). Thus, 63% of these acutely psychotic young 
patients reported hallucinogenic drug use of some degree 
within three years preceding admission. Degree of drug use 
was assessed using Bowers' (1977) 5-point scale. 
The study found that there was a preponderance of 
males in the psychotic drug abusing group. This is 
similar to a 1980 finding reported by Erard, Liusada, and 
Peele. Another sex difference was that in female drug 
using patients with the lowest full scale IQ's, psychosis 
was associated with small amounts of hallucinogen use. 
They also found that the incidence of psychiatrically 
hospitalized first degree relatives was approximately 30% 
and equal for both drug and nondrug groups. The authors 
suggest that prolonged psychosis following hallucinogen 
use is a legitimate form of major psychosis, and that 
these patients are just as vulnerable to psychosis as 
nondrug using patients. They suggest further that these 
patients should therefore not be considered a separate 
diagnostic group, as they are in DSM-III (and DSM-IIIR). 
Another study by Shearn & Fitzgibbons (1982) examined 
the drug use patterns of 167 young adult psychiatric 
inpatients, and compared their results with those of a 
survey of 26,000 college students conducted by Mizner, 
Barter, and Werme (1970). Shearn and Fitzgibbons found a 
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much higher incidence of drug use in their psychiatric 
sample. Overall, approximately 7 4 percent of their 
subjects reported some degree of use of one or more drugs, 
as compared to 30 percent of college students. Shearn & 
Fitzgibbons also found that there was a tendency toward 
heavy, repetitive use among the psychiatric patients. For 
example, half of the patients who had used marijuana had 
used it more than 100 times. They also noted that there 
was a stronger inclination towards polydrug use in the 
psychiatric sample than had been reported in the Mizner, 
et al. college sample. 
In a fourth study of young psychiatric patients 
(Cohen & Klein, 1970), subjects were 224 consecutive 
admissions under the age of 25 to a private psychiatric 
hospital. Thirty-nine of these patients were found to be 
heavy users of drugs, 16 were moderate polydrug users, 15 
were moderate users of marijuana only. These drug using 
patients, who constituted 31% of the whole sample, were 
compared to a group of 35 nondrug using patients. Cohen 
and Klein (1970) found that there were more character 
disordered patients, and fewer schizophrenics among the 
heaviest drug users. Psychotic patients were more likely 
to be moderate users or nonusers. They also found that in 
all of the drug using groups, the female patients were 
younger than the males. They noted that marijuana was the 
most widely used drug, followed by amphetamines. 
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In a fifth study (Sheets, Prevost, & Reihman, 1982), 
subjects were 966 chronic patients who were affiliated 
with an outpatient community mental health center. 
slightly over one-third of these patients were between the 
ages of 18 and 34. This young group had markedly greater 
problems in the domains of psychiatric symptoms, daily 
living skills, behavior problems, social isolation and 
drug and alcohol abuse, as compared to older patients from 
the same sample. 
There have also been two studies that have explored 
the relation between substance use and psychiatric illness 
in young psychiatric patients using some prospective 
follow-up measures. In one such study by Cohen and Klein 
(1974), which elaborated on some of their earlier 
findings, 218 inpatients between the ages of 15 and 25 
were the subjects. Of these 218 patients, 118 had 
previous histories of drug use, while 100 had no previous 
histories of drug use. Degree of drug use at the time of 
hospitalization (mild, moderate, or heavy) was assessed 
using a measure developed by Cohen and Klein (1971) for 
specific use with psychiatric populations. Weekly urine 
drug screenings were also conducted. Twenty-five patients 
(21%) were classified as mild users, while 45 patients 
(38%) were classified as moderate users, and 48 (41%) were 
classified as heavy users. 
Post-hospital follow-up interviews were conducted 
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after a six month period with the majority (93%) of the 
patients. 
were also 
Patients were re-assessed for drug use, and 
asked questions regarding their work 
functioning, social activities, 
psychological adjustment. 
and emotional and 
Cohen and Klein found that drug use during the 
follow-up period was significantly related to a history of 
drug use prior to hospitalization. In the control group, 
7 4 % ( 6 7 /91) did not use any drug in the post-hospital 
period. Of those who did use drugs, most had used 
marijuana a couple of times. Among the mild and moderate 
users, approximately half of these patients used no drugs 
in the post-hospital period. None became heavy users. 
Among the heavy users, 71% (30/42) used drugs in the 
follow-up period. Half of these users returned to heavy 
use. Twenty-nine percent of the heavy users reported no 
drug use in the follow-up period. Considering the entire 
sample as a whole, 64% reported a reduced degree of drug 
use. 
Cohen and Klein also reported that the majority of 
patients in their control sample (both male and female) 
were schizophrenic, while the majority of drug users had 
primary diagnoses of character pathology. Similar findings 
have been reported by Smart and Fejer (1969). They also 
noted that very few of the schizophrenics who did have a 
history of drug use returned to using drugs in the 
posthospital period. 
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On the other hand, a much higher 
proportion of the character disordered patients returned 
to drug use in the follow-up period. The authors 
concluded that even among schizophrenics who do use drugs, 
these patients relinquish their drug use much more readily 
than do character disordered patients. They also argued 
that schizophrenics tend to be less socially involved than 
character disordered patients, and therefore less likely 
to find themselves in situations leading to drug use. 
Moreover, the authors suggested that schizophrenics, 
who often suffer from poor ego boundaries and cognitive 
deficits, may find the subjective effects of drug use less 
appealing than would character disordered patients. It is 
noteworthy that other researchers (Tucker, Quinlan & 
Harrow, 1972) have shown that hallucinogen use is 
associated with increased thought disorder and boundary 
disturbances in psychiatric patients, regardless of 
diagnosis. This provides some evidence that drug use may 
produce subjective effects that are similar to 
schizophrenic symptoms. Cohen and Klein suggest that 
these subjective experiences may be particularly 
unpleasant for schizophrenic patients. 
Another finding was that of a significant interaction 
between diagnosis and drug use. Thus, it was reported 
that the character disordered patients had more positive 
post-hospital outcomes, compared to the schizophrenics, 
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except in cases in which the character disordered patients 
used drugs moderately or heavily. In these latter cases, 
the character disordered patients fared worse than the 
schizophrenics in the post-hospital period. Additionally, 
in an analysis of level of drug use, regardless of 
diagnosis, it was found that the heavy drug users had the 
worst post-hospital adjustment. These patients, as a 
group, were not working or going to school, and were 
experiencing diminished social functioning. Many had been 
re-hospitalized. On the other hand, mild drug use was 
comparable to no drug use in terms of post-hospital 
adjustment. 
In another prospective study of young psychiatric 
patients by Bergman and Harris (1985), subjects were 65 
patients who had been hospitalized numerous times and were 
being followed in an outpatient community program. 
Clinical records revealed that 52% of these patients 
(n=34) had a history of drug and/or alcohol use that was 
associated with their hospitalization. Five other 
patients also had a history of substance abuse that was 
not associated with the precipitant for their 
hospitalization. During the one year period of the study, 
there were 16 readmissions to the hospital among the 65 
patients. Eleven of these admissions (60%) were drug-
related. Twelve additional drug episodes required crisis 
management, but not re-hospitalization. 
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In the Bergman & Harris (1985) study, patients were 
also queried as to their reasons for substance use. Among 
the patients who used marijuana and/or PCP only (n=14), 
most of these patients attributed their use to a desire to 
fit in with their peer group. However, among the patients 
who were primarily alcohol users (n=lO), the principal 
reason cited for their drinking was a desire to relieve 
anxiety. It was also noted that there were six patients 
in this study who abused Cogentin. 
In summary, the existing research on substance use 
among young adult psychiatric patients suggests that the 
prevalence of substance use in this population is quite 
high, with estimates ranging from 49% to 74%. There is 
also evidence that substance use is associated with 
relapse and the need for rehospitalization. (Bergman & 
Harris, 1985; Cohen & Klein, 1974; Safer, 1987), as well 
as impairments in work and social functioning (Cohen & 
Klein, 1974). 
Substance Use in Schizophrenic Patients 
Schizophrenia and Amphetamines 
There have been some studies reported in the 
psychiatric literature (e.g., Janowsky, El-Yousef, & 
Davis, 1973) in which small doses of psychostimulants were 
administered to schizophrenics. The studies indicated 
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that psychostimulants appear to activate or exacerbate 
preexisting psychotic symptoms in actively psychotic 
schizophrenic patients. In a study examining the 
differential effects of specific stimulants administered 
intravenously (Janowsky & Davis, 1976), it was found that 
methylphenidate (ritalin) was more potent than 
dextroamphetamine, 
levamf etamine in 
symptoms. 
which in turn was more potent than 
catalyzing preexisting psychotic 
Based on these studies in which medical trials of 
psychostimulants demonstrated worsening effects on 
psychotic symptoms, other studies were undertaken to 
determine whether illicitly used psychostimulants would 
show comparable results. One such study focused on 
stimulant use among schizophrenics in an inpatient V.A. 
hospital setting (Richard, Liskow, & Perry, 1985). 
Subjects for the study were 40 schizophrenics and 40 
nonschizophrenic psychiatric patients (controls). 
Attempts were made to exclude patients who were simply 
experiencing drug-induced psychoses by eliminating 
schizophrenic patients who had not been symptomatic for at 
least six consecutive months. Among the schizophrenics, 
11 were stimulant users and 29 were nonusers of 
stimulants. Among the controls, 7 were psychostimulant 
users and 33 patients were nonusers. This disparity was 
statistically significant. Overall, these results 
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indicated that in this sample 11% of the psychiatric 
patients studied had used stimulants in the past six 
months. This finding is comparable to the finding by 
Rockwell and Ostwald (1968) that 15% of their psychiatric 
sample was using stimulants. Thirty-one percent of the 
patients acknowledged having used stimulants at some time 
in the past. The authors concluded that stimulant use may 
precipitate psychotic states that last beyond the drug 
effects, and that these substances partially contribute to 
relapse in schizophrenics. 
Schizophrenia and Mariiuana 
Treffert (1978) described four case studies in which 
marijuana use produced an exacerbation of the psychotic 
process in schizophrenic patients who had attained a 
stable level of functioning with the assistance of 
psychotropic medications. Treffert concluded that 
marijuana use, even at moderate levels, is associated with 
the recurrence of psychotic symptoms in schizophrenics. 
Schizophrenia and Hallucinogens 
In a study employing a correlational design, Breakey, 
Goodell, Lorenz, and, McHugh (197 4) investigated 
hallucinogenic drugs as precipitants of schizophrenia. As 
with amphetamines, there has been speculation that 
hallucinogenic drugs, particularly LSD and marijuana, may 
precipitate or induce schizophrenic illnesses 
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in 
vulnerable individuals (e.g. Stone, 1973). In the 
Breakey, et al. (1974) study, 46 drug using and nonusing 
schizophrenics were compared to 46 drug using and nonusing 
normal controls matched for sex and age. They found that 
the schizophrenics were heavier drug users than the 
controls. The schizophrenics also reported having taken 
a wider variety of drugs than the controls. 
Another major finding of the Breakey, et al (1974) 
study was that the drug using schizophrenics had better 
premorbid adjustment, as assessed by a modification of the 
Phillips Scale of Premorbid Adjustment, than did the 
nondrug using schizophrenics. Additionally, the drug 
using schizophrenic group experienced the onset of 
symptoms approximately four years earlier than the nondrug 
using schizophrenic group. These findings were 
interpreted to mean that the drugs may have precipitated 
a schizophrenic illness in individuals who might not 
otherwise have become schizophrenic. The authors also 
suggested that since the drug using schizophrenics had 
better premorbid adjustment, it is possible that drug use 
engenders a quicker onset of the disorder. An alternative 
possibility (that was not mentioned by the authors) is 
that the drug using schizophrenics might have become 
schizophrenic even if they had not used drugs, but that 
only relatively high functioning schizophrenics use drugs. 
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For instance, it may be that higher functioning 
schizophrenics are more likely to possess the social 
skills necessary to obtain illicit substances. 
Prosser and Pickens (1979) in their review of studies 
on schizophrenia and drug use concluded that 
schizophrenics show less drug abuse than other psychiatric 
groups, but at least as much if not more drug use than 
normal controls. 
Schizophrenia and Alcohol 
Within the schizophrenia literature, another group of 
studies has examined the incidence and prevalence of 
alcoholism (without taking drug use into account) within 
schizophrenic samples. Kesselman, Solomon, Beaudett, & 
Thornton ( 19 8 2 ) have commented that some controversy 
exists as to the prevalence of alcoholism among 
schizophrenics, with estimates ranging form 3% to 63%. 
Kesselman and his colleagues, for instance, reported that 
33% of the patients diagnosed with schizophrenia in their 
state hospital sample had concurrent alcohol abuse 
problems. On the other hand, Rimmer and Jacobsen (1977), 
in a family study of the occurrence of alcoholism in 
schizophrenics and their relatives, concluded that 
"although alcoholism and schizophrenia can occur in the 
same individual, it appears to be an unusual or even 
uncommon occurrence" (p.1784). The Rimmer and Jacobsen 
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study involved the comparison of schizophrenic adoptees 
and their biological relatives with control adoptees and 
their biological relatives using adoption records from 
Denmark. 
A more recent study by Drake, Osher, and Wallach 
(1989) examined patterns of alcohol use among 115 
schizophrenics participating in an aftercare program 
following a hospitalization from a state hospital. This 
study involved a one-year prospective follow-up. Forty-
five percent of the patients had used alcohol at least 
occasionally over the previous six months. Approximately 
22 percent of the patients used alcohol to an extent that 
could be classified as abuse or dependence by DSM III-R 
criteria. Thirty-four percent of the patients used street 
drugs, and most of these patients used more than one drug 
as well as alcohol. 
They also found that alcohol use was strongly 
associated with being younger and male; 76% of the heavy 
users were under 40 years old, and 80% of the heavy 
alcohol users were men. Alcohol use was also associated 
with a myriad of psychosocial problems including 
difficulties in obtaining regular meals, maintaining 
stable housing, and managing finances. Heavy alcohol use 
was associated with psychiatric symptoms, particularly 
hostile behaviors and disorganized speech. Furthermore, 
rehospitalization was strongly associated with alcohol 
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use. Sixty-eight percent of the heavy users returned to 
the hospital at least once in the course of a one year 
follow-up, whereas only 27% of the abstainers were 
rehospitalized during that period. Even mild alcohol use 
was associated with increased rehospitalization. 
Depression and suicidal behavior were weakly related to 
alcohol use. 
In another study of alcohol use in schizophrenics, 
Alterman, Erdlen, and McLellan (1978) found that 10% of 
the total population in a V.A. psychiatric hospital could 
be classified as both schizophrenic and alcoholic. They 
also found that 55% of these alcoholic schizophrenics were 
drinking during their inpatient hospitalizations. 
Drug and Alcohol Use in Schizophrenics 
Another category of studies has investigated both 
drug and alcohol use in schizophrenic patients. Test, 
Knoedler, Allness, & Burke (1985) studied a group of 105 
young adult, predominantly outpatient schizophrenics 
treated in a community setting. They interviewed these 
patients and asked them if they had ever used alcohol or 
street drugs. Almost all of the patients had used 
alcohol, and the majority had also used stimulants, as 
well as consciousness-altering drugs such as LSD and 
phencyclidine and marijuana. Many had also used sedatives 
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and narcotics. Nevertheless, they found that the number 
of frequent users was relatively small. They found no sex 
differences in the frequency of alcohol and drug use 
during the six months before the study. 
In a subsequent study by Test, Allness, and Ripp 
(1989), which elaborated on some of the earlier Test et 
al., (1985) findings, 82 patients with schizophrenia or 
schizophrenia-like disorders were interviewed to assess 
their degree of substance use, and reasons for substance 
use. Ratings of degree of substance use were made by the 
patients themselves, as well as by their case managers. 
Staff rated 25 percent of the patients as being daily 
users of alcohol or marijuana. Overall, staff rated 58.7 
percent of the males and 50.0 percent of the females as 
using at least one substance several times a week or more. 
The patients themselves reported significantly less 
frequent use, with 44. 2 percent of the men and 37 .1 
percent of the women acknowledging use of at least one 
substance several times per week. 
The authors also found that the male patients who 
were the heaviest substance users were more likely to be 
less educated and were more likely to be living alone than 
were the patients who occasionally or never used 
substances. These difference were not seen for the female 
patients. However, there were significant diagnostic 
differences between the heaviest using female patients and 
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the none to mild using female patients, with a greater 
proportion of the heavy substance using female patients 
diagnosed as schizophrenic, as compared to none to mild 
users who were more likely to be diagnosed with other 
disorders (schizoaffective or schizotypal by RDC 
criteria). 
When the patients who were significant substance 
users (n=27) were asked about their reasons for substance 
use, the following explanations were the most prevalent: 
to relieve boredom, to feel less anxious, to socialize 
with friends, and to make it easier to sleep. 
In summary, for schizophrenic patients, there is 
evidence that substance use is related to exacerbations of 
psychotic symptoms (Janowsky & Davis, 1976; Janowsky et 
al., 1973; Richard, et al., 1985; Treffert, 1978), as well 
as poorer social functioning and increased 
rehospitalization (Drake et al., 1989). There are 
divergent estimates of the prevalence of substance use 
among schizophrenic patients, but two of the most recent 
and systematic studies (Drake et al., 1989; Test et al., 
1989) provided consistent evidence that the rate of drug 
and alcohol use in this population is approximately 50%. 
Additionally, evidence from one study (Breakey et al., 
1974) indicated that schizophrenic patients were more 
severe drug users than normal controls, but less severe 
users than other psychiatric patients. They also found 
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that the drug using schizophrenics had higher premorbid 
functioning than the nonusing schizophrenics. 
Substance Use in Patients with Affective Disorders 
Few studies were found in which drug and alcohol use 
were investigated in patients identified primarily as 
having an affective disorder. In the most recent study 
(Hasin, Endicott, & Lewis, 1985), subjects were 835 
patients who participated in the NIMH Clinical Research 
Collaborative Program on the Psychobiology of Depression. 
All patients met the Research Diagnostic Criteria (RDC) 
-
for a major depressive or manic illness at the time they 
participated in the study. Approximately 24% of the 
patients had clinically significant levels of alcohol use, 
and approximately 9% of the patients had clinically 
significant levels of drug use. The following 
characteristics were found to be related to both drug and 
alcohol problems in these affectively disturbed patients: 
male gender, younger age, and less religious involvement. 
A further association was found for marital status, with 
alcohol involvement associated with being divorced or 
separated 12 months or longer, and drug involvement 
associated with having never been married, being divorced, 
or living together in a long-term homosexual relationship. 
For drug abuse, the lower the subject's SES, the more 
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likely he or she was to abuse drugs. For alcohol abuse, 
this relationship was only true of the male patients. The 
diagnostic bipolar/unipolar distinction was not 
significantly related to substance use. In comparing 
these findings to other studies of drug and alcohol 
patients, the authors concluded that this sample of 
patients with both substance abuse problems and affective 
illness resemble patients in the general population who 
are likely to abuse substances, i.e., people who are 
young, male, unmarried, and of lower socioeconomic status. 
They also concluded that affective disorder is associated 
with high rates of substance use, but that questions 
regarding specific causal pathways remain unanswered. 
An earlier study by Mayfield and Coleman (1968) 
explored alcohol use in a sample of 59 cyclic patients, 
and 21 patients with dual problems of depression and 
histories of excessive alcohol use who had been admitted 
to a V.A. Hospital. They found that 20% of the cyclic 
patients had histories of excessive drinking. They also 
found that two-thirds of the depressive group did not have 
an association between depressive episodes and excessive 
drinking. Indeed, many of these patients were the most 
depressed during the brief interval in which they were not 
drinking. The authors suggested that the increased 
drinking observed in manic patients is a reflection of the 
restlessness and impulsiveness associated with this 
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disorder. On the other hand, they speculated that the 
'decreased drinking observed in their depressed patients is 
a manifestation of the lethargy and lack of interests seen 
in these patients during a depressive episode. 
A second study by Reich, Davies, and Himmelhock 
(1974) was conducted using psychiatric inpatient and 
outpatient records from 65 manic-depressive patients 
treated at the Yale-New Haven Hospital. The authors found 
that excessive alcohol use differentiated the hospitalized 
from the never-hospitalized patients. For 13 of the 26 
patients hospitalized for mania, excessive drinking was 
noted in the history. Additionally, all of these patients 
reported to have increased their drinking immediately 
before admission. A number of these patients reported 
that they increased their use of alcohol for the specific 
purpose of alleviating their manic symptoms. The finding 
of an association between increased alcohol consumption 
and :manic-depressive illness is consistent with the 
findings of the aforementioned study by Mayfield and 
Coleman (1968). Of the 25 patients who had never been 
hospitalized, none had used alcohol excessively. 
Furthermore, of 14 patients who were hospitalized while 
they were in the depressive phase of :manic-depressive 
illness, 7 were excessive drinkers. 
In reviewing some of the research on alcoholism and 
affective disorders, Goodwin (1990) noted that although 
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there have been divergent reports of the prevalence of 
alcoholism in manic-depressive patients, most estimates 
are in the range of 35%. 
Although there has been a dearth of research in the 
area of substance use in patients primarily identified as 
having affective disorders, there has been much interest 
in investigating affective illnesses in patients primarily 
identified as drug or alcohol abusers. One particular 
focus is seen in studies that have attempted to ascertain 
the prevalence of affective illnesses among substance 
abusers. These studies have reported highly disparate 
findings, with prevalence estimates ranging from 3% to 98% 
(Solomon, 1982). 
In summary, the scarce research that exists regarding 
substance use in patients with affective disorders 
suggests that the prevalence of substance use in this 
population is approximately 33%, and that individuals who 
are younger and male are more likely to be substance 
users. (Has in et al, 19 8 5) • There have been some 
indications of an association between increased alcohol 
consumption and manic-depressive illness (Mayfield & 
Coleman, 1968; Reich et al., 1974). There is minimal 
evidence regarding the impact of substance use on 
depressive symptoms, although one study (Mayfield & 
Coleman, 1968) reported finding no association between 
depressive episodes and excessive drinking. 
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Substance Use in General Psychiatric Populations 
Alcohol Use in Psychiatric Patients 
Bernadt and Murray { 1986) conducted a study of 
alcohol use in a sample of 371 psychiatric inpatients in 
England. These patients represented a broad spectrum of 
diagnostic classifications {using RDC criteria), including 
affective and psychotic disorders, and alcoholics. They 
found that the alcoholics were the only patients to have 
higher alcohol consumption than the mean for the whole 
sample. The schizophrenics drank less alcohol than the 
mean. Patients with primary affective disorder did not 
differ significantly from the rest of the patients, but 
there was a non-significant tendency for patients with 
major depressive, anxiety, phobic, and obsessional 
disorders to drink less. 
Bernadt and Murray {1986) also explored the 
possibility that some groups of patients might have 
intensified their drinking in the period shortly before 
their admission. They found that no group other than the 
alcoholic group significantly increased their drinking in 
the month prior to admission. Unlike other studies that 
have suggested that manic patients drink more heavily as 
they become ill, (Reich, Davies, & HirnJtlelhock, 1974; 
Schuckit, 1979) this study found that the manic patients 
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actually drank less than the other patients prior to the 
acute phase of their illnesses. Furthermore, among the 
patients with minor depressive disorder, although there 
were a sizable minority who drank more as they became ill 
(32.4%), this was offset by a similar number who drank 
less (23.5%). 
Marijuana Use in Psychiatric Patients 
In order to study the relation between marijuana use 
and psychiatric illness, one group of researchers 
(Halikas, Goodwin, and Guze, 1972) conducted a study in 
which 100 regular marijuana users and 50 nonuser friends 
were interviewed by a psychiatrist. Subjects for the 
study were recruited by word of mouth from the community, 
and were not identified as psychiatric patients. They 
were all at least 18 years old, and white. Halikas et 
al., (1972) found that there was a notably high incidence 
of psychopathology in both the marijuana-using and the 
control groups ( 52% and 46%, respectively) • However, 
among the marijuana users, with the exception of one-
fourth of those with affective disorders, all of the 
diagnosed psychiatric illnesses began before the first 
marijuana use. The authors concluded that "at least some 
regular marijuana users come from a population at high 
risk for psychiatric problems, and these difficulties 
almost al ways precede the use of marijuana. " This 
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conclusion does not seem warranted on the basis of the 
data presented, since there are other equally plausible 
interpretations that cannot be ruled out. For instance, 
it may be that among young people in general, various 
forms of pathology tend to surface at certain 
developmental transition points, whether the individuals 
are using drugs or not. 
Amphetamine Use in Psychiatric Patients 
In a study of amphetamine use in a diverse sample of 
psychiatric inpatients (Robinson and Wolkind, 1970), 54 
out of 146 patients were tested for the presence of 
amphetamines in their urine using a ·gas chromatography 
procedure. Patients were selected for testing on the 
basis of some suspicion of drug use, or because they had 
severe character pathology, or an atypical clinical 
presentation. Of the 54 patients tested, 22 were found to 
have used amphetamines. This represented 15% of the ward 
population for that year. There was also evidence that 
some of these patients had used amphetamines illicitly 
while in the hospital. 
LSD Use in Psychiatric Patients 
In a study by Hensala, Epstein, and Blacker (1967) 
the inpatient records of 20 psychiatric patients who had 
a history of taking LSD at least once were compared to 
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those of 25 psychiatric inpatients of the same age group 
who were hospitalized during the same period. The 
researchers found that the LSD group was predominantly 
male, while the control sample was predominantly female. 
The LSD group was a significantly younger group, with a 
median age of 22 years. Additionally, the researchers 
noted that 45% of the drug-using patients were 
schizophrenic, and 35% had personality disorders. Of the 
control group, 36% were schizophrenic, and 48% were 
character disordered. Similar findings have been reported 
by Blumenfeld and Glickman (1967) and by Frosch, Robbins, 
and Stern (1965). These findings are in contrast to the 
findings by Cohen and Klein (1970, 1974) and by Smart and 
Fejer (1969) which indicated that psychotic patients were 
less likely than other patients to be drug users. 
Hensala, et al. (1967) also found that the LSD group 
had significantly poorer work histories and significantly 
more previous psychiatric treatment than the other 
patients. Additionally it was noted that most of the LSD 
patients had used a variety of other drugs as well, 
whereas only two of the patients in the control group 
acknowledged the use of other illicit substances. There 
were approximately equal numbers of psychotic patients in 
the LSD group and the control group. The control group 
had a higher percentage of personality disorders (48% 
compared to 30%), but the there was a higher proportion of 
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severe personality disturbance in the I.SD group. 
LSD Use in Psychotic Patients 
In a study by Bowers ( 1977) 15 patients who had 
developed prolonged psychotic reactions following 
psychotomimetic drug use (primarily LSD) were followed up 
1.9 to 5.8 years later. (There was no control group). At 
the time of the index hospitalization these patients as a 
group had better prognostic scores, as assessed by the 
Pretreatment Stephens-Astrup scale, than a group of 
patients who were hospitalized for psychosis but had no 
history of drug use. At follow-up, two of the patients 
had committed suicide, approximately half had poor 
outcomes, and half had positive outcomes. outcomes were 
evaluated in terms of social adjustment, vocational 
performance, and overall outcome, as assessed by the Brief 
Psychiatric Rating Scale, as well as by symptom picture 
and number of rehospitalizations. Premorbid functioning 
and extent of drug use prior to the onset of psychosis 
were not significantly correlated with outcome. In 
interpreting these data, Bowers (1977) advanced the 
hypothesis that the use of LSD and other psychotomimetic 
drugs sets into motion a behavioral pattern, including 
psychosis, that runs its own course well beyond the period 
of the initial drug effect in some patients. He suggested 
further that these patients may have some kind of genetic 
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vulnerability to psychiatric illnesses. Similar accounts 
have been advanced in clinical papers by Stone (1973) and 
by Hatrick and Dewhurst (1970). 
In a related study, Vardy and Kay (1983) investigated 
whether patients hospitalized for LSD psychosis are 
clinically distinct from acute schizophrenics. Subjects 
for the study were 29 psychiatric inpatients who had 
psychotic symptoms that first appeared and persisted at 
least two weeks after taking LSD. The comparison group 
consisted of 29 first break schizophrenics matched for age 
and other demographic features (DSM-II criteria) with no 
history of drug use. In the LSD group, the frequency of 
LSD intake was typically one to five times. All of the 
subjects were administered a battery of psychological 
tests including the WAIS, the Phillips Scale of premorbid 
adjustment, the Rorschach, the Benton, and symptom 
checklists. Twenty-one patients in each group were 
reassessed three to five years after the index admission. 
The researchers found no difference in overall level of 
adjustment between the LSD group and the schizophrenics on 
the Phillips Scale. This is contrary to the findings of 
Bowers (1977) and Breakey, et al. (1974) whose drug using 
patients had better premorbid adjustment. The percentage 
and distribution of rehospitalizations over time were 
strikingly similar for the two groups. At follow-up both 
groups also had significantly higher verbal than 
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performance IQ's on the WAIS, with similar subtest 
scatter. The two groups also showed no difference on most 
Rorschach scales. With regard to the family histories, 
the familial risk for psychosis was the same in both 
groups, but there was a higher proportion of parental 
alcoholism in the LSD group. Vardy and Kay concluded that 
LSD psychosis is not distinct from acute schizophrenia, 
and that LSD psychosis cannot be attributed only to toxic 
drug effects. They also proposed "a model of LSD 
psychosis as a drug-induced schizophreniform reaction in 
persons vulnerable to both substance abuse and psychosis" 
(p.877). 
Drug Use in Psychotic Patients 
In a study by Tsuang, Simpson, and Kronfol (1982) 
hospital records of 72 drug abusers with psychoses (DAP) 
were compared to those of 46 schizophrenics and 28 
atypical schizophrenics who were not drug abusers. The 
criteria developed by Feighner, et al. (1972) were used 
for all diagnoses. Further comparisons were made with a 
group of 32 nonpsychotic drug abusers. The psychotic drug 
abusing patients were separated into two different 
categories- 45 patients whose psychotic symptoms had a 
duration of less than six months (DAP-short) , and 27 
patients whose psychotic symptoms had a longer than six 
month duration (DAP-long). The authors assumed that the 
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psychotic reactions of the OAP-short patients were 
primarily drug-induced. They found that more patients in 
the OAP-short group had good premorbid functioning (based 
on DSM-II criteria) as compared to the OAP-long group. 
They also found that the DAP-long group resembled both the 
schizophrenic and atypical schizophrenic patients with 
regard to family risk for schizophrenia. On the other 
had, none of the families of the OAP-short patients had 
histories of schizophrenia. The DAP-long group and the 
atypical schizophrenics also had similar family risks for 
affective disorder. The families of the schizophrenic 
patients showed no risk for affective disorder. Overall, 
the DAP-long group had a greater percentage of premorbid 
personality disorders, longer hospital i z:ations, worse 
disposition at outcome, and greater familial risks for 
schizophrenia and affective disorders. Tsuang, et al. 
(1982) conclude that drug abusers with psychoses that last 
more than six months are highly similar to atypical 
schizophrenics, and that this diagnostic category might 
include both schizophrenic and affective disorder 
subgroups. 
Perkins, Simpson, and Tsuang (1986) conducted a ten 
year telephone follow-up of the patients in the previous 
study by Tsuang, et al. (1982). They found that the DAP-
short group were significantly more likel~ to have better 
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psychiatric outcome and occupational outcome than the DAP-
long patients. They also found that the OAP-short 
patients had similar outcomes to the nonpsychotic drug 
users. Furthermore, the OAP-short patients tended to have 
better outcomes than patients with schizophrenia or 
atypical schizophrenia. Perkins, et al. concluded that 
"drug abusers with chronic psychotic symptoms are a 
distinct subgroup of drug abusers who suffer from major 
psychotic illness" (p. 481). 
In summary, the research on substance use in general 
psychiatric samples provides some evidence that substance 
use is associated with work impairments (Hensala et al, 
1967; Perkins et al., 1986), exacerbations of psychotic 
symptoms (Bowers, 1977) and other symptoms (Perkins et 
al., 1986), and increased rates of rehospitalization 
(Tsuang et al., 1982). With regard to premorbid 
functioning, a study by Vardy and Kay (1983) found that 
there were no differences in premorbid functioning between 
LSD-using patients with enduring psychotic symptoms, and 
schizophrenics. A study by Tsuang et al. (1982) found 
that drug users with short-lived psychotic symptoms had 
better premorbid adjustment as compared to substance users 
with more prolonged psychotic symptoms. Another study by 
Bowers (1977) indicated that drug using psychotic patients 
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had better premorbid adjustment as compared to nonusing 
psychotic patients. 
CHAPTER III 
STATEMENT OF THE PROBLEM 
The following issues will be studied using 
prospective data from two successive follow-ups: 
1. Rate of substance use in the present sample. 
Several studies have reported that the substance use 
rate among young psychiatric patients approaches or 
exceeds 50% What is the percentage of patients in this 
sample (at the acute phase and at followup) who show 
evidence of significant drug and/or alcohol use? 
2. Course of substance use. 
Some evidence exists that substance use is a 
relatively persistent phenomenon among psychiatric 
patients (e.g., Cohen & Klein, 1974; Shearn & Fitzgibbons, 
1982). The longitudinal nature of the present research 
permits examination of the following question: Is 
substance abuse at index hospitalization associated with 
continued use in the subsequent followups? It is 
hypothesized that there is a significant positive relation 
between substance use at the index hospitalization and 
substance use at both follow-ups. It is also hypothesized 
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that there is a significant positive relation between 
substance use at follow-up I and substance use at follow-
up II. 
3. Level of substance use within different diagnostic 
groups. 
There is some controversy in the 1 i terature regarding 
the issue of whether psychotic patients tend to use 
illicit substances to a greater or lesser extent than 
other psychiatric patients. For instance, a few studies 
have indicated that schizophrenic patients tend to use 
substances to a lesser extent than do other psychiatric 
patients (e.g., Breakey, et al., 1974; Cohen & Klein, 
1987; Prosser & Pickens, 1974). A study by Bernadt and 
Murray (1986) also indicated that although schizophrenics 
tend to drink less alcohol than other psychiatric 
patients, there were no differences in drinking patterns 
between other diagnostic groups. Other studies, however, 
(Blumenfeld & Glickman, 1967; Frosch, et al., 1965; 
Hensala, et al., 1967) have found higher rates of 
substance use among psychotic patients than nonpsychotic 
patients. The present study permits further exploration 
of the following question: Do patients with different 
diagnoses show different levels of substance use? It is 
hypothesized that there are differences in level of 
substance use among the different diagnostic groups. The 
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direction of these differences cannot be predicted because 
of the equivocal findings of the existing research on this 
issue. 
4. Course and outcome of substance users versus nonusers. 
What is the clinical course and long-term outcome of 
psychiatric patients who are drug and alcohol users, as 
compared to psychiatric patients who are nonusers? 
Subjects for the study were classified into the following 
four diagnostic groups using RDC criteria: (a) 
nonpsychotic depressives; (b) other nonpsychotics; (c) 
schizophrenics; and (d) other psychotics. 
Course and outcome were assessed with regard to 
number of rehospitalizations, work functioning, social 
functioning, psychotic symptoms, thought disorder, 
depressive symptoms, suicide, and overall outcome. The 
specific questions and hypotheses related to each of these 
dependent variables are described below. 
Number of Rehospitalizations. 
A number of the previous studies have shown that 
substance use is associated with increased rates of 
rehospitalization among psychiatric patients (Alterman, et 
al., 1982; Bergman & Harris, 1985; Cohen & Klein, 1974; 
Simpson & Kronfol, 1982) . In light of these previous 
findings, it is hypothesized that substance use is 
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associated with increased rates of rehospitalization 
within the sample as a whole, as well as within each of 
the diagnostic groups. 
Instrumental Functioning- work, school, home. 
There have been some previous studies that have 
demonstrated a link between substance use and poorer work 
functioning. For instance, the Hensala, et al. (1967), 
study found that psychiatric patients who used LSD had 
poorer work histories. A subsequent prospective study by 
Cohen and Klein (1974) indicated that drug use was 
associated with detriments in work functioning at follow-
up. The present study tests the hypothesis that substance 
use is associated with concurrent and predictive 
detriments in work functioning for the sample as a whole, 
and within each of the diagnostic groups. 
Social Functioning 
A couple of studies have also examined the relation 
between substance use and social functioning in 
psychiatric patients. In a study of psychotic patients, 
Bowers (1977) found equivocal results with regard to the 
impact of LSD on social functioning. A study of alcohol 
use by schizophrenics, however, indicated that alcohol use 
was associated with poorer social functioning at follow-
up. The present-study tests the hypothesis that drug and 
43 
alcohol use is associated with concurrent and predictive 
deficits in social functioning among patients in each of 
the diagnostic groups, and for the sample as a whole. The 
present study builds on the previous research by examining 
social functioning over time in nonpsychotic, as well as 
psychotic patients. 
Psychosis 
A number of studies (Bowers, 1977; Janowsky, et al., 
1973; Perkins, 1986; Richard, et al., 1985; Tsuang, et 
al., 1982) have reported that substance use is associated 
with the onset and maintenance of psychotic symptoms in 
psychiatric patients. In line with these previous 
findings, the present study tests the hypothesis that drug 
and alcohol use is associated with concurrent and 
predictive exacerbations in psychotic symptoms for the 
sample as a whole, and within each of the diagnostic 
groups. 
Thought Disorder 
Research by Marengo and Harrow ( 19 8 7) has 
demonstrated that signs of thought disorder, while clearly 
more common to schizophrenia, are also seen in previously 
hospitalized patients who are not schizophrenic, including 
nonpsychotic patients. Marengo and Harrow (1987) also 
found that psychiatric patients with enduring signs of 
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thought disorder over the early course of their illnesses 
had poor outcomes in terms of work functioning, 
rehospitalization, and overall adjustment. Although no 
research examining differences in thought disorder as a 
function of substance use was found, thought disorder is 
an important variable to explore in light of its strong 
impact on overall adjustment. Consequently, the present 
study asks the question: Is substance use associated with 
increased signs of thought disorder within each of the 
diagnostic groups? It is hypothesized that substance use 
is related to intensifications of thought disorder within 
the sample as a whole, and within each of the diagnostic 
groups. 
Depressive Symptoms 
To date, there has not been much evidence reported 
regarding the relation between substance use and 
depressive symptoms in individuals primarily identified 
with other psychiatric disorders. The one study that 
explored this issue found no association between 
depressive symptoms and level of alcohol consumption. 
There are no studies describing the impact of substance 
use on depressive symptomatology, either in affectively 
disturbed patients, or in other psychiatric patients. 
From a clinical vantage point, however, most mental health 
professionals would probably expect that substance use 
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would be linked with exacerbations of depressive 
symptomatology. One reason for this belief is that some 
of the more widely used substances, such as alcohol, are 
central nervous system depressants. Another reason is 
that many people have depressive reactions in the 
aftermath of heavy drug or alcohol use. The present study 
examines the following question: What is the impact of 
drug and alcohol use on concurrent and predictive 
depressive symptoms within each of the diagnostic groups? 
It is hypothesized that substance use is associated with 
exacerbations in depressive symptomatology within each of 
the diagnostic groups, and for the sample as a whole. 
Suicide 
Previous research has indicated that the suicide rate 
in psychiatric patients is in the range of 10 to 15% 
(e.g. , Drake, Gates, Whitaker, & Cotton, 1985) • 
Furthermore, it has been observed that substance abuse in 
conjunction with other forms of psychopathology places the 
affected individuals at great risk for suicide. With 
regard to alcohol abuse in schizophrenics, for example, 
Kesselman, et al. ( 1982) have stated, "The alcoholic 
schizophrenic group is a suicidal group .••• one cannot 
emphasize strongly enough the impulsivity and suicidal 
potential of this group of patients" (p. 7 5-76) • The 
present study examines the rate of suicide in this sample 
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among the different diagnostic groups. It is hypothesized 
that higher levels of substance use are associated with 
increased rates of suicide within the sample as a whole, 
and within each of the diagnostic groups. 
overall Functioning 
There some evidence in the previous research that 
substance use is associated with poorer overall outcome in 
psychiatric patients (e.g., Cohen & Klein, 1974; Perkins, 
et al., 1986). In light of these findings, the present 
study asks whether substance use is associated with poorer 
concurrent and predictive overall functioning. It is 
hypothesized that higher levels of substance use are 
related to poorer concurrent and predictive overall 
functioning for the sample as a whole, and within each of 
the diagnostic groups. 
The general hypothesis is that substance use is 
associated with poorer concurrent and predictive 
functioning in each of the aforementioned areas. The 
review of the findings in each of these areas can also 
provide some exploratory information regarding whether the 
predictors are differentially affected depending on 
diagnosis. That is, is the impact of substance use on 
each of these areas diagnosis-specific? 
5. Premorbid 
Mediators of 
outcome. 
Functioning 
the Relation 
and Gender as 
Between Substance 
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Potential 
Use and 
There have been a couple of studies that have 
reported that substance using psychiatric patients have 
better premorbid functioning than nonusing patients. For 
instance, Breakey, et al., (1974) reported that drug using 
schizophrenics showed better premorbid functioning than 
other schizophrenics. Similarly, Bowers (1977) reported 
that drug using psychotic patients had better premorbid 
functioning than nonusing psychotics. However, Tsuang, et 
al. (1982) found that long-term psychosis in drug using 
patients was associated with poorer premorbid functioning 
(and poorer overall outcome) as compared to the premorbid 
functioning of drug using patients with short-term 
(presumably drug-induced) psychosis. Additionally, Vardy 
and Kay (1983) found no differences in premorbid 
functioning in drug using psychotic patients as compared 
to nonusing schizophrenic patients. 
There have also been numerous indications in the 
previous literature that substance use and abuse is more 
prevalent among males (e.g., Bowers & Swigar, 1987; Drake, 
et al., 1989; Hasin, et al., 1985; Hensala, et al., 1967). 
In the present study, the role of gender and 
premorbid functioning as possible modifiers of the 
relation between substance use and outcome is explored. 
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That is, these questions are asked: At follow-up, if there 
are differences in outcome associated with substance use, 
are these differences influenced by gender and/or 
premorbid functioning? Are significant effects for 
substance use still noted when the effects of gender and 
premorbid functioning are held constant? 
The present study also explores the hypothesis that 
substance users (within each diagnostic group) have poorer 
premorbid functioning, as assessed at the acute 
hospitalization phase, than the nonusing patients. 
These issues are important (particularly premorbid 
functioning) because previous research has shown that 
premorbid functioning is a strong predictor of post-
hospi tal functioning (Harrow & Westermeyer, 1986). 
Consequently, if it is the case that substance using 
psychiatric patients have poorer premorbid functioning 
than nonusing patients, and if substance users have poorer 
outcome than nonusers, the poor outcome could be due to 
premorbid functioning and/or substance use. The present 
research will attempt to clarify whether or not any of the 
relationships noted between substance use and outcome are 
primarily related to differences in premorbid functioning. 
CHAPTER IV 
METHOD 
Patient Sample 
The present research employed a subsample of data 
from the Chicago Followup Study, a multidisciplinary, 
longitudinal research program investigating thought 
disorders (Harrow & Miller, 1980; Harrow, Silverstein, & 
Marengo, 1983; Harrow, Lanin-Kettering, Prosen, & Miller, 
1983), psychotic symptoms and other symptoms (Harrow & 
Silverstein, 1977; Summers, Harrow, & Westermeyer, 1983), 
and prognosis and outcome in schizophrenia and other 
disorders on a longitudinal basis (Carone, Harrow, & 
Westermeyer, in press; Harrow, Grinker, Silverstein, & 
Holzman, 1978; Westermeyer & Harrow, 1980; Westermeyer & 
Harrow, 1983; Westermeyer & Harrow, 1988; Westermeyer, 
Harrow, & Carone, 1987). 
The sample employed in the present study included 267 
young adult patients who were initially treated at Michael 
Reese Hospital, a private hospital, and at the Illinois 
State Psychiatric Institute (ISPI), a state hospital. All 
of the patients were first assessed at the acute phase of 
hospitalization and then reassessed in two successive 
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follow-up interviews approximately 2. 5 and 5. O years after 
hospital discharge. 
Patients were selected for the present study if they 
met the following conditions: (1) either they had 
participated in at least two follow-ups, or they had 
committed suicide at some time in the post-hospital 
period, and (2) there was information recorded at the 
index hospitalization regarding whether or not the patient 
was a substance user. Seventy-eight patients from the 
larger study who did meet the first criterion were 
excluded from the study because there was no information 
available regarding these patients' substance use or 
abstinence. 
Diagnoses were made using the Research Diagnostic 
criteria (RDC; Spitzer, Endicott, & Robins, 1978) and DSM-
III (American Psychiatric Association, 1980) diagnostic 
rating systems. Information for RDC and DSM-III ratings 
was garnered from several sources: a detailed admission 
interview summarized in the patient's chart, the 
Schizophrenia State Interview (SSI; Grinker & Holzman, 
1973), a semi-structured, tape-recorded diagnostic 
research interview, and in some cases, a modified version 
of the Schedule for Affective Disorders and Schizophrenia 
(SADS; Endicott & Spitzer, 1978). All of the ratings were 
made by a trained diagnostic team that included senior 
clinicians. In light of the fact that the RDC criteria 
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have remained unchanged for several years, while the DSM-
III criteria have been revised and updated to a new 
version, DSM-IIIR, the RDC criteria were used in the 
present study. 
Based on RDC criteria, subjects were categorized in 
the following diagnostic groups: schizophrenics, other 
psychotics, nonpsychotic depressives, and other 
nonpsychotics. Table 1 illustrates the number of drug 
and/or alcohol users versus controls within each 
diagnostic category. 
Numerous specific diagnostic entities are encompassed 
by the four diagnostic categories used in the present 
study. Table 2 lists all of the RDC diagnoses of the 
patients in the sample, and the frequency of each 
diagnosis. 
Demographic Characteristics of the Sample 
Gender 
In the sample as a whole, there were 13 4 males 
(50.2%) and 133 females (49.8%). Of the drug users, 107 
were male and 73 were female. Of the nonusers, 27 were 
male and 60 were female. These differences were 
statistically significant, X: 2 (2, N=267) = 17.82, R <.001, 
and indicate that substance use is more prevalent among 
men in this sample. 
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Table 1 
Number of Patients With Each Level of Substance Use (None 
to Severe) Within Each Diagnostic Group at Index 
Hospitalization 
Level of Substance Use 
None Mild Mod Severe Tot 
Diagnosis 
Nonpsychotic depressives 34 15 16 16 81 
Other nonpsychotics 13 8 9 7 37 
Schizophrenics 15 12 14 21 62 
Other psychotics 25 16 18 28 87 
Totals 87 51 57. 72 267 
Table 2 
RDC Diagnoses of Patients in the Sample 
Diagnosis Frequency 
Nonpsychotic Depressives 
Minor depression, undifferentiated 
Major depression, unipolar, nonpsychotic 
Major depression, bipolar, nonpsychotic 
Other Nonpsychotics 
Panic and generalized anxiety 
Labile personality 
Antisocial personality 
Other psychiatric disorders-unspecified 
other psychiatric disorders-Anorexia 
Other psychiatric disorder-Bulimia 
Borderline personality 
Major depression superimposed on residual 
Manic disorder, bipolar, nonpsychotic 
Mixed bipolar 
Schizophrenic 
Schizophrenic, paranoid 
Schizophrenic, paranoid, acute 
Schizophrenic, paranoid, subacute 
Schizophrenic, paranoid, subchronic 
Schizophrenic, paranoid, chronic 
Schizophrenic, undifferentiated, acute 
Schizophrenic, undifferentiated, subacute 
sz 
Schizophrenic, undifferentiated, subchronic 
Schizophrenic, undifferentiated, chronic 
Schizophrenic, catatonic, acute 
Schizophrenia, residual 
Other Psychotic 
Schizoaffective, depressed, acute 
Schizoaffective, depressed, subacute 
Schizoaffective, depressed, subchronic 
Schizoaffective, depressed, chronic 
Schizoaffective, manic 
Schizoaffective, manic, acute 
Schizoaffective, manic, subacute 
Schizoaffective, manic subchronic 
Schizoaffective, namic, chronic 
Unspecified functiononal psychosis 
Major depression, unipolar, psychotic 
Major depression, bipolar, psychotic 
Manic disorder, undif f erntiated 
Manic disorder, unipolar, psychotic 
5 
68 
8 
3 
1 
1 
13 
5 
1 
7 
1 
1 
4 
1 
2 
7 
6 
8 
4 
6 
12 
13 
1 
2 
3 
9 
8 
8 
1 
2 
1 
1 
1 
10 
21 
2 
1 
11 
53 
% 
1.9 
25.5 
3.0 
1.1 
.4 
.4 
4.9 
1.9 
.4 
2.6 
.4 
.4 
1.5 
.4 
.7 
2.6 
2.2 
3.0 
1.5 
2.2 
4.5 
4.9 
.4 
.7 
1.1 
3.4 
3.0 
3.0 
.4 
.7 
.4 
.4 
.4 
3.7 
7.9 
.7 
.4 
4.1 
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There were no significant gender differences noted 
between users and nonusers for the depressive or other 
nonpsychotic patients. There were, however, significant 
gender differences for the schizophrenics, ):'2 (1, n =62) 
= 7.33, p= .007, with male schizophrenics more likely to 
be users than female schizophrenics. There were also 
significant gender differences for the other psychotics~ 
X:,2 c1, n= 87) =5.0l, p=.03, with male other psychotics 
more likely to be users than female other psychotics. 
There were also significant gender differences noted 
between the different diagnostic groups, °)(2(3, H=267) = 
20.43, p < .0001, with depression being more prevalent 
among women (n=54) thanmen Cn=27), and schizophrenia more 
prevalent among men Cn=44) than women (n=l8). There were 
roughly equal numbers of males and females among the other 
nonpsychotics (17 males, 20 females) and the other 
psychotics (46 males, 41 females). 
Age 
The mean age in the sample was 22. 4 years There were 
no significant differences in age noted for substance 
users versus nonusers. There were also no significant age 
differences noted for patients within the different 
diagnostic categories. 
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Marital Status 
In the sample as a whole, 87.3% of the sample (n=233) 
were single, while 12. 4% of the patients (n=34) were 
married. 
Among the substance using patients Cn=180), the vast 
majority were single (90%, n=l66). Among the nonusing 
patients (n=87), the majority were also single (n=67, 
77%). However, this disparity was statistically 
significant, )(_2 (2, li= 267) = 10.88, R <.001, indicating 
that a higher proportion of the substance using patients 
were single. There were no differences in Earital status 
noted among the different diagnostic groups. 
Race 
The majority of the sample (83.5%) was caucasian 
(n=223), while 16.5% of the sample (n=44) were minorities. 
There were no significant differences noted in substance 
users versus nonusers with regard to race. There were 
also no significant racial differences between the 
different diagnostic groups. 
Medication Status 
The majority of the patients (76.8%) were prescribed 
medications at their index hospitalization (n=116). A 
higher percentage of the substance using patients (70.7%) 
were medicated, as compared to the 29.3% of the non using 
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patients who were medicated. However, this difference was 
not statistically significant. 
Social Class 
Data on social class was obtained according to the 
five social classes defined by Hollingshead and Redlich 
(1957), which was derived using the father's occupation 
and education at the time that the patient was 18 years 
old. Parental social class was used because it seemed to 
be a particularly cogent indicator of the social context 
of a young adult. Additionally, the use of parental 
social class compensates for the potential downward drift 
in social class status in individuals whose education and 
work performance may be severely iIDpaired by mental 
illness. 
The mean SES for the sample as a whole was 2. 9, which 
is in the middle range of social classes. Substance use 
was associated with lower levels of socioeconomic 
standing, E(3,244) = 2.86, R <.05. 
No differences in socioeconomic standing were noted 
across the different diagnostic groups. 
Educational Level 
The mean educational level for the saIDple was 13.21 
years of education. The substance users were a less 
educated group than the nonusers, E(3,260) = 4.49, R <.01. 
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There were diagnostic differences noted in educational 
level, with the depressives having slightly more education 
(M= 13.85) than the other diagnostic groups, ~(3,244) = 
5.08, R <.01. 
Number of Prior Hospitalizations 
The mean number of prior hospitalizations was 1.16, 
with a range of o to 36. There were no significant 
differences between substance users and nonusers in the 
number of prior hospitalizations. There were also no 
significant diagnostic differences in nulnber of prior 
hospitalizations. 
Collection of Data 
Table 3 outlines the time sequence of data collection 
and delineates the variables explored in this research. 
The time periods for data collection relevant to the 
present study are 1) index hospitalization, 2) follow-up 
one, and 3) follow-up two. Two hundred sixty-seven 
patients were assessed at the index hospitalization. Two 
hundred fifty-one of these patients were then reassessed 
1-5 years later (mean 2.17 years) for their first follow-
up. The attrition of 16 subjects was due to the following 
factors: 1) 12 patients had committed suicide; 2) one 
patient had died of natural causes, and 3) data was 
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THE METHOD 
Time of Assessment 
Index First Followup Second Followup 
Hospitalization~~~~<2 years>~~~~~~~~<4 years) 
PREDICTORS 
Diagnosis 
RDC Criteria 
Substance Use 
No use to heavy use 
Based on Cohen and Klein 
(0-3 Scale) 
svmptoms 
Depression 
Gender 
Premorbid Functioning 
OUTCOME VARIABLES 
Substance Use 
Harrow Functioning Interview 
No use to heavy 
use (1-6 scale) 
Life Adjustment 
Re-hospitalizations 
Work functioning 
Social functioning 
Svrnptorns 
Depression 
Psychosis 
Thought disorder 
Suicide 
Overall Outcome. 
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missing for three subjects. Two hundred forty-seven of 
these patients were again assessed at the second follow-
up, which occurred 3- 7 years (mean 4.75 years) after the 
index admission. By the time of the second follow-up, 
another three patients had committed suicide, and one 
other patient had died of natural causes. 
Table 4 lists the var.iables explored in the study 
with regard to whether they were used as independent or 
dependent (outcome) measures. The primary independent 
measure was level of substance use, as assessed at index 
hospitalization, follow-up I and follow-up II. In all 
cases the relationship between substance use and the 
dependent variables was explored for the sample as a 
whole, as well as within each of the four diagnostic 
groups, since it was expected that diagnosis would have a 
major bearing on outcome. 
The outcome variables examined were continued 
substance use at follow-up, psychiatric symptoms 
(depression, psychosis, thought disorder), post-hospital 
adjustment (work functioning, social functioning, and re-
hospitalizations), overall outcome, and suicide. Table 5 
lists each of the dependent variables, the measures they 
were derived from, and the scales used. 
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Independent and Dependent Measures Employed in the Study 
I. Primary Independent Measures 
A. Substance use (none to heavy) at 
index hospitalization, follow-up I and follow-up II. 
B. Diagnosis (schizophrenic, other 
psychotic, depressed, other nonpsychotic) . 
II. Independent Measures Explored as Modifiers 
A. Gender 
B. Premorbid functioning as assessed by Zigler-Phillips 
Scale 
III. Dependent Measures 
A. Substance abuse at follow-up. 
B. Psychiatric symptoms 
1. Depression- measured at index hospitalization, 
Follow-up I and Follow-up II 
2. Psychosis- measured at Follow-up I and Follow-up 
3. Thought Disorder- measured at Follow-up I and 
Follow-up II 
c. Post-hospital level of adjustment 
1. work functioning 
2. social functioning 
3. re-hospitalizations 
D. overall outcome 
E. Suicide 
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Table 5 
Operationalization of Dependent Measures 
1. 
2. 
3. 
4. 
4. 
5. 
6. 
7. 
8. 
Dependent Variable 
Substance use at 
follow-up 
Depression 
Psychosis 
Thought disorder 
Work functioning 
Social functioning 
Rehospitalizations 
Overall outcome 
Suicide 
Data Derived From 
Harrow Functioning 
Interview 
Composite of 
Katz 
Scale 
(6-point) 
l=no use 
6=heavy use 
(5-point) 
Questionnaire l=good 
and 2 questions 5=bad 
on depressive feelings 
Modified SADS 
Proverbs Test 
Object Sorting Test 
Comprehension Scaled 
Score on the WAIS 
Harrow Functioning 
Interview 
Harrow Functioning 
Interview 
Harrow Functioning 
Interview 
Harrow Functioning 
Interview, SADS 
Family reports, 
coroner's reports 
( 3-point) 
l=not 
present 
3=present 
Marengo-
Harrow 
Scale(1972) 
1=good 
S=poor 
(5-point 
Strauss-
Carpenter 
scale) 
O=poor 
4=good 
(5-point 
Strauss-
Carpenter 
scale) 
(a) 5-point 
Strauss-
Carpenter 
LKP Scale 
1-10) 
l=best 
9=suicide 
lO=deceased 
l=suicided 
2=alive 
Predictive Variables Collected at 
Index Hospitalization 
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Initial Assessment of Degree of Substance Use at Index 
Hospitalization 
Based on the review of the information in the 
patient's chart from the initial hospital period (chart 
notes, diagnostic summaries, SSI, SADS), an assessment was 
made of each patient's degree of involvement with drugs or 
alcohol (control, mild, moderate, heavy) using a 
modification of the measure of multi-drug use developed by 
Cohen and Klein (1971). 
Cohen and Klein's measure was devised specifically 
for use with psychiatric populations. It employs three 
specific criteria of drug abuse: nulilber of different drugs 
used, frequency of use, and length of use. 
these criteria, the authors developed a series of ratings 
for a several kinds of drugs including marijuana and/or 
hashish, amphetamines and barbiturates, 
hallucinogens,heroin, inhalants, cough syrup and codeine, 
methamphetamine, and opium. An individual's use of each 
drug is rated independently and then a cumulative overall 
score is calculated. Overall scores range from zero to 
three, with a score of zero indicating no use (or very 
minimal use), a score of one indicting mild use, a score 
of two indicating moderate use, and a score of three 
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indicating heavy use. 
For example, a rating of 11 0 11 , or no use would be 
given in a case in which the patient had used marijuana 
only (no other drugs) 1-6 times at any point in the past. 
The general guideline was that it was apparent that this 
use constituted a discrete period of very minimal use, 
rather than an ongoing pattern of use. An example of a 
rating of 11 1 11 , or mild use would be a patient who used LSD 
once a week for a month, as well as amphetamines twice per 
month for three months. An example of a rating of 11 2 11 or 
moderate use would be a patient who used LSD once a week 
for six months and amphetamines once a week for six 
months. An example of a rating of "3" for heavy use is a 
patient who smoked marijuana at least once a day for 1-2 
years, took amphetamines several times a week for 6-12 
months, took barbiturates once a week for 1-2 years, took 
LSD once a week for 6-12 months, and used codeine once or 
twice a month for over two years. 
Additionally, for the present research the Cohen and 
Klein scale was modified to include ratings for alcohol 
use. The general principle used was that alcohol use that 
might be evaluated as abuse by DSMIII-R criteria was given 
a rating of 11 2 11 (moderate use), whereas use that might fit 
the categorization of alcohol dependence was given a 
rating of 11 3 11 (heavy use). Alcohol use was given a rating 
of 11 1 11 (mild use) if it involved more than one drink 
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several times a week or daily drinking that in either case 
did not meet the criteria for abuse. Thus, an individual 
who regularly drank a six-pack of beer in a weekend was 
classified as a mild alcohol user. On the other hand, 
individuals who drank only a couple of drinks per week 
were considered to have clinically insignificant drinking 
patterns, and were placed in the control group. As in the 
ratings of drug use, the alcohol ratings were considered 
in conjunction with any concurrent drug use, such that a 
person's score might be elevated if additional 
psychoactive substance use was noted. 
Assessments of drug use using the Cohen and Klein 
measure were made by the author. Substantial inter-rater 
reliability was found (~=.92) based on the rate of 
agreement between the author and another trained rater 
using a subset of the sample (n=20). 
Measures of Symptoms at Index Hospitalization 
Depressive symptoms at index hospitalization. 
Members of the diagnostic rating team culled 
information from all of the sources available at the index 
hospitalization (chart notes, Grinker interview tapes, 
SSI, and so forth) and rated whether the patient had any 
of the following nine symptoms of depression: 
concentration difficulties, dysphoria, suicidal ideation 
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or intent, appetite loss or gain, sleep increase or 
decrease, lack of energy, psychomotor agitation or 
retardation, anhedonia, and guilt. Each of these items 
was rated on a three-point scale, with "1 11 indicating that 
the symptom was absent; 11 2 11 indicating that the symptom 
was suspected or weak, and "3" indicating that the symptom 
was present. Following this, each symptom was given a 
score of 11 1 11 if it had previously been rated as a 11 2 11 
(suspected) or 11 311 (clearly present). All of these scores 
were then summed to give a final o to 9 rating. 
Assessment of Premorbid Competence--Collected at Index 
Hospitalization 
The current research used a modification of the 
Zigler-Phillips Social Competence Scale (Zigler & Levine, 
1981) to assess overall premorbid adjustment. The 
original Zigler-Phillips (1961) scale was based on six 
items: age, education, marital status, occupational 
status, employment history, and intelligence. Each item 
is rated on a 3-point scale (O=lowest category: 2=highest 
category). 
Al though various combinations of the six original 
items have been used, the present research used a four 
item Social Competence Scale (based on age, education, 
marital status, and employment history). These attributes 
were rated blindly for diagnosis and subsequent outcome 
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for all of the subjects. 
Information on the social competence items was 
collected for all patients using the Schizophrenia State 
Interview (SSI) or the SADS. Although the ratings of age, 
education, and marital status were made according to the 
original guidelines established by Zigler and Phillips 
(1961), ratings of work competence were expanded in this 
research to include functioning as a homemaker or student. 
The purpose of this modification was to make this rating 
more applicable to women and young adults. This revised 
system has been used previously by Westermeyer and Harrow 
(1984), who found that inter-rater reliability for pre-
hospital work was .75 (Pearson~). 
Follow-up Assessment of Degree of Substance Use 
Follow-up assessments of the extent of continued 
substance use in the posthospital period were made using 
information derived from the Harrow Functioning Interview 
(Bromet, Harrow, & Kasl, 1974; Harrow, Grinker, 
Silverstein, & Holzman, 1978), a structured interview of 
several aspects of functioning, including substance use. 
The Harrow Functioning Interview includes the following 
questions regarding substance use: ( 1) "Have you been 
taking any kind of drug, like pot, LSD, heroin, sleeping 
pills, tranquilizers or speed, since leaving the hospital? 
If yes, what kind? How often?"(2) "How often do you have 
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a drink? 11 (3) "How easy is it for you to pass up a drink?" 
(4) "How much do you usually drink?" Based on these 
questions, rating of degree of use were made for each of 
the following substances: heroin, psychedelics, marijuana, 
barbiturates, and alcohol. Ratings were on a five-point 
scale ranging from 11 1 11 for no use to "5" for heavy use. 
Following these ratings, an overall substance use rating 
was derived by taking the highest score on any of the 
aforementioned substances. If an individual received 
scores of "3" or higher for two or more different 
substances, then one additional point was added to their 
score. Thus, the overall score was computed on a 1-6 
scale. For the purposes of data analysis, this 1-6 scale 
was transformed into a 1-3 scale indicating no use, mild 
use, and moderate to heavy use. 
Follow-up Assessment of Adjustment: Symptomatology 
at Follow-up One and Follow-up Two 
Depression Ratings at Follow-up 
Depression was assessed using Forlll Sl of the Katz 
Adjustment Scale (Katz & Lyerly, 1963). This is a self-
report questionnaire that requires patients to rate 55 
psychological symptoms on a 1 to 4 scale, ranging from not 
symptomatic to heavily symptomatic. Nine of the items 
assess depressed mood and behavior. 
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For the present research, a composite depression 
score was derived from two sets of scores: the nine 
depression-related questions on the Katz Scale, and two 
additional questions which were part of the self-
administered component of the follow-up battery-- 1) Have 
you been depressed over the past few months? 2) Have you 
been feeling sad or blue over the past few months? 
The composite score was derived in the following way: 
For the nine Katz items, each of the 1-4 scores were 
summed across the nine items. Thus, the maximum possible 
score was 36. Total scores of 10-12 indicated absence of 
depressive symptoms and given a rating of 11 1 11 ; total 
scores of 13-14 indicated mild depressive symptoms and 
were given a rating of 11 2 11 ; total scores of 15-16 
indicated moderate depressive symptoms and were given a 
rating of 11 3 11 ; total scores of 17-21 indicated severe 
depressive symptoms and was given a rating of 11 4 11 ; and 
totaled scores of 22 and higher indicated very severe 
depressive symptoms and was given a rating of 11 5 11 • 
The two additional questions were also rated on a 
one to four scale that was summed, yielding a maximum 
possible total score of 8. A total score of 2 was given 
a rating of 11 1 11 , indicating mild depression. A total 
score of 3 was given a rating of 11 3 11 , indicating moderate 
depression. A total score of 4-5 was given a rating of 
11 4 11 , indicating severe depression. A total score of 6-8 
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was given a rating of "5", indicating very severe 
depression. 
The two scaled scores (from the Katz items and from 
the two additional questions) were then averaged to yield 
a final depression score on the same five-point scale. 
Ratings of Psychosis at Follow-up 
Psychosis was assessed using a modified form of the 
SADS. This modified version includes all of the major 
items on psychosis from an earlier modification of the 
Present State Examination. In one section of the SADS 
there are 17 questions concerning psychotic symptoms, 
primarily delusions and hallucinations. The results are 
transformed into an overall psychosis score on a three-
point scale (present, absent, or uncertain). 
Measures of Thought Disorder at Follow-up 
During both the inpatient and follow-up assessments, 
three cognitive tests were used to assess bizarre 
thinking, the Goldstein-Scheerer Object Sorting Test, part 
1, (Goldstein & Scheerer, 1941), the Gorham Proverbs Test 
(Gorham, 1956) , and the Comprehension subtest of the 
Wechsler Adult Intelligence Scales (Wechsler, 1955). 
These tests assess various aspects of idiosyncratic 
thinking such as incoherence, looseness of associations, 
tangentiality, and illogical thinking. Each of the 
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individual Proverbs and Comprehension test responses was 
scored for bizarre-idiosyncratic thinking using the scale 
developed by Marengo, Harrow, Wilson, and Lanin-Kettering 
(1985). According to this scale, each response is scored 
on a 4-point continuum corresponding to whether the 
response showed (1) no bizarre thinking, (2) a mild degree 
of cognitive slippage or mildly strange features, (3) 
definite signs of abnormal thinking, or (4) very bizarre 
or idiosyncratic features, at times making the response 
incomprehensible. Following this assignment of scores, 
the individual items (based on the four-point scales) were 
summed to obtain a raw score for each patient on that 
test. The raw scores were then classified into one of 
five qualitative categories of thought pathology: (1) 
none, (2) minimal to mild, (3) definite signs of abnormal 
thinking, (4) severe, and (5) very severe. 
The rating system was devised so that a high 
percentage of bizarre responses was required in order for 
a patient to be assessed as having severe thought 
pathology (level 4 or 5). For example, if a patient were 
to produce five clearly bizarre responses from the 12 
Proverbs or comprehension questions, and another four 
responses that were mildly strange, this person would be 
rated as severely thought disordered. 
The individual Object-Sorting Test responses were 
scored for bizarre-idiosyncratic thinking on a three-
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point scale, corresponding to responses that were (1) not 
bizarre or idiosyncratic, (2) somewhat bizarre, and (3) 
severely bizarre or idiosyncratic. Harrow, Rattenbury, 
Marengo, and King (1990) have reported substantial inter-
rater reliability on ratings of the Object Sorting Test, 
with an intra-class correlation of .85 on ratings made by 
five trained raters using ten different protocols from a 
range of "normal" and mentally disturbed patients. They 
also reported a high degree of internal consistency on the 
measure, with inter-item reliability ratings ranging from 
.92 to .96 using Chronbach's alpha. 
In the same way that the raw scores for the Proverbs 
and Comprehension tests were summed and then classified 
into a qualitative score, the scores for all of the items 
on the Object-Sorting Test were also suillll\ed into a raw 
score. Each of the individual scores from the three tests 
was categorized into one of the five qualitative levels of 
bizarre-idiosyncratic thinking, ranginq from no thought 
pathology to very severe thought pathology. 
A combination of the three tests was used to provide 
a composite index of thought pathology. This composite 
score represents the most severe score received by the 
patient on any of the three tests. This composite index, 
which has been used successfully in several previous 
studies (Harrow, Grossman, Silverstein, & Meltzer, 1982; 
Harrow, Grossman, Silverstein, Meltzer, & Kettering, 1986; 
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Harrow & Silverstein, 1980; Harrow, Silverstein, & 
Marengo, 1983), is the measure of thought pathology used 
in the current research. Using this composite index, each 
patient was assigned to one of the five qualitative 
categories, ranging from no bizarre-idiosyncratic thinking 
(level 1) to very severe bizarre-idiosyncratic thinking 
(level 5). 
Follow-up Assessments of Outcome at Follow-up I and 
Follow-up II 
Work Functioning.Social Functioning, andRehospitalization 
Follow-up assessments of outcome in the post-hospital 
period were made using the Harrow Functioning Interview 
which includes questions regarding re-hospitalization as 
well as social and work functioning. The interview also 
assesses the patient's subjective evaluation of his or her 
own mental health, and participation in leisure 
activities. 
Using the information gathered from the Harrow 
Functioning Interview, scores for social and work 
functioning, as well as re-hospitalization were derived 
using three five-point scales developed by Strauss and 
Carpenter (1972). The re-hospitalization scale examines 
the duration of re-hospitalizations during the past year, 
ranging from a score of 4 which would indicate that the 
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person had not been in the hospital during the past year 
to a score of o which would indicate that the person had 
been hospitalized more than nine months in the past year. 
The social functioning scale examines the frequency 
of social contacts within the past month. The scale 
ranges from a score of 4, which would refer to a person 
who met with friends approximately once a week, to a score 
of O, which would refer to a person who did not socialize 
at all. 
The work functioning scale examines the percentage of 
time that the individual was employed in the past year. 
A score of 4 would be used to describe an individual who 
was employed continuously during the past year, while a 
score of O would indicate that the individual had not been 
employed at all during the previous year. Housewives and 
students were considered as employed. 
The social and work functioning scales emphasize the 
amount of social contact and work involvement rather than 
the quality of these experiences. Although this form of 
appraisal neglects many aspects of an individual's social 
and work adaptation, the advantage to this approach is 
that it is highly reliable (with reported reliability 
coefficients ranging form!:_= .87 to .96). Other advantages 
are that the Strauss-Carpenter scales are longitudinal, 
and they allow for ratings of student and housewife work 
performance. 
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Overall Outcome 
A 9-point measure of overall adjustment (LKP Scaie; 
Levenstein, Klein, & Pollack, 1966) was used to assess 
functioning in the areas of work, self-support, 
symptomatology, potential suicide, relapses, and 
rehospitalization. The LKP also enables a categorization 
of patients according to whether they had favorable 
outcomes (good functioning in all areas), equivocal 
outcomes ( good functioning in one or two areas with 
difficulties in other areas), or 
(difficulties in almost all areas 
symptomatology, or suicide). 
Suicide 
poor outcomes 
and significant 
Fourteen patients in this sample committed suicide in 
the post-hospital period. These fourteen patients include 
12 patients who committed suicide prior to the first 
follow-up, and two patients who committed suicide prior to 
the second follow-up. There were an additional nine 
patients who committed suicide at some point after the 
second follow-up. Suicide was established by either: 1) 
death certificate, or 2) the family's report that the 
patient had committed suicide in a case in which suicide 
appeared to be a likely cause of death (e.g., falling from 
the 23rd floor of a building after expressing suicidal 
ideation). 
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Procedure 
Data for the present study were gathered as part of 
a larger ongoing, NIMH-sponsored longitudinal research 
project, the Chicago Follow-up study, under the direction 
of Martin Harrow, the principal investigator. The general 
procedure for this project is briefly described below. 
Index Hospitalization 
Patients were initially approached within three days 
of index admission to enlist their participation in the 
research project. The project was described as a study to 
determine the relationship between a person's symptoms, 
particularly in terms of their style in responding to the 
test material, and subsequent adjustment. Patients were 
informed that there were no known risks involved in 
participating in the project. They were also informed 
that the information they provided would be treated 
confidentially, and that they could withdraw their consent 
and discontinue their participation in the project at any 
time. Additionally, they were advised that the project 
would involve follow-up interviews, and that they would be 
re-contacted approximately every two years and asked to 
participate in subsequent interview sessions. Patients 
were also asked to sign a formal consent form. 
During the index hospitalization, all of the subjects 
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were interviewed extensively by members of the hospital 
staff, as well as by trained interviewers involved in the 
research project. These interviews addressed general 
diagnostic issues such as presenting problem, previous 
psychiatric history including family history, and mental 
status. 
Follow-up Interviews 
At the beginning of each follow-up session, patients 
were again advised that their participation in the study 
was completely voluntary, and that all of the information 
gathered would be kept confidential. Subjects were also 
paid for their participation in each follow-up session. 
Follow-up sessions were conducted by trained research 
assistants who had achieved satisfactory inter-rater 
reliability on the standardized follow-up assessment 
battery. 
CHAPTER V 
RESULTS 
Overview of Analyses 
All of the results are presented by first describing 
the pattern of findings in the sample as a whole, and then 
examining the findings within each diagnostic group 
(nonpsychotic depressives, other nonpsychotics, 
schizophrenics, other psychotics). The first section of 
the results addresses the course of substance use in 
psychiatric patients, and the degre~ of substance use 
among these patients. The percentage of patients at each 
time period (index hospitalization, follow-up I, follow-up 
II) who are involved in substance use is described. The 
levels of substance use by patients in the sample (none, 
mild, moderate, heavy) are also explored. 
The second section addresses whether substance use in 
the acute phase is associated with continued substance use 
in the post-hospital period. 
The third section addresses the question of whether 
patients with different diagnoses use different levels of 
substances. 
The fourth and fifth sections examine the relation 
between substance use and current as wel 1 as future 
functioning in several different realms. Because of the 
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longitudinal nature of the project, a number of concurrent 
and predictive analyses involving each of the dependent 
variables were conducted. Thus, for example, concurrent 
relations between substance use and overall outcome on the 
LKP scale were examined in two separate analyses, one for 
follow-up I and the other for follow-up II. Predictive 
relations between substance use and overall outcome were 
also examined. Thus, the relation between substance use 
at index as a predictor of overall outcome at follow-up I 
was examined, followed by a separate analysis of the 
predictive relation between substance use at index as a 
predictor of overall outcome at follow-up II. Finally, 
the predictive relation between substance use at follow-up 
I and overall outcome at follow-up II was examined. 
The fourth section includes analyses that describe 
whether differences in level of substance use at each of 
the three time periods are associated with differences in 
concurrent functioning at each time period. 
The fifth section includes analyses that describe 
whether differences in level of substance use at each time 
period are predictive of subsequent differences in 
functioning in the follow-up period. 
Analyses for the fourth and fifth sections were 
conducted as follows. In terms of concurrent functioning 
at the index hospitalization, the only dependent variable 
examined was depressive symptoms, because the other 
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potential dependent variables at the acute phase were 
often a component of the patients' diagnoses. For 
instance, all of the schizophrenic and other psychotic 
patients were psychotic at the index hospitalization. 
Thus, it would have been tautological (and statistically 
questionable) to examine the impact of substance use on 
psychotic symptoms for the schizophrenics at the index 
hospitalization. 
The impact of substance use at index hospitalization 
on concurrent depressive symptoms was examined by means of 
an analysis of variance, with depressive symptoms as the 
dependent variable, and level of substance use as the 
independent variable. (Although all of the depressed 
patients, obviously had depressive symptoms at the index 
hospitalization, there was variability in the number of 
symptoms present.) 
With regard to concurrent and predictive functioning 
at follow-up I and follow-up II, for each of the 
concurrent and predictive time periods three sets of 
analyses were done for the sample as a whole, as well as 
within each of the diagnostic groups. First, a 
multivariate analysis of variance (MANOVA) was conducted 
in which the Strauss-Carpenter indices of work 
functioning, social functioning, and rehospitalization 
were the dependent variables, and level of substance use 
was the independent variable. Second, another MANOVA was 
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conducted in which depressive symptoms, psychotic 
symptoms, and thought disorder were the dependent 
variables, and level of substance use was the independent 
variable. Third, an ANOVA was conducted in which the 
overall outcome, as assessed by the LKP scale was the 
dependent variable, and level of substance use was the 
independent variable. 
All of the interpretations of the multivariate 
analyses were based on the Wilks' Lambda test statistic. 
In order to compensate for the fact that the 
probability of finding statistically significant results, 
purely on the basis of chance, increases as the number of 
statistical procedures employed increases, the Bonferroni 
criterion was used. In this case, because three 
statistical tests were employed within each of the 
diagnostic categories, the traditional .05 criterion was 
divided by three. Thus, for all of these analyses the 
probability level of .017 was required in order to rule 
out the null hypothesis. 
The sixth section examines the role of potential 
modifiers of the relation between substance use and 
outcome- premorbid functioning and gender. [First, the 
issue of whether there are diagnostic differences, at the 
acute phase, in premorbid functioning based on differences 
in level of substance use is explored. ] In cases in which 
previous MANOVAs and ANOVAs showed differences in outcome 
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as a function of differences in level of substance use, a 
series of multivariate analyses of covariance (MANCOVA) 
and analyses of covariance (ANCOVA) were conducted in 
order to ascertain whether these differences would still 
be obtained when the variance due to gender and premorbid 
functioning was removed. Also explored was the issue of 
whether there are diagnostic differences, at the acute 
phase, in premorbid functioning based on differences in 
level of substance use. Differences were tested using t 
tests. 
The seventh section examines the relation between 
substance use and suicide. 
Course of Substance Use at Index Hospitalization, 
Follow-up I, and Follow-up II 
Whole Sample 
At the index hospitalization, 180 (67.4%) of the 267 
patients in the sample showed some evidence of drug or 
alcohol use, whereas 87 (32.6%) patients showed no 
evidence of drug or alcohol use. As can be seen in Table 
6, in the sample as a whole, among the 87 patients who 
showed no evidence of substance use at index 
hospitalization, 48 patients or 55. 2% continued to show no 
evidence of substance use at follow-up I. Also, one of 
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Course of Substance Use at Three Time Periods for the 
Sample as a Whole (N=267)* 
Index Hospitalization Follow-up I Follow-up II 
1 suicide 
No Use 
36 
Level 1 8 
Level 2 3 
Total 11 
No Use 
87 
o Use 8 
Level 1 
evel 2 
Total 39 
Level 1 21 
evel 2 7 
Total 28 
No use 
1 suicide 
12 27 
No 
54 
1 14 
Level 1 51 2 10 
Level 2 57 24 
Level 3 72 
Total 180 
use 
Level 1 58 
evel 2 55 
Total 113 
Level 1 49 
evel 2 39 
Total 88 
Note. Level 1= no use; level 2= mild use; level 3= 
moderate to heavy use. 
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the nonusing patients had died by the time of follow-up I. 
However, in this group, 39 (44.8%) patients began to 
acknowledge substance use at the first follow-up. Of the 
48 patients who were nonusers at both index 
hospitalization and follow-up I, 36 (75%) patients 
continued to be nonusers at follow-up II. There was one 
person who did not use substances at index hospitalization 
or at follow-up I who had suicided prior to follow-up II, 
and there were 11 patients (22.9%) who showed their first 
signs of substance use at follow-up II. Thus, in a sample 
of 267 psychiatric patients studied at three points in 
time, only 36 patients (13.5%) showed no evidence of 
substance use at any of these time periods. 
Of the 180 patients who demonstrated mild, moderate, 
or heavy substance use at the index hospitalization, 113 
patients (62.8%) continued to use substances at follow-up 
I. Furthermore, of the 180 substance using patients, 12 
(6.7%) had committed suicide by the time of follow-up I. 
Of the patients who were users at index hospitalization 
and follow-up I, 88 (77.9%) continued to use substances at 
follow-up II (one additional person died by the time of 
the second follow-up). Thus, in our sample of 267 
hospitalized psychiatric patients, 88 patients (33.0%) 
showed evidence of sustained substance use throughout the 
early course of their illnesses. Additionally, there 
were 23 patients (12.8%) who reported substance use at the 
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index hospitalization and at follow-up I who had stopped 
using substances by the time of the second follow-up. 
Among the 180 patients who were using substances at 
the index hospitalization, 51 (28.3%) were mild users, 57 
(31. 7%) were moderate users, and 72 (40%) were heavy 
users. Among the patients who did not use at index, but 
became users at follow-up, most became mild users. 
Of the 39 patients who began using drugs at follow-up 
I, 28 continued to use substances at follow-up II, while 
8 showed no evidence of substance use at follow-up II. 
There were also 54 patients who had used substances at the 
index hospitalization, and then stopped using substances 
by the time of the first follow-up. Of these 54 patients, 
half of the patients (27) continued to refrain from 
substance use at follow-up II, while the other half (24) 
resumed substance use at follow-up II. 
Depressed Patients 
As shown in Table 7, among the depressed patients, 34 
(42.0%) showed no evidence of substance use at the index 
hospitalization, while 4 7 patients ( 58. 0%) did acknowledge 
substance use. By the time of the first follow-up, among 
those with no evidence of substance use at time period 
one, half of these patients (17) did show evidence of 
substance use, while the other half of these patients (17) 
continued to refrain from using. Among the no nus ing 
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course of substance Use at Three Time Periods for the 
Nonpsychotic Depressives (N=Sl)* 
Index Hospitalization 
No Use 
34 
Level 
Level 
Level 
Total 
1 15 
2 16 
3 16 
47 
Follow-up I 
No Use 
17 
Level 
Level 
Total 
No Us 
1 
2 
2 suicide 
13 
Level 1 
evel 2 
Total 
16 
1 
17 
Follow-up II 
No Use 
5 
Level 
evel 
Total 
No use 
5 
Level 
Level 
Total 
1 
2 
1 
2 
1 
2 
2 
1 
3 
10 
2 
12 
6 
3 
9 
1 16 
2 10 
26 
Note. Level 1= no use; level 2= mild use; level 3= 
moderate to heavy use. 
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depressives there were no deaths or suicides at either of 
the follow-ups. By the time of the second follow-up, of 
the 34 patients who were nonusers at index 
hospitalization, 17 patients continued to be nonusers, 
while 17 patients showed evidence of substance use. 
Of the 47 patients who were substance users at the 
index hospitalization, 31 continued to use substances at 
follow-up I, while 13 had stopped using substances at 
follow-up I. Among the substance using depressives, two 
patients had suicided by the time of the first follow-up. 
The majority of the depressed patients who were substance 
users at index hospitalization and follow-up I continued 
to be substance users at follow-up II (n=26), while only 
five of the patients who had used substances at the index 
hospitalization and follow-up I had st~pped using 
substances by follow-up II. 
Among the 4 7 depressed patients who were users at the 
index hospitalization, 15 were mild users, 16 were 
moderate users, and 16 were heavy users. Of the patients 
who were users at time period one, these patients' levels 
of use remained roughly equivalent at follow-up I and 
follow-up II. However, the patients who were nonusers at 
index, who later became substance users, tended to be mild 
users at follow up. 
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Other Nonpsychotics 
As shown in Table 8, among the nonpsychotic patients, 
13 (35.1%) showed no evidence of substance use at the 
index hospitalization, while 24 (64.9%) patients did show 
evidence of such use. Of the 13 patients who did not use 
substances at time period I, 5 patients continued to 
refrain throughout the course of follow-up I and follow-up 
II. However, of the 13 nonpsychotic patients who started 
out refraining from substance use at the index 
hospitalization, 7 had begun using substances by the time 
of follow-up I. All of these seven patients continued to 
use substances at the second follow-up. There were no 
suicides among the nonusing nonpsychotics, but there was 
one death by the time of the first follow-up. 
Of the 24 nonpsychotic patients who did show evidence 
of substance use at the index hospitalization, 17 patients 
continued to use substances at the first follow-up, while 
7 patients stopped using substances by the time of the 
first follow-up. By the time of the second follow-up, 17 
out of the 24 patients were still using substances, while 
7 of the patients had stopped using substances. There 
were no deaths or suicides among the substance using 
nonpsychotic patients. 
Among the 24 substance using other nonpsychotic 
patients, 8 were mild users, 9 were moderate users, and 7 
were heavy users. The patients who continued to use 
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Course of Substance Use at Three Time Periods for the 
Other Nonpsychotics (N=37)* 
Index Hospitalization Follow-up I Follow-up II 
No Use 
5 
Level 1 0 
Level 2 0 
Total 0 
No Use 
13 
0 
1 4 
2 3 
7 
Level 1 4 
Level 2 3 
Total 7 
use 
No Use 
7 
1 3 
Level 1 8 2 2 
Level 2 9 5 
Level 3 7 
Total 24 
Level 1 9
/'o use 
Level 2 
Total 1~ Level 1 6 
vel 2 6 
Total 12 
Note. Level 1= no use; level 2= mild use; level 3= 
moderate to heavy use. 
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substances in the follow-up period were roughly split 
between mild users and moderate to heavy users. 
Schizophrenics 
As shown in Table 9, among the 62 schizophrenic 
patients, 15 of the patients (24. 2%) were not using 
substances at the index hospitalization, while 47 of the 
patients (75.8%) were using substances. Of the 15 
patients who were nonusers, 11 continued to be nonusers at 
follow-up I, while 2 patients began their substance use at 
follow-up I. Furthermore, of these 15 patients who were 
initially nonusers, 11 patients continued to be nonusers 
by the time of the second follow-up·, while 3 patients 
began using substances at the second follow-up. There 
were no deaths or suicides among the nonusing 
schizophrenics at the first follow-up, but there was one 
suicide, at the second follow-up, of a patient who had not 
used substances at either the index admission or follow-up 
I. 
Among the 47 schizophrenic patients who were using 
substances at the index hospitalization, 26 continued to 
use substances at follow-up I, while 16 patients had 
stopped using substances by follow-up I. Of the 26 
schizophrenic patients who used substances at both index 
hospitalization and follow-up. I, 21 continued their 
substance use at follow-up II. Of the 16 patients who had 
Table 9 90 
Course of Substance Use at Three Time Periods for the 
Schizophrenics (N=62)* 
Index Hospitalization Follow-up I Follow-up II 
No Use 
1 suicide 
17 
Us 
Level 1 2 
evel 2 2 
Total 4 
No Use 
15 
No Use 
Level 1 1 1 
evel 2 2 
Total 3 
Level 1 1 
Level 2 1 
Total 2 
1 suicide 
0 use 
10 
5 suicides 
No Use Level 1 0 
Level 1 16 Level 2 3 
Level 2 Total 3 
Level 3 
Total 
No use 
1 4 
2 
Level 1 10 
Level 2 11 
Total 21 
Note. Level 1= no use; level 2= mild use; level 3= 
moderate to heavy use. 
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started out using substances at index hospitalization and 
had stopped using substances by follow-up I, 10 continued 
to refrain from substance use at follow-up II, while 3 
resumed their substance use at follow-up II. Among the 
substance using schizophrenics there were 5 suicides by 
the time of the first follow-up, and one additional 
suicide by the time of the second follow-up. The latter 
patient had stopped using substances at the first follow-
up. 
Among the 47 schizophrenics who were substance users 
at the index hospitalization, 12 were mild users, 14 were 
moderate users, and 21 were heavy users. The patients who 
continued to use in the follow-up period were roughly 
divided between mild users and moderate to heavy users. 
Other Psychotics 
As shown in Table 10, among the 87 other psychotic 
patients, 25 (28.7%) patients were not using substances at 
the index hospitalization, while 62 patients (71.3%) were 
using substances. Of the 25 patients who were nonusers at 
the index hospitalization, 14 patients continued to be 
nonusers at follow-up I, while 11 of these patients began 
using substances at follow-up I. Of the 25 patients who 
started out as nonusers at the index hospitalization, 14 
continued to be nonusers at the second follow-up, while 11 
patients did use substances at the second follow-up. 
Table 10 92 
Course of Substance Use at Three Time Periods for the 
Other Psychotics (N=87)* 
Index Hospitalization Follow-up I Follow-up II 
Use 
No Use 
14 1 4 
2 0 
4 
No Use 
25 1 suicide 
No Use 2 
Level 1 
Level 2 
Total 
Level 1 6 
Level 2 1 
Total 7 
use 
5 suicide 
No Use 
17 
1 5 
Level 1 16 2 2 
Level 2 18 7 
Level 3 28 
Total 62 
use 
Level 1 17 
Level 2 22 
Total 39 
Level 1 17 
evel 2 12 
Total 29 
Note. Level 1= no use; level 2= mild use; level 3= 
moderate to heavy use. 
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There was one suicide at follow-up II of a patient who had 
not used substances at the index hospitalization who had 
started using substances at the first follow-up. 
Of the 62 psychotic patients who were substance users 
at the index hospitalization, 39 patients continued to use 
substances at the first follow-up, while 17 of these 
patients stopped using substances by the time of the first 
follow-up. Of these 62 psychotic patients who were 
initially using substances, 39 patients were still using 
at the second follow-up, while 17 patients were not using 
substances at the time of the second follow-up. Among the 
substance using other psychotic patients, there were five 
suicides by the time of the first follow-up. 
Among the other psychotic patients who were substance 
users at the index hospitalization, 16 were mild users, 18 
were moderate users, and 28 were heavy users. The 
patients who continued to use substances in the follow-up 
period were again roughly divided between mild users and 
moderate to heavy users. Among the few patients who were 
nonusers at the index hospitalization who later became 
users at follow-up I (n=ll) and follow-up II (n=4), the 
majority were mild users. 
Continuity of Substance Use 
As shown in Table 11, for the sample as a whole 
(N=247), substance use at the index hospitalization was 
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The Relationship Between Substance Use at Index 
Hospitalization, Follow-up I, and Follow-up II CN=247l 
Index 
Hospitalization 
Follow-up I 
Follow-up II 
Note: *p<.01 
**p<.001 
Index 
Hospitalization 
1.00 
.36** 
.30** 
Substance Use 
Follow-up Follow-up 
I II 
.36** .30** 
1. 00 .43** 
.43** 1. 00 
Pearson Product Moment Correlations 
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significantly associated with continued substance use at 
both the first, ~(247) =.36, R <.001, and second, ~(247) 
= .30, R <.001, follow-ups. Furthermore, substance use at 
follow-up I was strongly associated with substance use at 
follow-up II, ~ (247) =.43, R <.001. 
Degree of Substance Use Among the Different 
Diagnostic Groups 
To address the question of whether patients with 
different diagnoses tend to use drugs and alcohol to 
different extents, a series of ANOVAs were conducted in 
which substance use at each of the three time periods 
(index hospitalization, follow-up I, follow-up II) was the 
dependent variable and diagnosis (nonpsychotic depressed, 
other nonpsychotic, schizophrenic, other psychotic) was 
the independent variable. At the time of the index 
hospitalization there were significant differences in the 
level of substance use by patients with different 
diagnoses, E(3,263) = 2.63, R <.05. Specifically, the 
schizophrenic patients were the heaviest users (M=l.66) 
and the depressives were the mildest users (M=l.17). 
However, a subsequent analysis of covariance (ANCOVA) 
using gender as a covariate revealed a significant effect 
for gender, E(l,262)= 17.51, R =.0001, with males showing 
higher levels of substance use than females. When the 
effect of gender was held constant, there was no longer a 
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significant main effect for diagnosis. Thus, the 
previously noted difference in level of substance use for 
different diagnostic groups, was at least in part 
attributable to gender differences between these groups. 
The schizophrenic patients who were predominantly male had 
the highest levels of use, and the depressed patients, who 
are predominantly female had the lowest levels of 
substance use. 
At both follow-up I and follow-up II there were no 
significant differences among the diagnostic groups in 
their degree of substance use. There were also no 
significant effects obtained for gender. Thus, at follow-
up I and follow-up II neither diagnosis nor gender had any 
demonstrable relationship to the level of substance use 
among patients in the sample. 
Relation Between Substance Use at the Acute Phase and 
Concurrent Symptomatology: Depressive Symptoms 
In order to assess whether higher levels of substance 
use at the acute phase were associated with concurrent 
elevations in depressive symptomatology for the sample as 
a whole, an ANOVA was conducted with depressive symptoms 
at index hospitalization as the dependent variable and 
level of substance use at index (none, mild, moderate, 
heavy) as the independent variable. The analysis was 
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nonsignificant, ~(3,247) = .41, R = .75, which indicates, 
that contrary to the hypothesis, higher levels of 
substance use at index were not associated with elevations 
in depressive symptomatology for the sample as a whole. 
Four separate ANOVAs were also carried out within 
each of the diagnostic groups (nonpsychotic depressives, 
other nonpsychotics, schizophrenics, other psychotics). 
As in the above analysis, which collapsed across 
diagnostic groups, each of these analyses was conducted 
using level of depression as the dependent variable and 
level of substance use (none, mild, moderate, heavy) as 
the independent variable. None of these analyses were 
significant which indicates that among the different 
diagnostic groups there were no significant differences in 
level of depression associated with differences in level 
of substance use at the time of the initial 
hospitalization. Means and standard deviations for these 
analyses are reported in Table 12. 
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Table 12 
Mean Depressive Symptom Scores at Index Hospitalization 
as a Function of Concurrent Level of Substance Use 
Within Each Diagnostic Group 
Depressive Symptoms at Index 
Level of Use 
Within Each 
Diagnostic Group 
at Index N M SD 
Whole Sample 
None 82 4.2 2.7 
Low 49 3.9 2.7 
Moderate 53 4.2 2.5 
Severe 64 3.8 2.6 
Depressives 
None 30 6.1 1.3 
Low 15 6.3 .8 
Moderate 14 6.3 1.5 
Severe 15 5.1 1.7 
Other Nonpsychotics 
None 12 2.4 2.2 
Low 8 3.3 2.7 
Moderate 7 3.1 2.3 
Severe 6 1.5 1.2 
Schizophrenics 
None 13 2.2 2.1 
Low 11 1. 6 1.1 
Moderate 12 1.8 2.0 
Severe 16 1. 6 1. 3 
Other Psychotics 
None 22 3.8 3.0 
Low 14 3.4 2.9 
Moderate 15 4.7 2.3 
Severe 21 4.4 2.7 
Note. Lower scores represent less symptomatology. 
The Impact of Substance Use at Follow-up I on 
Concurrent Functioning and Symptoms 
Analyses for The Sample as a Whole 
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Strauss-Carpenter Variables: Work Functioning. Social 
Functioning, Rehospitalization 
To test the hypothesis that substance use is 
associated with poorer concurrent functioning in the 
sample as a whole, a MANOVA was conducted with the 
Strauss-Carpenter indices of social functioning, work 
functioning, and rehospitalization at follow-up I as the 
dependent variables, and level of substance use at follow-
up I (none, mild, moderate to heavy) as the independent 
variable. (Note that the measure of substance use at 
follow-up I and follow-up II contains only three groups: 
none, mild, and moderate to heavy, unlike the measure of 
substance use at the index hospitalization which contains 
four groups: none, mild, moderate, and heavy.) The overall 
MANOVA was significant, E(6,480)=7.44, p= .0001. 
The univariate results indicated significant findings 
for rehospitalization, E(2,241) = 10.05, p = .0001, social 
functioning, E(2,241) = 15.98, p = .0001, and work 
functioning, E(2,241) = 5.25, p =.006. These findings 
continue to be significant when the Bonferroni criterion 
of .017 is applied. An examination of the direction of 
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these means, as seen in Table 13, however, shows that none 
of the means were in the predicted direction. Contrary to 
the predictions, for the sample as a whole, higher levels 
of concurrent substance use at the first follow-up was 
associated with better work functioning, better social 
functioning, and fewer rehospitalizations. 
Symptoms- Depression, Thought Disorder, Psychosis 
To test the hypothesis that substance use is 
associated with elevations in concurrent symptoms for the 
sample as a whole, a MANOVA was conducted with depressive 
symptoms, psychosis, and thought disorder as the dependent 
variables, and level of substance use at follow-up I 
(none, mild, moderate to heavy) as the independent 
variable. The overall MANOVA was nonsignificant, 
indicating that there is no evidence that substance use is 
associated with poorer concurrent symptomatology for 
sample as a whole. The means and standard deviations for 
this analysis are reported in Table 14. 
Overall Outcome-LKP Scale 
To test the concurrent relation between substance use 
at the acute phase and overall functioning at follow-up I 
for the sample as a whole, an ANOVA was conducted with 
overall functioning as the dependent variable, and level 
of substance use (none, mild, moderate, heavy) as the 
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Table 13 
Mean Strauss-Carpenter Scores at Follow-up I CF!) as a 
Function of Concurrent Level of Substance Use Within 
Each Diagnostic Group 
Work Social Rehosp. 
FI FI FI 
Level of Use 
Within Each 
Diagnostic Group 
at FI N M SD M SD M SD 
Whole Sample 
None 98 2.1 1. 7 2.6 1.5 3.0 1.3 
Low 86 2.8 1.5 3.4 1.0 3.8 .6 
Moderate 
Severe 60 2.7 1. 6 3.6 .9 3.4 .9 
Depressives 
None 29 2.4 1. 7 2.9 1.5 3.0 1. 3 
Low 33 3.3 1. 3 3.7 .7 3.8 .5 
Moderate 
Severe 15 3.4 1.2 3.4 1.1 3.5 .7 
Other Nonpsychotics 
None 12 2.4 1. 7 3.2 1.2 3.3 1.2 
Low 13 2.2 1. 7 3.2 1.1 3.9 . 6 
Moderate 
Severe 10 2.6 1. 6 3.9 .3 3.6 1.0 
Schizophrenics 
None 27 1.4 1.6 2.2 1.6 2.9 1.5 
Low 16 2.3 1.5 3.0 1.4 3.7 .6 
Moderate 
Severe 11 1.5 1.8 3.3 1.4 2.9 1.1 
Other Psychotics 
None 12 1.8 1. 7 2.6 1.4 3.1 1. 7 
Low 11 3.0 1.3 2.9 1.4 3.6 .7 
Moderate 
Severe 8 2.5 1.8 3.6 .7 3.4 1.1 
Note. Higher scores represent better functioning. 
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Table 14 
Mean Symptom Scores at Follow-up I CFI) as a 
Function of Concurrent Level of Substance Use Within 
Each Diagnostic Group 
Depression Thought Dis. Psychosis 
FI FI FI 
Level of Use 
Within Each 
Diagnostic Group 
at Follow-up I N M SD M SD M SD 
Whole Sample 
None 95 3.6 1.3 2.6 1.2 1.8 .9 
Low 83 3.6 1. 3 2.3 1. 0 1. 6 .8 
Moderate 
Severe 53 3.7 1. 3 2.8 1.2 1. 6 .8 
Depressives 
None 27 4.1 1. 0 2.0 1.0 1.6 .8 
Low 32 4.0 1.1 2.2 1. 0 1.4 .7 
Moderate 
Severe 12 3.5 1.2 2.7 .9 1.5 .8 
Other Nonpsychotics 
None 12 3.8 1.2 2.2 .6 1. 3 .8 
Low 13 3.3 1. 3 2.2 .8 1.5 .7 
Moderate 
Severe 10 3.8 1. 3 2.9 1.4 1. 5 .9 
Schizophrenics 
None 26 3.0 1.5 3.2 1.2 1.9 .9 
Low 15 3.7 1. 0 2.4 .9 2.1 .9 
Moderate 
Severe 11 3.5 1.5 3.3 1.6 1. 8 .9 
Other Psychotics 
None 30 3.5 1.2 2.8 1.3 2.0 .9 
Low 23 3.4 1.5 2.4 1.3 1.5 .8 
Moderate 
Severe 20 3.8 1.3 2.7 1.0 1. 7 .9 
Note. Lower scores represent less symptomatology. 
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independent variable. An examination of the means, as 
shown in Table 15 indicates that, contrary to the 
prediction, higher levels of substance use at follow-up I 
was associated with better overall outcome at follow-up I 
for the sample as a whole. The differences between the 
means were statistically significant, E(2,247) = 5.14, p 
= .001. 
Analyses for the Nonpsychotic Depressive Sample 
Work functioning, Social Functioning, Rehospitalization 
To test the hypothesis that substance use is 
associated with poorer concurrent functioning for 
depressives, a MANOVA was conducted with the Strauss-
Carpenter indices of social functioning, work functioning, 
and rehospitalization at follow-up I as the dependent 
variables, and level of substance use at follow-up I 
(none, mild, moderate to heavy) as the independent 
variable. The overall MANOVA was significant, E(6,144) = 
2.74, p=.015. 
In contrast to the hypothesis, an examination of the 
means, as shown in Table 13, indicates that higher levels 
of substance use are associated with better concurrent 
functioning for depressives. Following this significant 
multivariate effect, the univariate comparisons showed a 
significant effect for social functioning, E(2,74)=5.56, 
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Table 15 
Mean Overall Functioning Scores as a Function of 
Concurrent Level of Substance Use Within Each Diagnostic 
Group* 
Time Period 
FI by FI** FII by FII** 
Level of Use 
Within Each 
Diagnostic Group N M SD N M SD 
Whole Sample 
None 100 4.8 2.6 93 3.6 2.6 
Low 89 3.7 2.2 92 3.3 2.4 
Severe 61 4.0 2.4 58 3.8 2.3 
Depressives 
None 30 4.6 2.9 29 3.2 2.6 
Low 33 3.0 2.0 33 3.0 2.4 
Severe 15 3.2 2.3 16 2.4 1. 3 
Other Nonpsychotics 
None 12 3.8 2.6 12 1.9 1. 7 
Low 13 3.5 2.1 13 2.5 2.5 
Severe 11 3.1 2.3 11 2.6 1.0 
Schizophrenics 
None 27 5.6 2.6 21 4.7 2.8 
Low 17 4.9 2.1 13 3.8 2.6 
Severe 11 5.7 1.9 16 5.6 2.3 
Other Psychotics 
None 31 4.7 2.4 31 3.9 2.6 
Low 26 4.0 2.3 33 3.7 2.4 
Severe 24 4.2 2.3 15 4.4 2.4 
* Note. Lower numbers represent better functioning. 
** FI = Follow-up I; FII = Follow-up II. 
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12=.006, work functioning, r_(2,74) = 3.34, J2=.041, and 
rehospitalization, r_(2,74)= 5.51, Q=.006. (The effect for 
work functioning was no longer significant after the 
application of the Bonferroni criterion of .017.) These 
significant univariate comparisons suggest that the 
depressives who used substances during the first follow-up 
period had better social functioning, and fewer 
rehospitalizations during the first follow-up. 
Symptoms- Depression. Psychosis, and Thought Disorder 
To test the hypothesis that substance use is 
associated with elevations in concurrent symptoms for 
depressives, a MANOVA was conducted with depression, 
psychosis, and thought disorder as the dependent 
variables, and level of substance use at follow-up I 
(none, mild, moderate to heavy) as the independent 
variable. The overall MANOVA was nonsignificant, 
indicating that there is no evidence that substance use is 
associated with poorer concurrent symptomatology for 
depressives. The means and standard deviations for this 
analysis are reported in Table 14. 
Overall Functioning- LKP Scale 
To test the concurrent relation between 
substance use at follow-up I and overall functioning at 
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follow-up I for the depressives, an ANOVA was conducted 
with the LKP as the dependent variable, and level of 
substance use (none, mild, moderate to heavy) as the 
independent variable. The ANOVA was significant (~ (2,75) 
= 3.74, p = .03). An analysis of the means and standard 
deviations, as shown in Table 15 indicates that, contrary 
to the predictions, higher levels of concurrent substance 
use were associated with better overall functioning for 
the nonpsychotic depressives at the first follow-up. This 
finding was no longer significant when the Bonferroni 
criterion was used. 
Analyses for the Other Nonpsychotic Sample 
Including: Work Functioning, Social Functioning, 
Rehospitalization; Depressive Symptoms, Psychosis, 
Thought Disorder; and Overall Outcome 
All of the analyses of the relationship between 
substance use at follow-up I and concurrent functioning 
and symptoms were nonsignif icant for the other 
nonpsychotics. That is, the MANOVA of the relation 
between substance use at follow-up I and work functioning, 
social functioning, and rehospitalization was 
nonsignificant; the MANO VA of the relation between 
substance use at follow-up I and depression, thought 
disorder, and psychosis was nonsignificant; and the ANOVA 
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of the relation between substance use at follow-up I and 
overall functioning was nonsignificant. Thus, there is no 
evidence to support the hypothesis that substance use at 
follow-up I is associated with concurrent detriments in 
functioning and symptoms for the other nonpsychotics. The 
means and standard deviations for these analyses are 
reported in Tables 13, 14, and 15, respectively. 
Analyses for the Schizophrenic Sample 
Work Functioning, Social Functioning, Rehospitalization 
To test the hypothesis that substance use is 
associated with poorer concurrent functioning for the 
schizophrenics, a MANOVA was conducted with the Strauss-
Carpenter indices of social functioning, work functioning, 
and rehospitalization at follow-up I as the dependent 
variables, and level of substance use at follow-up I 
(none, mild, heavy) as the independent variable. The 
overall MANOVA was nonsignificant, indicating that there 
is no evidence that substance use is associated with 
poorer concurrent functioning for the schizophrenics. The 
means and standard deviations for this analysis are 
reported in Table 13. 
Symptoms- Depression, Psychosis, Thought Disorder 
To test the hypothesis that substance use is 
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associated with poorer concurrent symptomatology for the 
schizophrenics, a MANOVA was conducted with psychosis, 
depression, and thought disorder at follow-up I as the 
dependent variables, and level of substance use at follow-
up I (none, mild, moderate to heavy) as the independent 
variable. The overall MANOVA was significant (E (6,94) = 
2.29, R = .04). This indicates that there were 
differences in the symptom picture for the schizophrenics 
based on differences in level of concurrent substance use 
at follow-up I. Following this significant multivariate 
finding, however, analyses of the univariate results for 
psychosis, depression, and thought disorder, as shown in 
Table 14, revealed no significant differences. However, as 
shown in Table 14. the direction of the means suggests 
that higher levels of substance use are associated with 
increased symptomatology. This suggests that while 
substance use is associated with a general elevation of 
psychopathological symptoms, the effect is not robust 
enough to be apparent when each of the three symptoms is 
examined separately. Furthermore, the overall MANOVA was 
no longer significant when the Bonferroni criterion was 
applied. 
Overall Outcome- LKP Scale 
To test the concurrent relation between substance use 
at follow-up I and overall functioning on the LKP scale at 
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follow-up I for the schizophrenics, an ANOVA was 
conducted. The ANOVA was not significant, f(2,52) = .67, 
p = .51, which suggests that substance use at the first 
follow-up was not significantly related to overall 
functioning in the first follow-up for the schizophrenics. 
The means and standard deviations for this analysis are 
shown in Table 15. 
Analyses for the Other Psychotic Sample 
Including: Work Functioning, Social Functioning, 
Rehospitalization; Depressive Symptoms, Psychosis, 
Thought Disorder; and Overall Outcome 
All of the analyses of the relation between substance 
use at follow-up I and concurrent functioning and symptoms 
for the other psychotics were nonsignificant. That is, 
the MANOVA of the relation between substance use at 
follow-up I and work functioning, social functioning, and 
rehospitalization was nonsignificant; the MANOVA of the 
relation between substance use at follow-up I and 
depression, psychosis and thought disorder was 
nonsignificant; and the ANOVA of the relation between 
substance use at follow-up I and concurrent overall 
outcome was nonsignificant. Thus, there was no evidence 
that substance use is related to concurrent detriments in 
functioning or symptoms for the other psychotics at the 
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first follow-up. The means and standard deviations for 
these analyses are reported in Tables 13, 14, and 15, 
respectively. 
The Impact of Substance Use at Follow-up II on 
Concurrent Functioning and Symptoms 
Analyses for the Whole Sample, Depressives, 
Other Nonpsychotics. Schizophrenics, and 
Other Psychotics 
Work Functioning, Social Functioning, Rehospitalization 
To test the hypothesis that substance use results in 
concurrent detriments in post-hospital adjustment for the 
sample as a whole at follow-up II, a MANOVA was conducted 
using social functioning, work functioning, and 
rehospitalizations at follow-up II as the dependent 
variables and level of substance use (none, mild, moderate 
to heavy) as the independent variable. The overall MANOVA 
was nonsignificant, which indicates that there is no 
overall concurrent relation between substance use and 
post-hospital functioning at follow-up II for the sample 
as a whole. 
Four separate multivariate analyses were also carried 
out within each of the diagnostic groups (depressives, 
other nonpsychotics, schizophrenics, other psychotics). 
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In each case, the Strauss-carpenter indices of social 
functioning, work functioning, and rehospitalization at 
follow-up II served as the dependent variables, and level 
of substance use at follow-up II (none, mild, moderate to 
heavy) served as the independent variable. All four of 
these multivariate analyses were nonsignificant. This 
suggests that, contrary to the predictions, within each of 
the diagnostic groups there was no significant concurrent 
relation between substance use at follow-up II and 
functioning at follow-up II. The means and standard 
deviations for these analyses are shown in Table 16. 
Symptoms- Depression. Psychosis, Thought Disorder 
To test the hypothesis that substance use at follow-
up II is associated with concurrent elevations in 
symptomatology at follow-up II, five separate MANOVAS were 
conducted, one of which included the whole sample, and one 
for each of the diagnostic groups (depressives, other 
nonpsychotics, schizophrenics, other psychotics). In each 
case the dependent variables consisted of the measures of 
depression, thought disorder, and psychosis at follow-up 
II. The independent measure was the level of substance 
use (none, mild, moderate to heavy) at follow-up II. Each 
of these multivariate analyses were nonsignificant. 
Therefore, the results did not support the hypothesis that 
substance use at follow-up II was associated with a 
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Table 16 
Mean Strauss-Carpenter Scores at Follow-up II CFII) as a 
Function of Concurrent Level of Substance Use Within 
Each Diagnostic Group 
Work Social Rehosp. 
FII FII FII 
Level of Use 
Within Each 
Diagnostic Group 
at Follow-up II N M SD M SD M SD 
Whole Sample 
None 93 2.7 1.6 3.1 1. 3 3.5 1.1 
Low 92 2.9 1.5 3.4 1. 0 3.7 .8 
Moderate 
severe 48 2.7 1.4 3.4 1.0 3.7 .5 
Depressives 
None 29 3.1 1.6 3.3 1.2 3.5 1.1 
Low 33 3.2 1.4 3.5 .9 3.8 .5 
Moderate 
Severe 16 3.3 1.1 3.4 1.2 3.9 . 3 
Other Nonpsychotics 
None 12 3.2 1.2 3.4 1. 2 3.9 .9 
Low 13 3.5 1.2 3.5 1.1 3.8 .8 
Moderate 
Severe 11 2.6 1. 3 3.4 .7 4.0 • 0 
Schizophrenics 
None 21 1.8 1.8 2.5 1. 5 3.2 1.4 
Low 13 2.4 1.6 3.2 1.1 3.7 . 6 
Moderate 
Severe 16 1.8 1.5 1.8 1.5 3.6 • 6 
Other Psychotics 
None 9 2.1 1. 6 2.7 1. 5 3.2 1.4 
Low 16 2.7 1.4 3.0 1.4 3.7 . 6 
Moderate 
Severe 5 1. 6 1.8 3.4 .5 3.5 .9 
Note. Higher scores represent better functioning. 
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concurrent worsening of symptoms in any of the diagnostic 
groups studied. The means and standard deviations for 
these analyses are reported in Table 17. 
overall Functioning- LKP Scale 
To test the concurrent relation between substance use 
at follow-up II and overall functioning on the LKP scale 
at follow-up II, five separate ANOVAS were conducted, one 
for the whole sample, and one for each of the diagnostic 
groups (depressives, other nonpsychotics, schizophrenics, 
and other psychotics) . In each case the dependent 
variable was the LKP scale of overall functioning, and the 
independent variable was substance use at follow-up II. 
Each of these analyses was nonsignificant. Therefore, the 
results did not support the hypothesis that substance use 
at follow-up II is associated with concomitant detriments 
in overall functioning at follow-up II. The means and 
standard deviations for these analyses are reported in 
Table 15. 
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Table 17 
Mean Symptom Scores at Follow-up II CFII) as a 
Function of Concurrent Level of Substance Use Within 
Each Diagnostic Group 
Depression Thought Dis. Psychosis 
FII FII FII 
Level of Use 
Within Each 
Diagnostic Group 
at Follow-up II N M SD M SD M SD 
Whole Sample 
None 75 3.2 1. 3 2.3 1.3 1. 3 .7 
Low 72 3.3 1. 2 2.2 1.2 1.4 .8 
Moderate 
Severe 49 3.7 1. 3 2.4 1. 3 1. 5 .7 
Depressives 
None 24 3.3 1.4 1. 9 1.2 1.1 . 3 
Low 24 3.7 1.2 2.0 1.1 1.5 .8 
Moderate 
Severe 12 3.4 1.5 1. 8 .6 1.3 .5 
Other Nonpsychotics 
None 9 2.7 1.4 1. 7 1.. 0 1.1 • 3 
Low 12 3.3 1.2 1. 6 1.. 2 1.3 .5 
Moderate 
Severe 11 3.6 1.3 2.1 1..4 1. 3 .5 
Schizophrenics 
None 19 2.9 1.3 3.2 1.. 4 1.6 .9 
Low 9 2.9 1.1 2.3 .9 1.8 1. 0 
Moderate 
Severe 13 3.7 1.5 3.3 1.0 1.8 .9 
Other Psychotics 
None 6 3.8 .6 2.5 1.5 1.5 .8 
Low 13 3.2 1.1 2.5 1.4 1.5 .8 
Moderate 
Severe 4 4.3 .6 2.5 1. 3 1.3 .5 
Note. Lower scores represent less SYJilptomatology. 
Substance Use and outcome: The Predictive 
Relation Between Substance Use at 
Index Hospitalization and Outcome at Follow-up I 
Analyses for the Whole Sample 
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Work Functioning, Social Functioning, Rehospitalization 
To test the hypothesis that substance use at the 
index hospitalization is associated with poorer 
functioning for the sample as a whole in the post-hospital 
period, an overall multivariate analysis of variance 
(MANOVA) was carried out using the Strauss-carpenter 
indices of social functioning, work functioning, and 
rehospitalization as the dependent variables and level of 
drug use (none, mild, moderate, heavy) as the independent 
variable. As expected the overall MANOVA using Wilk's 
criterion was significant, f (9,581.81) = 2.19, p = .02. 
Following this significant multivariate finding, an 
examination of the univariate results showed a significant 
effect for work functioning, r(3,241) = 2.71, p = .046, 
but not for social functioning or rehospitalizations. 
Based on the means, as shown in Table 18, this finding 
indicates that for the sample as a whole, substance use at 
the index hospitalization was specifically associated with 
poorer work functioning in the first follow-up. Using the 
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Table 18 
Mean Strauss-Carpenter Scores at Follow-up I (Fl) as a 
Function of Level of Substance Use at Index 
Hospitalization Within Each Diagnostic Group 
Work Social Rehosp. 
FI FI FI 
Level of Use 
Within Each 
Diagnostic Group 
at Index N M SD M SD M SD 
Whole Sample 
None 83 2.8 1. 5 3.0 1.4 3.6 .7 
Low 47 2.4 1. 5 3.3 1.3 3.3 1.3 
Moderate 53 2.4 1. 6 3.2 1.2 3.3 1.1 
Severe 62 2.1 1.8 3.2 1.3 3.3 1. 0 
Depressives 
None 32 3.0 1. 6 3.3 1.2 3.5 .8 
Low 14 3.1 1. 3 3.3 1.3 3.3 1. 0 
Moderate 14 2.2 1.8 3.4 1.3 3.0 1.5 
Severe 14 3.4 .9 3.7 .8 3.8 .4 
Other Nonpsychotics 
None 12 3.0 1.4 3.3 1.1 3.8 .6 
Low 7 1.6 1. 7 3.6 1.1 3.3 1.5 
Moderate 9 2.6 1. 6 3.3 1. 0 3.3 .7 
Severe 5 2.4 2.2 3.4 1. 3 3.2 1. 3 
Schizophrenics 
None 13 1. 7 1. 5 2.1 1.5 3.5 .8 
Low 12 2.0 1.5 2.8 1. 7 2.9 1. 7 
Moderate 12 2.2 1.6 3.1 1. 4 3.7 .5 
Severe 17 1.1 1. 7 2.6 1. 7 2.6 1.4 
Other Psychotics 
None 23 3.1 1.2 2.8 l. 5 3.7 .6 
Low 14 2.5 1.4 3.6 • 8 3.5 1.1 
Moderate 15 2.3 1. 6 3. :2 l.4 3.0 1.4 
Severe 20 2.3 1. 7 3.4 1.0 3.4 .9 
Note. Higher scores represent better functioning. 
117 
Bonferroni probability adjustment the multivariate effect 
remained significant, but the univariate effect was no 
longer significant. 
Symptoms- Depression, Psychosis, Thought Disorder 
To test the hypothesis that substance use at the 
index hospitalization is associated with elevations in 
psychopathology for the sample as a whole in the post-
hospi tal period, an overall multivariate analysis of 
variance (MANOVA) was carried out using degree of 
psychosis, thought disorder, and depression as the 
dependent variables and level of drug use (none, mild, 
moderate, heavy) as the independent variable. As expected 
the overall MANOVA using Wilk' s criterion was significant, 
~ (9,550.18) = 2.52, p = .008. 
Following the multivariate analysis, the univariate 
comparisons for each of symptoms, as shown in Table 19, 
were examined in order to determine which of these 
symptoms were responsible for the overall significant 
effect. These comparisons revealed that higher levels of 
substance use at time period one were significantly 
associated with higher levels of thought disorder at 
follow-up I, ~(3, 228) = 4.04, p = .ooa, and with 
increased depression at follow-up I, ~(3,228) = 2.52, p = 
• 05) • The effect for depression was not significant 
using the Bonferroni criterion. 
118 
Table 19 
Mean Symptom Scores at Follow-up I CFI) as a Function of 
Level of Substance Use at Index Hospitalization Within 
Each Diagnostic Group* 
Depression Thought Dis. Psychosis 
FI FI FI 
Level of Use 
Within Each 
Diagnostic Group 
at Index N M SD M SD M SD 
Whole Sample 
None 76 3.8 1.2 2.4 1.1 1.6 .8 
Low 48 3.4 1.4 2.4 1.1 1.8 .9 
Moderate 47 3.4 1.3 2.5 1.1 1. 6 .8 
Severe 48 3.9 1.2 3.0 1.3 1.9 .9 
Depressives 
None 32 4.1 1.1 2.1 .9 1.4 .7 
Low 14 3.9 1. 0 2.3 1.1 1.9 .9 
Moderate 12 3.7 1. 0 2.4 1.0 1.3 .5 
Severe 10 3.8 1.1 2.3 1. 0 1.5 .7 
Other Nonpsychotics 
None 12 3.6 1.2 2.17 • 6 1.2 .4 
Low 7 3.4 1.8 2.3 1.0 1. 7 1. 0 
Moderate 9 3.4 1.3 3.3 1.1 1.6 .7 
Severe 7 4.1 .7 3.0 1.3 1.6 1. 0 
Schizophrenics 
None 12 3.4 1. 3 3.0 1.2 2.2 .9 
Low 12 3.2 1.5 3.0 1.3 1.8 1.0 
Moderate 12 2.9 1.4 2.2 .7 1.8 .9 
Severe 16 3.6 1.4 3.6 1.4 2.1 .9 
Other Psychotics 
None 6 3.9 .9 1.5 .5 1.8 1. 0 
Low 6 3.0 .8 2.2 1. 2 1.8 1. 0 
Moderate 7 2.9 1. 5 2.4 1. 0 1.9 .9 
Severe 11 4.2 .a 3.0 1.4 2.3 .a 
Note. Lower scores represent less symptomatology. 
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Overall functioning CLKP) 
To test the predictive relation between substance use 
at the acute phase and overall functioning at follow-up I 
for the sample as a whole, an ANOVA was conducted with the 
LKP as the dependent variable, and level of substance use 
(none, mild, moderate, heavy) as the independent variable. 
The analysis was nonsignificant which indicates that, 
contrary to the prediction, there is no evidence of a 
uniform association between substance use at index 
hospitalization and subsequent overall functioning at 
follow-up I for the sample as a whole. The means and 
standard deviations for this analysis are shown in Table 
20. 
Analyses for the Depressive Sample Including: 
Work Functioning, Social Functioning. and 
Rehospitalization; Depressive Symptoms. Thought Disorder 
and Psychosis; and Overall Functioning 
All of the analyses of the predictive relation 
between substance use at the index hospitalization and 
subsequent symptoms and functioning at fol low-up I for the 
depressives were nonsignificant. That is, the MANOVA of 
the relation between substance use at the index 
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Table 20 
Mean Overall Functioning Scores as Predicted by Earlier 
Level of Substance Use Within Each Diagnostic Group 
Time Period 
FI by TpI* FII by FI** FII by TPI 
Level of Use 
Within Each 
Diagnostic Group N M SD N M SD N M SD 
Whole Sample 
None 84 3.8 2.4 98 4.1 2.6 82 3.1 2.3 
Low 50 4.4 2.5 87 3.0 2.2 49 3.4 2.4 
Moderate 54 4.1 2.5 53 3.6 2.5 
Severe 63 4.7 2.4 61 3.5 2.6 63 4.3 2.8 
Depressives 
None 34 3.6 2.5 30 3.9 2.5 34 3.0 2.2 
Low 14 4.1 2.7 33 2.5 2.0 14 3.3 2.6 
Moderate 15 4.2 3.0 15 2.8 2.2 
Severe 15 2.9 1.8 15 2.2 1.9 15 2.7 2.4 
Other Nonpsychotics 
None 12 3.0 1. 7 12 2.3 1. 9 12 2.0 .9 
Low 8 5.0 2.7 13 2.4 1. 9 8 2.4 2.3 
Moderate 9 2.7 1.9 9 2.3 2.2 
Severe 7 3.4 2.9 11 2.4 2.1 7 3.0 2.3 
Schizophrenics 
None 13 5.0 2.7 25 5.2 2.6 12 4.8 2.6 
Low 12 5.1 2.4 16 4.2 2.5 11 3.9 2.6 
Moderate 13 4.5 2.3 12 4.1 2.2 
Severe 17 6.6 1.4 11 5.2 2.8 17 6.1 2.7 
Other Psychotics 
None 25 4.0 2.3 31 4.2 2.5 24 3.0 2.3 
Low 16 3.7 2.3 25 3.3 2.3 16 3.6 2.2 
Moderate 17 4.6 2.6 17 4.6 2.6 
Severe 24 4.9 2.2 24 4.0 2.6 24 4.4 2.6 
Note. *TPI= Index Hospitalization 
**FI= Follow-up I 
**FII= Follow-up II 
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hospitalization and work functioning, social functioning, 
and rehospitalization at follow-up I was nonsignificant; 
the MANOVA of the relation between substance use at the 
index hospitalization and depressive SYIDptoms, psychosis, 
and thought disorder was nonsignificant; and the ANOVA of 
the relation between substance use at the index 
hospitalization and overall functioning at follow-up was 
nonsignificant. 
these analyses 
respectively) . 
(The means and standard deviations for 
are shown in Tables 18, 19, and 20, 
Thus, there was no support for the 
hypotheses that substance use at the index hospitalization 
is associated with poorer functioning, and exacerbations 
in SYIDptomatology at follow-up I for the depressives. 
Analyses for the Other Nonpsychotic Sample 
Including: Work Functioning, Social Functioning, 
Rehospitalization; Depressive Symptoms, Thought Disorder 
and Psychosis; and Overall Functioning 
All of the analyses of the predictive relation 
between substance use at the index hospitalization and 
subsequent SYIDptoms and functioning at follow-up I for the 
other nonpsychotics were nonsignificant. That is, the 
MANOVA of the relation between substance use at the index 
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hospitalization and work functioning, social functioning, 
and rehospitalization at follow-up I was nonsignificant; 
the MANOVA of the relation between substance use at the 
index hospitalization and depressive SYIDptoms, psychosis, 
and thought disorder was nonsignificant; and the ANOVA of 
the relation between substance use at the index 
hospitalization and overall functioning at follow-up was 
nonsignificant. (The means and standard deviations for 
these analyses are shown in Tables 18, 19, and 20, 
respectively) . Thus, there was no support for the 
hypotheses that substance use at the index hospitalization 
is associated with poorer functioning, and exacerbations 
in SYIDptomatology at follow-up I for the other 
nonpsychotics. 
Analyses for the Schizophrenic Sample 
Work Functioning, Social Functioning, Rehospitalization 
To test the predictive relation between substance use 
at the index hospitalization and post-hospital functioning 
for the schizophrenic patients, a MANOVA was conducted 
with the Strauss-Carpenter indices of social functioning, 
work functioning, and rehospitalization at follow-up I as 
the dependent variables and level of substance use (none, 
mild, moderate, heavy) as the independent variable. The 
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MANOVA was nonsignificant, which indicates that there was 
no evidence that substance use at the acute phase predicts 
poorer functioning at follow-up I for the schizophrenics. 
The means and standard deviations for this analysis are 
reported in Table 18. 
Symptoms- Depression, Psychosis. Thought Disorder 
To test the predictive relation between substance use 
at the index hospitalization and post-hospital 
symptomatology for the schizophrenic patients, a MANOVA 
was conducted with depression, thought disorder, and 
psychosis at follow-up I as the dependent variables and 
level of substance use (none, mild, moderate, heavy) as 
the independent variable. The MANOVA was nonsignificant 
which indicates that, contrary to the predictions, for the 
schizophrenic patients, substance use at the index 
hospitalization was not predictive of elevations in 
symptomatology at the first follow-up. 
Overall Functioning 
To test the predictive relation between substance use 
at the acute phase and overall functioning at follow-up I 
for the schizophrenics, an ANOVA was conducted with the 
LKP as the dependent variable, and level of substance use 
(none, mild, moderate, heavy) as the independent variable. 
The analysis was significant, E(J,51) = 2.74, R =.05. An 
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examination of the means, as shown in Table 20 indicates 
that, consistent with the hypothesis, substance use at the 
index hospitalization was associated with poorer overall 
functioning for the schizophrenics in the post-hospital 
period at the first follow-up. This result is no longer 
significant following the application of the Bonferroni 
criterion. 
Analyses for the Other Psychotic Sample 
Work Functioning, Social Functioning, Rehospitalization 
To test the predictive relation between substance use 
at the index hospitalization and post-hospital functioning 
for the other psychotic patients, a MANOVA was conducted 
with the Strauss-Carpenter indices of social functioning, 
work functioning, and rehospitalization as the dependent 
variables and level of substance use (none, mild, 
moderate, heavy) as the independent variable. The MANOVA 
was significant using a .05 criterion for significance, 
~(9,177.81)= 2.02, ~ = .04, but was not significant using 
the Bonferroni criterion of .017. 
Following this multivariate finding, an examination 
of the univariate results, as shown in Table 18, revealed 
no significant effects. Thus, there was no clear support 
for the hypothesis that higher levels of substance use at 
the index hospitalization are associated with poorer 
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functioning at follow-up I for the other psychotics. 
Symptoms- Depression. Psychosis, Thought Disorder 
To test the predictive relation between substance use 
at the index hospitalization and post-hospital 
symptomatology for the other psychotic patients, a MANOVA 
was conducted with depression, psychosis, and thought 
disorder as the dependent variables and level of substance 
use (none, mild, moderate, heavy) as the independent 
variable. The MANOVA was nonsignificant, which indicates 
that for the other psychotic patients, there was no 
evidence that substance use at the index hospitalization 
was predictive of elevations in symptomatology at the 
first follow-up. The means and standard deviations for 
this analysis are reported in Table 19. 
Overall Functioning 
To test the predictive relation between substance use 
at the acute phase and overall functioning at follow-up I 
for the other psychotics, an ANOVA was conducted with the 
LKP as the dependent variable, and level of substance use 
(none, mild, moderate, heavy) as the independent variable. 
The analysis was nonsignificant which indicates that, 
contrary to the prediction, there is no evidence of an 
association between substance use at index hospitalization 
and subsequent overall functioning at follow-up I for the 
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other psychotics. The means and standard deviations for 
this analysis are reported in Table 20. 
Substance Use and Outcome: The Predictive Relation 
Between Substance Use at Follow-up I and 
outcome at Follow-up II 
Analyses for the Whole Sample 
Work Functioning, Social Functioning, Rehospitalization 
As a test of the hypothesis that there is a 
predictive relation between substance use at follow-up I 
and subsequent functioning at follow-up II for the sample 
as a whole, a MANOVA was conducted with the Strauss-
Carpenter measures of social functioning, work 
functioning, and rehospitalization at follow-up II as the 
dependent variables and level of substance use (none, 
mild, moderate to heavy) at follow-up I as the independent 
variable. The MANOVA was nonsignificant, which indicates 
that there is no evidence of a relation between substance 
use at follow-up I and functioning at follow-up II for the 
sample as a whole. The means and standard deviations 
relevant to this analysis are presented in Table 21. 
Symptoms- Depression, Psychosis, Thought Disorder 
To test the hypothesis that there is a predictive 
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Table 21 
Mean Strauss-Carpenter Scores at Follow-up II (F!I) as a 
Function of Level of Substance Use at Follow-up I 
Within Each Diagnostic Group 
Work 
FII 
Social 
FII 
Rehosp. 
FII 
Level of Use 
Within Each 
Diagnostic Group N M SD M SD M SD 
Whole Sample 
None 97 2.5 1. 7 3.1 1. 3 3.5 1. 0 
Low 87 3.1 1. 2 3.4 1. 0 3.8 . 6 
Moderate 
Severe 61 2.7 1. 5 3.3 1.1 3.7 .8 
Depressives 
None 30 2.9 1. 7 3.0 1.4 3.5 1.1 
Low 33 3.4 1.1 3.6 • 6 3.8 .4 
Moderate 
Severe 15 3.4 1.2 3.7 .8 4.0 .o 
Other Nonpsychotics 
None 12 3.3 1.2 3.5 1.7 3.9 . 3 
Low 13 3.1 1.4 3.7 .6 3.8 .8 
Moderate 
Severe 11 3.0 1.1 3.1 1.1 4.0 .o 
Schizophrenics 
None 24 1.8 1. 7 2.7 1.4 3.3 1.2 
Low 16 1.3 2.5 3.2 1.4 3.8 .4 
Moderate 
Severe 11 1.6 1. 7 1.6 1. 7 3.1 1.3 
Other Psychotics 
None 12 1.8 1. 6 2.8 1.5 3.3 1.2 
Low 11 3.0 1. 0 2.8 1.5 3.5 .8 
Moderate 
Severe 8 2.3 1. 7 3.1 .6 3.6 .5 
Note. Higher scores represent better functioning. 
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relation between substance use and subsequent elevations 
in symptomatology for the sample as a whole, a MANOVA was 
conducted with depression, psychosis, and thought disorder 
at follow-up II as the dependent variables and level of 
substance use (none, mild, moderate to heavy) at follow-up 
I as the independent variable. The MANOVA was 
nonsignificant. This indicates that, contrary to the 
prediction, there is no evidence that substance use at 
follow-up I is associated with poorer functioning in the 
realm of symptomatology at follow-up II. The means and 
standard deviations for this analysis are reported in 
Table 22. 
Overall Functioning 
To test the predictive relation between substance use 
at follow-up I and overall functioning at f ollpw-up II for 
the sample as a whole, an ANOVA was conducted with the LKP 
as the dependent variable, and level of substance use 
(none, mild, moderate, heavy) as the independent variable. 
The analysis was significant, E(2,243) = 4.37, Q =.01. An 
examination of the means, as shown in Table 20, indicates 
that substance use at follow-up I was associated with 
better overall functioning for the sample as a whole in 
the post-hospital period at the second follow-up. 
However, the results were not unifonn within the total 
sample. The significant result for the whole sample was 
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Table 22 
Mean Symptom Scores at Follow-up II CFII) as a 
Function of Level of Substance Use at Follow-up I Within 
Each Diagnostic Group 
Depression Thought Dis. Psychosis 
FII FII FII 
Level of Use 
Within Each 
Diagnostic Group N M SD M SD M SD 
Whole Sample 
None 71 3.3 1.4 2.3 1.3 1.3 • 6 
Low 65 3.4 1.2 2.3 l. 2 1.4 .8 
Moderate 
Severe 48 3.4 1.3 2.3 1.4 1.5 .8 
Depressives 
None 23 3.8 1.2 2.2 1.3 1.3 .5 
Low 26 3.6 1.3 1.8 1.0 1.3 .7 
Moderate 
Severe 11 2.8 1. 3 1.5 .5 1.3 .6 
Other Nonpsychotics 
None 10 3.1 1.3 1.5 1.0 1.1 .3 
Low 12 3.1 1.1 2.1 1.5 1.3 .5 
Moderate 
Severe 10 3.7 1.5 1. 7 l.1 1.2 .4 
Schizophrenics 
None 21 3.0 1.4 3.1 1.3 1.5 .8 
Low 12 3.5 1.1 2.9 .8 2.0 1.0 
Moderate 
severe 9 3.2 1.5 3.8 1.5 1.9 1.1 
Other Psychotics 
None 8 3.1 .9 2.3 1.0 1.4 .7 
Low 7 3.6 1.1 2.7 1. 7 1.3 .8 
Moderate 
Severe 8 3.9 • 8 2. 5 1. 4 1.6 .9 
Note. Lower scores represent less symptomatology. 
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largely due to one particular diagnostic group, the 
depressives, as subsequent analyses will show. 
Analyses for the Nonpsychotic Depressive Sample 
Work Functioning, Social Functioning, Rehospitalization 
As another test of the hypothesis that there is a 
predictive relation between substance use and subsequent 
functioning for the depressed patients, a MANOVA was 
conducted with the Strauss-Carpenter measures of social 
functioning, work functioning, and rehospitalization at 
follow-up II as the dependent variables and level of 
substance use (none, mild, moderate to heavy) at follow-up 
I as the independent variable. The MANOVA was 
nonsignif icant, which indicates that there was no overall 
multivariate effect of substance abuse at follow-up I on 
subsequent functioning at follow-up II for the 
depressives. 
Symptoms- Psychosis. Depression, Thought Disorder 
To test of the hypothesis that there is a predictive 
relation between substance use and subsequent elevations 
in symptomatology for the depressed patients, a MANOVA was 
conducted with depression, psychosis, and thought disorder 
at follow-up II as the dependent variables and level of 
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substance use (none, mild, moderate to heavy) at follow-up 
I as the independent variable. The MANOVA was 
nonsignificant. This indicates that there was no evidence 
to support the hypothesis that substance use at follow-up 
I is associated with increased SYll\ptomatology at follow-up 
II for the depressives. The means and standard deviations 
for this analysis are reported in Table 22. 
Overall Functioning 
To test the predictive relation between substance use 
at follow-up I and overall functioning at follow-up II for 
the depressives, an ANOVA was conducted with the LKP as 
the dependent variable, and level of substance use (none, 
mild, moderate to heavy) as the independent variable. The 
analysis was significant, f.(2,76) = 4.10, J2 =.02. An 
examination of the means, as shown in Table 20, indicates 
that, contrary to the hypothesis, substance use at follow-
up I was associated with better overall functioning for 
the depressives in the post-hospital period at the second 
follow-up. This effect was no longer significant 
following the application of the Bonferroni criterion. 
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Analyses for the Other Nonpsychotic Sample 
Including: Work Functioning, Social Functioning, and 
Rehospitalization; Depressive Symptoms, Thought Disorder 
and Psychosis; and Overall Functioning 
All of the analyses of the predictive relation 
between substance use at the first follow-up and 
subsequent symptoms and functioning at the second follow-
up for the other nonpsychotics were nonsignif icant. That 
is, the MANOVA of the relation between substance use at 
follow-up I and work functioning, social functioning, and 
rehospitalization at follow-up II was nonsignificant; the 
MANOVA of the relation between substance use at follow-up 
I and depressive symptoms, psychosis, and thought disorder 
at follow-up II was nonsignificant; and the ANOVA of the 
relation between substance use at follow-up I and overall 
functioning at follow-up II was nonsignificant. (The 
means and standard deviations for these analyses are shown 
in Tables 21, 22, and 20, respectively). Thus, there was 
no support for the hypotheses that substance use at the 
first follow-up is associated with poorer functioning, and 
exacerbations in symptomatology at follow-up II for the 
other nonpsychotics. 
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Analyses for the Schizophrenic Sample Including: 
Work Functioning, Social Functioning, and 
Rehospitalization; Depressive Symptoms, Thought Disorder 
and Psychosis; and Overall Functioning 
All 
between 
of the analyses 
substance use at 
of the predictive relation 
the first follow-up and 
subsequent symptoms and functioning at the second follow-
up for the schizophrenics were nonsignificant. That is, 
the MANOVA of the relation between substance use at 
follow-up I and work functioning, social functioning, and 
rehospitalization at follow-up II was nonsignificant; the 
MANOVA of the relation between substance use at follow-up 
I and depressive symptoms, psychosis, and thought disorder 
at follow-up II was nonsignificant; and the ANOVA of the 
relation between substance use at follow-up I and overall 
functioning at follow-up II was nonsignificant. (The 
means and standard deviations for these analyses are shown 
in Tables 21, 22, and 20, respectively). Thus, there was 
no support for the hypotheses that substance use at the 
first follow-up is associated with poorer functioning, and 
exacerbations in symptomatology at follow-up II for the 
schizophrenics. 
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Analyses for the Other Psychotic Sample Including: 
Work Functioning, Social Functioning. and 
Rehospitalization;Depressive Symptoms, Thought Disorder 
and Psychosis;and overall Functioning 
All of the analyses of the predictive relation 
between substance use at the first follow-up and 
subsequent symptoms and functioning at the second follow-
up for the other psychotics were nonsignificant. That is, 
the MANOVA of the relation between substance use at 
follow-up I and work functioning, social functioning, and 
rehospitalization at follow-up II was nonsignificant; the 
MANOVA of the relation between substance use at follow-up 
I and depressive symptoms, psychosis, and thought disorder 
at follow-up II was nonsignificant; and the ANOVA of the 
relation between substance use at follow-up I and overall 
functioning at follow-up II was nonsignificant. (The 
means and standard deviations for these analyses are shown 
in Tables 21, 22, and 20, respectively). Thus, there was 
no support for the hypotheses that substance use at the 
first follow-up is associated with poorer functioning, and 
exacerbations in symptomatology at follow-up II for the 
other psychotics. 
Substance Use and Outcome: The Predictive Relation 
Between Substance Use at 
Index Hospitalization and Outcome at Follow-up II 
Analyses for the Whole Sample 
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Work Functioning, Social Functioning, Rehospitalization 
To test the predictive relation between substance use 
at index hospitalization and functioning at follow-up two 
for the whole sample, a MANO VA was conducted with the 
Strauss Carpenter measures of work functioning, social 
functioning, and rehospitalization as the dependent 
measures, and level of drug use (none, mild, moderate, 
heavy) as the independent variable. As predicted, the 
overall MANOVA was significant, E(9 1 584.25) = 1.98, R = 
.04. This effect is not significant, however, using the 
Bonferroni criterion. 
Following this significant multivariate finding, the 
univariate results indicated a significant effect for 
employment, ~(3,243) = 4.85, R = .003. An examination of 
the means, as shown in Table 23, suggests that drug use at 
the index hospitalization is specifically associated with 
impairments in work functioning at follow-up II. 
Symptoms 
To test the hypothesis that there is a predictive 
relation between substance use at index hospitalization 
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Table 23 
Mean Strauss-Carpenter Scores at Follow-up II (FII) as a 
Function of Level of Substance Use at Index 
Hospitalization Within Each Diagnostic Group 
Work Social Rehosp. 
FII Fil FII 
Level of Use 
Within Each 
Diagnostic Group 
at Index N M SD M SD M SD 
Whole Sample 
None 82 3.1 1.4 3.2 1.1 3.7 .7 
Low 49 3.0 1.4 3.3 1.3 3.7 .9 
Moderate 53 2.7 1.5 3.2 1.0 3.6 .8 
Severe 62 2.2 1. 7 3.3 1.2 3.4 1.1 
Depressives 
None 34 3.3 1.4 3.3 1.0 3.7 .8 
Low 14 3.0 1. 7 3.2 1.5 3.7 1.1 
Moderate 15 2.9 1.5 3.3 1.1 3.7 . 6 
Severe 15 3.5 1.1 3.9 .3 3.8 .6 
Other Nonpsychotics 
None 12 3.8 . 6 3.5 .5 4.0 .o 
Low 8 3.0 1.2 3.4 1.4 4.0 .o 
Moderate 9 2.7 1. 6 3.6 .7 3.7 1. 0 
Severe 7 2.6 1. 3 3.3 1.5 3.9 .4 
Schizophrenics 
None 12 1.8 1.5 2.9 1.5 3.9 .3 
Low 11 2.5 1.4 3.2 1.6 3.6 .7 
Moderate 12 2.8 1. 6 2 .8 1.2 3.6 .5 
Severe 16 1.0 1. 5 2.6 1.4 2.8 1.5 
Other Psychotics 
None 6 3.5 .5 2.2 1. 7 3.3 1. 0 
Low 6 3.0 .9 3.0 1. 7 3.7 .5 
Moderate 7 1. 7 1. 6 2.7 1. 3 3.1 1.6 
Severe 12 1.8 1. 6 3.3 .9 3.6 .5 
Note. Higher scores represent better functioning. 
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and subsequent elevations in symptomatology at follow-up 
II for the sample as a whole, a MANOVA was conducted with 
depression, psychosis, and thought disorder at follow-up 
II as the dependent variables and level of substance use 
(none, mild, moderate to heavy) at follow-up I as the 
independent variable. The MANOVA was nonsignificant. This 
indicates that the data did not support the hypothesis 
that substance use at index hospitalization is associated 
with exacerbations in symptoms at follow-up II for the 
sample as a whole. The means and standard deviations for 
this analysis are shown in Table 24. 
Overall Outcome 
To test the predictive relation between substance use 
at the index hospitalization and overall functioning at 
follow-up II for the sample as a whole, an ANOVA was 
conducted with the LKP as the dependent variable, and 
level of substance use (none, mild, moderate, heavy) as 
the independent variable. The analysis was significant, 
f.(3,243) = 2.79, 12 = .04. An examination of the means, as 
shown in Table 20, indicates that, consistent with the 
predictions, substance use at the index hospitalization 
was predictive of subsequent detriments in overall 
functioning in the post-hospital period at the second 
follow-up for the sample as a whole. However, this 
finding does not reach significance according to the 
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Table 24 
Mean Symptom Scores at Follow-up II (FII) as a Function of 
Level of Substance Use at Index Hospitalization Within 
Each Diagnostic Group 
Depression Thought Dis. Psychosis 
FII FII FII 
Level of Use 
Within Each 
Diagnostic Group 
at Index N M SD M SD M SD 
Whole Sample 
None 65 3.4 1.3 2.3 1.2 1. 3 • 6 
Low 41 3.5 1.2 2.3 1.2 1.3 .7 
Moderate 43 3.1 1.4 2.1 1.1 1.5 .8 
Severe 49 3.4 1.2 2.5 1.6 1. 6 .8 
Depressives 
None 28 3.4 1.5 2.1 1.1 1.2 .5 
Low 11 3.8 1.1 2.0 1.1 1.4 .8 
Moderate 10 3.5 1. 6 1.6 1.0 1.3 .7 
Severe 11 3.6 • 9 1.7 1.2 1.4 .7 
Other Nonpsychotics 
None 10 3.6 1.1 1.6 1.1 1.2 .4 
Low 7 3.7 1. 4 2.0 1. 7 1.1 .4 
Moderate 9 2.7 1.4 2.0 1. 3 1.3 .5 
Severe 6 2.9 1.4 1.5 .5 1.2 .4 
Schizophrenics 
None 10 3.6 1. 3 3 .1 1. 4 2.0 .9 
Low 10 3.1 1.4 3.1 1. 2 1.4 .7 
Moderate 10 3.1 1.2 2.7 .9 1.5 .9 
Severe 12 3.1 1.5 3.8 1. 4 1.9 1.0 
Other Psychotics 
None 4 3.1 1.4 1. 8 1. 0 1.0 0.0 
Low 4 3.2 .6 2.0 . 8 1.5 1. 0 
Moderate 4 3.4 1.1 2.0 • 8 1.8 1.0 
Severe 11 3.9 .a 3.1 1. 6 1.5 .8 
Note. Lower scores represent less symptomatology. 
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Bonferroni criterion. The results of this analysis were 
not uniform and differed according to diagnosis. As will 
be seen in the subsequent analyses, the results were 
stronger for the nondepressive patients. 
Analyses for the Nonpsychotic Depressive Sample 
For the depressed patients, all of the analyses of 
the relation between substance use at the index 
hospitalization and outcome at follow-up II were 
nonsignificant. That is, the MANOVA of the relation 
between substance use and subsequent social functioning, 
work functioning, and rehospitalizations at follow-up II 
was nonsignificant; the MANOVA of the relation between 
substance use at the index hospitalization and subsequent 
symptomatology at follow-up II was nonsignificant; and the 
ANOVA of the relation between substance use at the index 
hospitalization and overall functioning at follow-up II 
was nonsignificant. Therefore, there was no support for 
the hypothesis that substance use at the index 
hospitalization would predict poorer outcome at the second 
follow-up for the depressives. Means and standard 
deviations for these analyses are reported in Tables 20, 
23, and 24. 
Analyses for the Other Nonpsychotic Sample 
Similarly, for the other nonpsychotic patients, all 
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of the analyses of the relation between substance use at the 
index hospitalization and outcome at the second follow-up were 
nonsignificant. That is, the MANOVA of the relation between 
substance use and subsequent social functioning, work 
functioning, and rehospitalizations at the second follow-up 
was nonsignificant; the MANOVA of the relation between 
substance use at the index hospitalization and symptomatology 
at the second follow-up was nonsignif icant; and the ANOVA of 
the relation between substance use at the index 
hospitalization and overall functioning at the second follow-
up was nonsignificant. Therefore, there were not sufficient 
differences between the groups to support the hypothesis that 
substance use at index predicts poorer outcome at the second 
follow-up for the other nonpsychotics. The means and standard 
deviations for these analyses are shown in Tables 20, 23, and 
24. 
Analyses for the Schizophrenic Sample 
Work Functioning. Social Functioning. Rehospitalization 
To test the predictive relation between substance use at 
index and functioning at follow-up II for the schizophrenics, 
a MANOVA was conducted with the Strauss Carpenter measures of 
work functioning, social functioning, and rehospitalization as 
the dependent measures, and level of drug use (none, mild, 
moderate, heavy) as the independent variable. The MANOVA 
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was significant, E(9,109.67) = 2.09 R=.036, according to 
the standard . 05 criterion. This finding is not, however, 
significant according to the Bonferroni criterion of . 017. 
Following this multivariate finding, an examination 
of the univariate results indicated a significant effect 
for employment, E(3, 47) = 3. 61, R=· 02, and for 
rehospitalizations, E(3,47)=3.96, R=.013. An examination 
of the means, as shown in Table 23, suggests that drug use 
at the index hospitalization is specifically associated 
with impairments in work functioning and increased 
rehospitalization at follow-up II for the schizophrenics. 
Depressive Symptoms. Psychosis. Thought Disorder 
To test of the hypothesis that there is a predictive 
relation between substance use at index hospitalization 
and subsequent elevations in symptomatology at follow-up 
II for the schizophrenics, a MANOVA was conducted with 
depression, psychosis, and thought disorder at follow-up 
II as the dependent variables and level of substance use 
(none, mild, moderate to heavy) at follow-up I as the 
independent variable. The MANOVA was nonsignif icant. This 
indicates that, contrary to the prediction, there was no 
evidence that substance use at the index hospitalization 
is associated with exacerbations in syxiptomatology at 
follow-up II for the schizophrenics. The means and 
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standard deviations for this analysis are shown in Table 
24. 
Overall Functioning 
To test the predictive relation between substance use 
at the index hospitalization and overall functioning at 
follow-up II for the schizophrenics, an ANOVA was 
conducted with the LKP as the dependent variable, and 
level of substance use (none, mild, moderate, heavy) as 
the independent variable. The analysis was nonsignificant. 
This indicates that there was not sufficient evidence to 
establish an association between substance use at the 
index hospitalization and subsequent overall functioning 
at follow-up II for the schizophrenics. The means and 
standard deviations for this analysis are shown in Table 
20. 
Analyses for the Other Psychotic Sample 
Including: Work Functioning. Social Functioning, 
Rehospitalization; Depressive Symptoms, Psychosis, Thought 
Disorder; Overall Outcome 
For the other psychotic patients, all of the analyses 
of the relation between substance use at the index 
hospitalization and outcome at follow-up II were 
nonsignificant. 
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That is, the MANOVA of the relation 
between substance use and subsequent social functioning, 
work functioning, and rehospitalizations at follow-up II 
was nonsignificant; the MANOVA of the relation between 
substance use at the index hospitalization and subsequent 
symptomatology at follow-up II was nonsignificant; and the 
ANOVA of the relation between substance use at the index 
hospitalization and overall functioning at follow-up II 
was nonsignificant. Therefore, there was no support for 
the hypothesis that substance use at the index 
hospitalization would predict poorer outcome at the second 
follow-up for the other psychotics. Means and standard 
deviations for these analyses are reported in Tables 23, 
24, and 20, respectively. 
Potential Covariates: Differences in Gender and 
Premorbid Functioning at the Acute Phase 
Gender 
Previous analyses, reported in Chapter IV indicated 
that at the acute phase, for the sample as a whole, there 
were gender differences between substance users and 
nonusers, with users being predominantly male. This 
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finding held for the psychotic groups (schizophrenics and 
other psychotics), but not for the nonpsychotic groups 
(depressives and other nonpsychotics) . 
Premorbid Functioning 
To address the hypothesis that at the acute phase, 
substance users within each diagnostic group have poorer 
premorbid functioning than nonusers, a series of five t-
tests were conducted 
within each of the 
(for the sample as 
diagnostic groups) 
a whole, 
in which 
and 
the 
relationship between premorbid functioning and substance 
use was explored. Premorbid functioning, as assessed by 
the Zigler-Phillips Scale, was the dependent variable and 
substance use at the index hospital (yes, no) was the 
independent variable. Consistent with the prediction, for 
the sample as a whole, substance use was associated with 
worse premorbid functioning, t(267) = -2.65, R=.009. There 
were no significant differences between users and nonusers 
in premorbid functioning within any of the diagnostic 
groups, except for the nonpsychotic depressives. For the 
depressives, consistent with the prediction, the substance 
users had better premorbid functioning than the nonusers, 
t(74) = -2.50, R=.015. The means and standard deviations 
for these analyses are presented in Table 25. 
The relationship between substance use and premorbid 
functioning (within each of the diagnostic groups, and for 
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Table 25 
Mean Premorbid Functioning Scores for Substance Users 
Versus Nonusers at Index Hospitalization 
Substance Use 
N M 
Whole Sample 
Substance User 165 1.47 
Nonuser 82 1.29 
Depressives 
Substance User 45 1.29 
Nonuser 32 1.06 
Other Nonpsychotics 
Substance User 21 1.67 
Nonuser 13 1. 38 
Schizophrenics 
Substance User 44 1.59 
Nonuser 14 1.64 
Other Psychotics 
Substance User 55 1.44 
Nonuser 23 1.35 
SD 
.55 
.46 
.46 
.25 
.48 
.51 
.50 
.50 
.50 
.49 
Note. Lower scores represent better premorbid functioning 
as assessed by the Zigler-Phillips Scale. 
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the whole sample) was also explored separately for males 
and females. For the male patients, there were no 
significant differences in premorbid functioning as a 
function of substance use within any of the diagnostic 
groups. The means and standard deviations for the 
analyses of the male patients are presented in Table 26. 
For the female depressives, the nonusers had significantly 
better premorbid adjustment than the users, .t ( 51) = -2. 48, 
p = .017. There were no other significant differences in 
premorbid adjustment as a function of substance use for 
the female patients. The means and standard deviations 
for the analyses of the female patients are presented in 
Table 27. 
More detailed descriptions of the data regarding each 
of the outcome measures as a function of substance use and 
gender and premorbid functioning are presented in the 
appendix. 
The Role of Covariates in the Concurrent Relation 
Between Substance Use and 
outcome at Follow-up I 
Analyses for the Whole Sample 
Work Functioning, Social Functioning, Rehospitalization 
In light of the fact that a MANOVA had shown that 
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Table 26 
Mean Premorbid Functioning Scores for Male Substance Users 
Versus Male Nonusers at Index Hospitalization 
Substance Use 
N M SD 
Whole Sample 
Substance User 99 1.56 .50 
Nonuser 26 1.42 .50 
Depressives 
Substance User 18 1.28 .46 
Nonuser 8 1.12 .35 
Other Nonpsychotics 
Substance User 10 1.90 .32 
Nonuser 5 1.40 .55 
Schizophrenics 
Substance User 36 1.67 .48 
Nonuser 5 1.80 .45 
Other Psychotics 
Substance User 35 1.51 .51 
Nonuser 8 1.50 .53 
Note. Lower scores represent better premorbid functioning 
as assessed by the Zigler-Phillips Scale. 
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Table 27 
Mean Premorbid Functioning Scores for Female Substance 
Users Versus Nonusers at Index Hospitalization 
Whole Sample 
Substance User 
Nonuser 
Depressives 
Substance User 
Nonuser 
Other Nonpsychotics 
Substance User 
Nonuser 
Schizophrenics 
Substance User 
Nonuser 
Other Psychotics 
Substance User 
Nonuser 
N 
66 
56 
27 
24 
11 
8 
8 
9 
20 
15 
Substance Use 
M 
1. 32 
1.23 
1. 30 
1. 04 
1.45 
1. 37 
1.25 
1.55 
1.30 
1.27 
SD 
.47 
.43 
.46 
.20 
.52 
.52 
.46 
.53 
.47 
.46 
Note. Lower scores represent better premorbid functioning 
as assessed by the Zigler-Phillips Scale. 
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substance use at follow-up I was associated with better 
concurrent work functioning, social functioning, and re-
hospitalizations for the sample as a whole, a multivariate 
analysis of covariance (MANCOVA) was conducted with work 
functioning, social functioning, and rehospitalization at 
follow-up I as the dependent variables, substance use at 
follow-up I as the independent variable, and gender and 
premorbid functioning as covariates. This MANCOVA yielded 
a significant effect for the covariates, .f(6,444.00)= 
3.70, R=.001. This suggests that gender and premorbid 
functioning are related to outcome for the sample as a 
whole. Specifically, a univariate analysis of the 
covariates revealed a significant relationship between 
premorbid functioning and subsequent work functioning, 
t(225)=-3.55, R=.001. 
However, when the variance due to the covariates 
(premorbid functioning and gender) is removed, there is 
still a significant effect for the relationship between 
drug use at follow-up I and concurrent functioning for the 
sample as a whole, .f(6,444)=7.17, R =.001. This indicates 
that the variance associated with drug use is not just an 
artifact of differences in premorbid functioning, al though 
premorbid functioning also accounts for some of the 
variance. Furthermore, there were significant univariate 
effects indicating a relationship between substance use at 
follow-up I and concurrent rehospitalization, 
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f'.(2,169)=9.53, }2=.0001, social functioning, 1(2,169)=9.07, 
}2=.0001, and work functioning, 1(2,169)=3.82, }2=.024. 
This latter effect is not significant according to the 
Bonferroni criterion. The adjusted means for these 
analyses are presented in Table 28. The direction of 
these means again indicates that, contrary to the 
predictions, substance use at follow-up I is associated 
with better functioning in each of these areas. This 
effect still holds when the variance due to gender and 
premorbid functioning is removed. 
In order to further explore these significant 
findings to determine which of the groups differed from 
one another, three Student-Newman-Keuls tests were 
conducted. With regard to rehospitalization, there were 
significant differences between each of the levels of 
substance use, with the mild users spending the least time 
in the hospital, followed by the moderate to heavy users, 
and the abstainers. For social functioning, again there 
were significant differences between all of the levels of 
substance use. However, in the realm of social 
functioning, the moderate to heavy users fared best, 
followed by the mild users, and the abstainers. 
Overall Functioning 
To follow up on the significant finding seen for the 
sample as a whole in overall functioning, as assessed by 
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Table 28 
Mean* Functioning Scores at Follow-up I (Fil as a Function of 
Concurrent Level of Substance Use Within Each Diagnostic 
Group 
Level of Use Work Social Rehosp. Overall 
Within Each FI FI FI FI 
Diagnostic Group 
at Follow-up I M M M M 
Whole Sample 
None 2.09 2.64 3.04 4.94 
Low 2.77 3.20 3.82 3.61 
Mod-heavy 2.65 3.80 3.61 3.97 
Depressives 
None 2.44 2.89 3.00 4.72 
Low 3.15 3.72 3.72 2.97 
Mod-heavy 3.44 3.82 3.53 3.19 
Severe 
*~· All means are adjusted means derived from analyses of 
covariance and multivariate analyses of covariance. 
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the LKP scale, an ANCOVA was conducted with overall 
functioning at follow-up I as the dependent variable, 
substance use at follow-up I as the independent variable, 
and gender and premorbid functioning as covariates. There 
were no significant effects for gender or premorbid 
functioning, which indicates that gender and premorbid 
functioning were not significant covariates. 
Furthermore, in a subsequent multivariate analysis in 
which the variance due to gender and premorbid functioning 
was removed, a significant effect was still obtained for 
substance use, £:(2,225)= 6.83, 12=.00l. (The adjusted means 
for this analysis are presented in Table 28.) This 
suggests that the better overall functioning seen in 
relation to heavier substance use for the sample as a 
whole at follow-up I is not primarily a function of 
differences in premorbid functioning or gender. 
A post hoc Student-Newrnan-Keuls test revealed that 
there were significant differences between all of the 
levels of substance use, with the mild users having the 
best overall functioning, followed by the moderate to 
heavy users, and the abstainers. All scores were in the 
moderately impaired range, indicating difficulties in 
some, but not all areas of functioning. 
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Analyses for the Depressives 
Work Functioning, Social Functioning, Rehospitalization 
Given that a MANOVA showed that substance use was 
associated with better concurrent functioning for the 
depressives (as assessed at follow-up I), a MANCOVA was 
conducted with work functioning, social functioning, and 
rehospitalization at follow-up I as the dependent 
variables, substance use at follow-up I as the independent 
variable, and premorbid functioning and gender as 
covariates. These covariates did not have a significant 
multivariate impact on functioning for the depressives at 
follow-up I. 
Furthermore, in a subsequent multivariate analysis in 
which the covariates were held constant, the overall 
multivariate effect remained significant using the 
standard .05 criterion, E(6,134)= 2.42, R=.03, but was not 
significant using the Bonferroni criterion. There were 
significant univariate effects for rehospitalization, E( 
2,69)= 4.59, R=.013, and for social functioning, E( 2,69) 
= 5.49, R=.006. Again, these means indicate that more 
severe substance use at follow-up I is associated with 
better concurrent functioning for the depressives. These 
differences are not just a function of differences in 
premorbid functioning or gender. The adjusted means for 
these analyses are presented in Table 28. 
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Post hoc contrasts revealed that for social 
functioning and rehospitalization there were significant 
differences between all of the levels of substance use. 
With regard to social functioning, the moderate to heavy 
users fared best, followed by the mild users, and the 
abstainers. For rehospitalization, the mild users spent 
the least time in the hospital, followed by the moderate 
to heavy users, and the abstainers. 
Overall Functioning 
To follow up on the significant finding seen for the 
depressives in overall outcome, an analysis of covariance 
(ANCOVA) was conducted with overall outcome at follow-up 
I as the dependent variable, substance use at follow-up I 
as the independent variable, and gender and premorbid 
functioning as covariates. There were no significant 
relationships between gender or premorbid functioning and 
overall outcome, which indicates that gender and premorbid 
functioning were not significant covariates. Furthermore, 
in a subsequent multivariate analysis in which the 
variance due to gender and premorbid functioning was 
removed, a significant effect was still obtained for 
substance use, ~(2,69)= 4.05, R=.022. This suggests that 
the improvements in overall functioning seen in relation 
to higher levels of substance use for the depressives at 
follow-up I is not just a function of differences in 
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premorbid functioning or gender. The adjusted means for 
this analysis are presented in Table 28. 
A post hoc Student-Newman-Keuls analysis revealed 
that there were significant differences between the 
abstainers and the mild users, with the mild users having 
better overall functioning than the abstainers. All of 
the mean scores were in the moderately impaired range. 
Analyses for the Schizophrenic Sample 
Depressive Symptoms, Thought Disorder, Psychosis 
Given that a MANOVA showed that substance use has a 
deleterious impact on concurrent symptomatology for the 
schizophrenics (as assessed at follow-up I), a MANCOVA was 
conducted with depressive symptoms, psychosis, and thought 
disorder at follow-up I as the dependent variable, 
substance use at follow-up I as the independent variable, 
and premorbid functioning and gender as covariates. 
These covariates did not have a significant multivariate 
relationship with symptoms for the schizophrenics at 
follow-up I. Furthermore, in a subsequent multivariate 
analysis in which the variance due to the covariates was 
removed, the overall multivariate effect remained 
significant, ~( 6,66)=2.46, R= .033. (This effect is not 
significant according to the Bonferroni criterion). 
(adjusted means for depression were 3 • 13 , 3 • 71, 3 • 52 , 
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respectively; for thought disorder were 3.22, 2.50, 3.24, 
respectively; for psychosis were 1.97, 2.25, 1.79, 
respectively). There were no significant univariate 
findings. Thus, the differences seen in symptoms 
(worsening) as a function of higher levels of concurrent 
substance use at follow-up I are not attributable to 
differences in gender or premorbid functioning. 
The Role of Covariates in the Predictive Relation 
Between Substance Use at Index Hospitalization and 
outcome at Follow-up I 
Analyses for the Whole Sample 
Work Functioning, Social Functioning. Rehospitalization 
Given that a MANOVA showed that substance use at 
index hospitalization is associated with detriments in 
functioning at follow-up I for the sample as a whole, a 
MANCOVA was conducted with wor~ functioning, social 
functioning, and rehospitalization at follow-up I as the 
dependent variables, substance use at the index 
hospitalization as the independent variable, and premorbid 
functioning and gender as covariates. These covariates 
did have a significant multivariate relationship with 
functioning, E(6,444)= 2.89, ~=.009. Specifically, there 
was a significant univariate effect for the impact of 
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premorbid functioning on work adjustment, t(226) = -3.54, 
p=.001. 
In a subsequent multivariate analysis in which the 
variance due to the gender and premorbid functioning was 
removed, the overall multivariate effect was 
nonsignificant. (The adjusted means for this analysis are 
presented in Table 29.) This suggests that the 
previously observed deleterious effect of substance use at 
index on functioning at follow-up I for the sample as a 
whole was significantly influenced by the relationship 
between premorbid functioning and subsequent functioning. 
As it was not a robust effect, it was no longer 
significant when the variance due to the covariates was 
removed. 
Depressive Symptoms, Thought Disorder, Psychosis 
Given that a MANOVA showed that substance use at 
index hospitalization has a detrimental impact on 
symptomatology at follow-up I for the sample as a whole, 
a MANCOVA was conducted with depressive symptoms, thought 
disorder, and psychosis at follow-up I as dependent 
variables, substance use at the index hospitalization as 
the independent variable, and premorbid functioning and 
gender as covariates. These covariates had a significant 
multivariate relationship to symptoms for the whole sample 
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Table 29 
Mean* Functioning Scores at Follow-up I CFil as a Function of 
Substance Use at Index Hospitalization Within Each 
Diagnostic Group 
Level of Use Work Social Rehosp. Overall 
Within Each FI FI FI FI 
Diagnostic Group 
at Index M M M M 
Whole Sample 
None 2.65 2.92 3.56 
Low 2.37 3.32 3.25 
Moderate 2.39 3.26 3.30 
Heavy 2.37 3.28 3.26 
Schizophrenics 
None 5.89 
Low 5.12 
Moderate 4.03 
Heavy 6.89 
Other Psychotics 
None 3.03 2.85 3.74 
Low 2.44 3.67 3.52 
Moderate 2.35 3.17 2.88 
Heavy 2.29 3.33 3.40 
*Note. All means are adjusted means derived from analyses of 
covariance and multivariate analyses of covariance. 
at follow-up I, ~(6,422)=3.77, p= .001. 
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There were 
significant univariate relationships between premorbid 
functioning and psychosis, t(215) = 2.35, p= .02, and 
depression, t(215) = -2.21, R =.03. 
Furthermore, in a subsequent multivariate analysis in 
which the variance due to the covariates was removed, the 
overall multivariate effect was no longer significant. 
(adjusted means for thought disorder were 2. 49, 2. 39, 
2.42, 2.91, respectively; for psychosis were 1.65, 1.78, 
1.55, 1.87, respectively; for depression were 3.69, 3.42, 
3.42 3.97, respectively). This suggests that the 
previously observed finding of a relationship between 
substance use at index hospitalization and subsequent 
symptoms at follow-up I was influenced by these 
covariates, and they accounted for some of the variance. 
Analyses for the Schizophrenic Sample 
Overall Functioning 
To follow up on the significant finding seen in for 
the schizophrenics on the LKP scale, an ANCOVA was 
conducted with overall functioning at follow-up I as the 
dependent variable, substance use at the index 
hospitalization as the independent variable, and gender 
and premorbid functioning as covariates. There was a 
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significant relationship between premorbid functioning and 
overall outcome, £:.(1,45)=11.34, p= .002. Nevertheless, 
there continued to be a significant main effect for 
substance use at index hospitalization, .[(3,45)=4.36, 
p=. 009, when the variance due to the covariates was 
removed. This suggests that premorbid functioning does 
relate to overall outcome for the schizophrenics at 
follow-up,and makes the test of the effect more 
conservative, or reduces the substance use effect. 
Despite this more conservative test, the results remained 
significant, and indicate a relationship between substance 
use at the index hospitalization and poorer overall 
outcome at follow-up I for the schizophrenics. The 
adjusted means for this analysis are presented in Table 
29. 
A post hoc Student-Newman-Keuls test indicated that 
there were significant differences between all of the 
levels of substance use, with the heavy users having the 
worst overall functioning, followed by the mild users, the 
abstainers, and the moderate users. 
Analyses for the Other Psychotic Sample 
Work Functioning, Social Functioning, Rehospitalization 
Given that a MANOVA showed that substance use at 
index hospitalization is associated with detriments in 
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functioning at follow-up I for the other psychotics, a 
MANCOVA was conducted with work functioning, social 
functioning, and rehospitalization at follow-up I as the 
dependent variables, substance use at the index 
hospitalization as the independent variable, and premorbid 
functioning and gender as covariates. These covariates 
did not have a significant multivariate relation to 
functioning. 
Nevertheless, in a subsequent multivariate analysis 
in which the variance due to these covariates was removed, 
there was no longer a significant effect for substance use 
at the index hospitalization. Thus, despite the fact that 
gender and premorbid functioning are not significant 
covariates, they did have some mediating role on the 
impact of substance use at index hospitalization for the 
other psychotics. Therefore, the previously observed 
effect for substance use at the index hospitalization was 
not robust enough to remain significant when the variance 
due to gender and premorbid functioning was removed. The 
adjusted means for this analysis are presented in Table 
29. 
The Role of Covariates in the Predictive Relation 
Between Substance Use at Follow-up I and 
Outcome at Follow-up II 
Analyses for the Whole Sample 
Overall Functioning 
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An ANCOVA was conducted to elaborate on the finding 
that substance use at follow-up I predicted better overall 
functioning for the sample as a whole at follow-up II. 
Overall outcome at follow-up II was the dependent 
variable, substance use at follow-up I was the independent 
variable, and premorbid functioning and gender were the 
covariates. Premorbid functioning and gender did not have 
a significant relation to overall functioning •. Furthermore 
the effect of substance use on overall outcome continued 
to be significant, l(2,226) = 4.48, R =.012, in a 
subsequent analysis in which the variance due to gender 
and premorbid functioning was removed. Therefore, the 
difference in overall outcome seen as a function of 
substance use cannot be attributed to differences in 
premorbid functioning or gender. The adjusted means for 
this analysis are presented in Table 30. 
A post-hoc Student-Newman-Keuls analysis revealed 
that there were significant differences between the mild 
users and the abstainers, with the mild users functioning 
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Table 30 
Mean* Overall Functioning Scores at Follow-up II CFII> as a 
Function of Substance Use at Follow-up I Within Each 
Diagnostic Group 
Level of Use 
Within Each 
Diagnostic Group 
at Follow-up I 
Whole Sample 
None 
Low 
Mod-heavy 
Depressives 
None 
Low 
Mod-heavy 
Overall 
FII 
M 
4.10 
3.20 
3.47 
3.84 
2.67 
2.02 
*Note. All means are adjusted means derived from analyses of 
covariance and multivariate analyses of covariance. 
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better than the abstainers. All of these scores were in 
the moderately impaired range, indicating difficulties in 
some, but not all areas of functioning. 
Analyses for the Depressive Sample 
Overall Functioning 
An ANCOVA was conducted to elaborate on the finding 
that substance use at follow-up I predicted improvements 
in overall functioning for the depressives at follow-up 
II. Premorbid functioning and gender did not have a 
significant relationship to overall functioning. 
Furthermore the ef feet of substance use on overall outcome 
continued to be significant, ~(2,69) = 4.15, ~ =.02, when 
the effects of gender and premorbid functioning were 
controlled for. Therefore, the difference in overall 
outcome seen as a function of substance use in the 
depressed patients cannot be attributed to differences in 
premorbid functioning or gender. The adjusted means for 
this analysis are presented in Table 30. 
A post hoc Student-Newman Keul s test showed that 
there were significant differences between the mild users 
and the abstainers, with the mild users at follow-up I 
having better overall functioning at follow-up II, as 
compared to the abstainers. 
The Role of Covariates in the Predictive Relation 
Between Substance Use at Index Hospitalization 
and Outcome at Follow-up II 
Analyses for the Whole Sample 
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Work Functioning, Social Functioning. Rehospitalization 
In order to further examine the finding that 
substance use at index hospitalization predicted 
impairments in functioning (as assessed by the Strauss-
Carpenter at follow-up II), a MANCOVA was conducted with 
gender and premorbid functioning as covariates. The 
analysis was significant, E(6,438.00)= 3.25, R= .004, 
which suggests that these covariates did have an impact on 
outcome. 
Following this significant multivariate finding, an 
examination of the univariate results showed a significant 
relation between premorbid functioning and subsequent work 
performance, t(223) = -3.12, R=.OO. Furthermore, in a 
subsequent multivariate analysis in which the variance due 
to the covariates is removed, there is no longer a 
significant main effect for substance use, .r'.(9,533.14)= 
1.25, R= .26. This indicates that the differences seen in 
functioning at follow-up II as a function of level of 
substance use at the index hospitalization in the sample 
as a whole are related more to differences in gender and 
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premorbid functioning than to differences in level of 
substance consumption at index hospitalization. The 
adjusted means for this analysis are presented in Table 
31. 
Overall Functioning 
A MANCOVA was conducted to elaborate on the finding 
that substance use at index hospitalization predicted 
detriments in overall functioning for the sample as a 
whole at follow-up II. Premorbid functioning and gender 
did not have a significant multivariate impact on overall 
functioning on the LKP. Nevertheless, the effect of 
substance use at index on overall outcome at follow-up II 
was no longer significant when the effects of gender and 
premorbid functioning were controlled for. Therefore, the 
detriments in overall outcome previously seen as a 
function of substance use at the index hospitalization in 
the sample as a whole are, at least partially attributable 
to differences in the covariates. As this finding was not 
robust, it did not remain significant when the variance 
due to the covariates was removed. The adjusted means for 
this analysis are presented in Table 31. 
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Table 31 
Mean* Functioning Scores at Follow-up II (FIIl as a Function 
of Level of Substance Use at Index Within Each Diagnostic 
Group 
Level of Use Work Social Rehosp. Overall 
Within Each FII FII FII FII 
Diagnostic Group 
at Index M M M M 
Whole Sample 
None 2.98 3.20 3.68 3.71 
Low 2.90 3.23 3.64 3.59 
Moderate 2.83 3.23 3.60 3.69 
Heavy 2.32 3.41 3.44 4.72 
Schizophrenics 
None 1. 84 2.74 3.63 
Low 2.42 3.18 3.66 
Moderate 3.15 3. 16 3.87 
Heavy 1. 11 2.55 2.75 
*Note. All means are adjusted means derived from analyses of 
covariance and multivariate analyses of covariance. 
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Analyses for the Schizophrenic Sample 
Work Functioning, Social Functioning, Rehospitalization 
To test whether the covariates of gender and 
premorbid functioning are related to the outcome variables 
of post-hospital functioning, a MANCOVA was conducted. 
This analysis was nonsignif icant which suggests that 
gender and premorbid functioning did not have an impact on 
outcome. 
Nevertheless, in a subsequent analysis in which the 
effects of the covariates were held constant, there was no 
longer a significant main effect for substance use at the 
index hospitalization. This suggests that, despite the 
nonsignif icant effect for gender and premorbid 
functioning, when the variance due to these covariates was 
removed, the pattern of results was significantly changed. 
Consequently, there was no longer a significant 
relationship between substance use at the index 
hospitalization and poorer functioning at follow-up II for 
the schizophrenics. The adjusted means for this analysis 
are presented in Table 31. 
Suicide 
This section addresses the relation between substance 
use and suicide among the young psychiatric patients in 
this sample. 
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In light of the fact that suicide is a 
relatively infrequent occurrence, the analyses concerning 
suicide were conducted using the entire sample of patients 
who have committed suicide (n= 23) (and for whom there was 
information on substance use), without regard to the time 
period in which they committed suicide. Thus, the sample 
used in these analyses is a slightly larger sample than 
the sample used for all of the other analyses in the 
study, including nine additional patients who committed 
suicide. Table 32 illustrates the diagnostic composition 
of the patients who committed suicide versus those who did 
not. 
The first question addressed was the following: in 
the sample as a whole, is suicide associated with higher 
levels of substance use? The mean level of substance use 
at the index hospitalization was 2.22 (between moderate 
and heavy) for the patients who comJnitted suicide (n=23) 
and 1.38 (between mild and moderate) for the patients who 
did not commit suicide (n=254). This difference was 
statistically significant, ~(277) =3.29, R <.01, and 
indicates that higher levels of substance use are 
associated with suicide in the sample as a whole. 
Turning now to an examination of the different 
diagnostic groups, there were no statistically significant 
differences noted between patients who committed suicide 
and those who did not in level of substance use within the 
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Table 32 
Numbers of Patients Who Did Commit Suicide Versus Those 
Who Did Not Within Each of the Diagnostic Groups 
Diagnostic group Suicide Nonsuicide 
depressives 4 80 
other nonpsychotics 2 37 
schizophrenics 8 55 
other psychotics 9 82 
23 254 
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depressive, other nonpsychotic, schizophrenic, or other 
psychotic groups. This lack of significant findings may be 
due to the very small number of suicides within each 
diagnostic group. The means and standard deviations for 
these analyses within each of the diagnostic groups, as 
well as for the sample as a whole, are presented in Table 
33. 
These latter results were also further examined 
separately for males and females in a series of Chi-square 
analyses. No significant differences in suicide, as a 
function of substance use, within each of the diagnostic 
groups, were noted for the male or for the female 
patients. Table 34 depicts the number of male patients 
within each diagnostic group who coilllllitted suicide versus 
those who did not, as a function of level of substance 
use. Table 35 depicts the number of female patients 
within each diagnostic group who committed suicide versus 
those who did not, as a function of level of substance 
use. 
As illustrated in Table 34, 15 of the 23 patients who 
committed suicide were male (65.2%). Furthermore, among 
the male patients, 11 of the patients who committed 
suicide (73.3%) were heavy substance users. Among the 
female patients who committed suicide, on the other hand, 
three patients (37. 5%) were heavy substance users, as 
shown in Table 35. An equal percentage (37.5%) of the 
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Table 33 
Mean Substance Use Scores at Index Hospitalization for 
Patients Who Committed Suicide Versus those Who Did Not 
Substance Use 
N M SD 
Whole Sample 
Suicide 23 2.21 1.17 
No suicide 254 1. 38 1.18 
Depressives 
Suicide 4 2.25 1.50 
No Suicide 80 1.12 1.15 
Other Nonpsychotics 
Suicide 2 1.50 2.12 
No suicide 37 1.35 1.16 
Schizophrenics 
Suicide 8 2.37 1. 06 
No suicide 55 1.56 1.17 
Other Psychotics 
Suicide 9 2.22 1. 09 
No suicide 82 1.52 1. 21 
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Table 34 
Number of Male Patients Who Cornrni tted Suicide Versus Those 
Who Did Not As a Function of Level of Substance Use Within 
each of the Diagnostic Groups 
Level of Substance Use 
None Mild Mod Severe 
Suicide versus 
No suicide Within 
Each Diagnostic Group 
Whole Sample 
Suicide 1 1 2 11 
No suicide 26 28 33 37 
Depressives 
Suicide 0 0 0 1 
No Suicide 8 8 4 6 
Other Nonpsychotics 
Suicide 0 0 0 1 
No suicide 5 3 6 4 
Schizophrenics 
Suicide 0 0 1 4 
No suicide 6 9 13 12 
Other Psychotic 
Suicide 1 1 1. 5 
No suicide 7 8 10 15 
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Table 35 
Number of Female Patients Who Committed suicide Versus 
Those Who Did Not As a Function of Level of Substance Use 
Within each of the Diagnostic Groups 
Level of Substance Use 
None Mild Mod Severe 
Suicide versus 
No Suicide Within 
Each Diagnostic Group 
Whole Sample 
Suicide 3 0 2 3 
No suicide 58 24 22 26 
Depressives 
suicide 1 0 0 2 
No suicide 26 8 12 8 
Other Nonpsychotics 
Suicide 1 0 0 0 
No suicide 7 5 3 4 
Schizophrenics 
Suicide 1 0 1 1 
No Suicide 8 3 0 4 
Other Psychotic 
Suicide 0 0 1 0 
No suicide 17 8 7 10 
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females who committed suicide were nonusers. Thus there 
appeared to be a stronger link between substance use and 
suicide for the male patients, rather than the female 
patients, particularly for the male patients who were 
heavy substance users. 
To address the question of whether there might be an 
association between substance use and suicide for the 
psychotic patients, but not the nonpsychotic patients, the 
sample was divided into two groups, psychotic and 
nonpsychotic, and t-tests of the relation between 
substance use and suicide were conducted for each of these 
groups. There was a significant association between level 
of substance use and suicide for the psychotic patients, 
t(l54) =2.76, R <.05, with the psychotic patients who 
committed suicide (n=17) showing higher levels of 
substance use than those who did not commit suicide 
(n=l37). On the other hand, however, no significant 
differences in level of substance use were seen for 
nonpsychotic patients who committed suicide (n=6) versus 
those who did not (n=l17). 
CHAPTER VI 
DISCUSSION 
Incidence and Severity of Substance Use 
in This Sample 
The rate of substance use in this sample of young 
adult nonchronic psychiatric patients was 67 .4%, which 
corroborates other reports that the rate of substance use 
among psychiatric patients approaches or exceeds 50% 
(Bergman & Harris, 1985; McLellan, et al., 1978; Pepper & 
Ryglewicz, 1984; Safer, 1986; Test et al., 1985; Test et 
al. I 1989) o 
Alcohol was the most widely used substance, with 
51. 8% of the sample acknowledging alcohol use at follow-up 
I and 51.4% of the sample acknowledging alcohol use at 
follow-up II. Marijuana was the second most widely used 
substance, with 36.3% of the sample using marijuana at 
follow-up I and 32% of the sample using marijuana at 
follow-up II. There were significantly smaller 
percentages of patients using barbiturates, psychedelics, 
and heroin at the two follow-ups. 
It was also found that a higher percentage of the 
psychotic patients (73.2%), as compared to the 
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nonpsychotic patients (60%), were substance users. This 
latter finding is contrary to the findings of some earlier 
published reports (e.g., Cohen & Klein, 1970; Cohen & 
Klein; 1974; Prosser & Pickens, 1974; Smart & Fejer, 
1969), but consistent with studies by Blumenfeld & 
Glickman (1967), Frosch, et al, (1965), and Hensala et 
al., (1967). The Cohen and Klein sample was a private 
hospital sample, whereas the Blumenfeld & Glicklllan, Frosch 
et al., and Hensala et al. samples were drawn from public 
hospitals. The present sample contains both public and 
private hospital patients. Cohen and Klein (1970) have 
suggested that it is possible that substance users 
admitted to public hospitals are ~ore likely to be 
psychotic, or to be diagnosed as psychotic, than those at 
private hospitals. Thus, sampling differences may account 
for the disparate findings on this issue, with samples 
containing at least some public hospital patients, like 
the present sample, having higher percentages of psychotic 
substance users than samples made up exclusively of 
private hospital patients. 
However, data from the present study do not support 
this theory. In this sample, although a higher percentage 
of the public hospital (67%), as co:mpared to private 
hospital (50%), patients were diagnosed as psychotic, 
there were no differences in the percentages of substance 
using psychotic patients in the private versus the public 
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patients in both settings were substance users. 
In the sample as a whole, at the index 
hospitalization 87 patients (32.6%) were nonusers, 51 
(19.1%) were mild users, 57 (21.3%) were moderate users 
and 72 (27%) were heavy users. At follow-up I, 102 
patients (40%) were nonusers, 90 were mild users (35.4%), 
and 62 were moderate to heavy users (24.4%). At follow-up 
II, 94 (38.4%) patients were nonusers, 92 (37.6%) were 
mild users, and 59 (24.1%) were moderate to heavy users. 
Thus, at all three of the measurement periods, substantial 
numbers of patients were using drugs and alcohol. 
With regard to diagnostic differences in severity of 
use, the schizophrenics were the heaviest users, while the 
depressives were the mildest users. Among the substance 
using depressives, 15 (31.9%) were mild users, 16 (34.0%) 
were moderate users, and 16 ( 3 4 . 0%) were heavy users. 
Among the substance using schizophrenics, 12 (25.5%) were 
mild users, 14 (29.8%) were moderate users, and 21 (44.7%) 
were heavy users • Further analysis of this finding, 
however, in which gender was examined as a covariate, 
indicated that these diagnostic differences were actually 
attributable to gender differences. Male patients were 
heavier users than female patients, and the majority of 
the schizophrenics were male, while the Eajority of the 
depressives were female. Thus, there were no significant 
diagnostic differences in level of substance use when the 
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effects of gender were held constant. 
It is possible, however, that there may be some 
attributes of schizophrenia that are intrinsically linked 
to being male. Similarly, depression may be, in part, 
intrinsically linked to the female gender. Conceptualized 
from this perspective, it would be incorrect to remove the 
effects of gender from the analysis of differences in 
level of substance use as a function of diagnosis. From 
this vantage point, then, the schizophrenics are indeed 
the heaviest users, while the depressives are the mildest 
users. 
Furthermore, from this vantage point, it would not 
have been necessary to control for the effects of gender 
in the analyses of the relation between substance use and 
outcome. In any case, there were no significant 
multivariate relationships noted between gender and the 
dependent variables for the analyses in which there was a 
significant multivariate relationship between substance 
use and outcome. Thus, the results of these analyses were 
highly comparable, regardless of whether or not gender was 
included as a potential covariate. Therefore, using gender 
as a covariate had no demonstrable effects on the findings 
of this study. 
However, the use of gender as a covariate was not a 
particularly robust test of the variance accounted for by 
gender, since gender is a dichotomous variable. Thus, the 
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variance was constrained. Consequently, it may be that 
gender did exert an impact on outcome, independent of 
patterns of substance use, but that the statistical method 
employed did not capture this effect. 
The finding that the schizophrenics were heavier 
users than the depressives is not consistent with previous 
reports (Cohen and Klein 1970; 1974}, that heavier users 
were more likely to be character disordered 
(nonpsychotic), while moderate users and abstainers were 
more likely to be psychotic. 
A hindrance in comparing the results of these studies 
is that character pathology was not routinely assessed in 
the present study, as it was in the Cohen and Klein 
studies. It is possible, however, that if there had been 
a character disordered group in the present sample, that 
this group might have been heavier users than the 
psychotics. 
Course of Substance Use 
In recent years, longitudinal methodologies have made 
it possible to examine the long-term course of various 
psychiatric illnesses. Much of this research, 
particularly in the area of schizophrenia, has shown that 
while there tend to be some consistencies in symptoms and 
functioning over time, there are also significant 
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fluctuations. One patient who is floridly psychotic at 
the index hospitalization may show no signs of psychosis 
in several successive follow-ups, while another may have 
persistent hallucinations and delusions throughout the 
course of his or her illness. The present findings 
suggest a comparable interpretation regarding the course 
of substance use in psychiatric patients. That is, while 
there does appear to be some consistency in patients' 
tendencies to use substances over time, there is also 
substantial variability. Forty-three percent of the 
sample showed variability in substance use patterns, 
changing from using to abstaining, or vice versa over the 
course of the three assessment periods covering a span of 
approximately five years. 
on the side of consistency, 33% of the sample showed 
evidence of sustained substance use over the course of 
both follow-ups. Considering each of the diagnostic 
groups separately, in all cases approximately one-third of 
the patients showed evidence of sustained use. on the 
other hand, 13.5% of the sample as a whole showed evidence 
of sustained abstinence. overall, substance use at the 
index hospitalization was significantly associated with 
continued substance use at the first and second follow-
ups. Furthermore, substance use at fol low-up I was 
strongly associated with substance use at follow-up II. 
There was also a trend within all of the diagnostic 
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groups that among the patients who started out as nonusers 
and then became users at follow-up, the majority became 
mild users. Among patients who started out as users at 
the index hospitalization, and then continued their 
substance use, approximately half were mild users while 
half were moderate to heavy users at follow-up. Thus, it 
appears that presence or absence of substance use at the 
index hospitalization is a relatively good predictor of 
subsequent level of substance use in the follow-up period. 
The majority of nonusers remained nonusers or became mild 
users, while the majority of users continued their 
substance use, with approximately half of the continuous 
users becoming moderate to heavy users at follow-up. 
Substance Use and Outcome 
Whole Sample 
For the sample as a whole, there were three main 
findings. The first was that higher levels of substance 
use at follow-up I were associated with better concurrent 
social functioning and less time in the hospital in the 
previous year. With regard to rehospitalization there 
were significant differences between each of the levels of 
substance use, with the mild users spending the least time 
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in the hospital (with most having no rehospitalizations), 
followed by the moderate to heavy users (with most being 
rehospitalized less than three months or not 
rehospitalized), and the abstainers (most rehospitalized 
less than three months). With regard to social 
functioning, again there were significant differences 
between all of the levels of substance use. However, in 
the realm of social functioning, the moderate to heavy 
users fared best (with most meeting with friends at least 
once a week) , followed by the mild users (with most 
meeting with friends at least two to three tililes a month), 
and the abstainers (with most meeting with friends between 
once a month and two to three times a month). 
The second main finding was that higher levels of 
substance use at follow-up I were associated with better 
concurrent overall functioning for the sample as a whole. 
There were significant differences between all of the 
levels of substance use, with the mild users having the 
best overall functioning, followed by the liloderate to 
heavy users, and the abstainers. All scores were in the 
moderately impaired range, indicating difficulties in 
some, but not all areas of functioning. 
The third finding was that higher levels of substance 
use at follow-up I predicted better overall functioning at 
follow-up II for the sample as a whole. There were 
significant differences between the mild users and the 
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abstainers, with the mild users functioning better than 
the abstainers. Again, all of these scores were in the 
moderately impaired range, indicating difficulties in some 
areas of functioning. 
In summary, for the sample as a whole, the mild users 
at follow-up I spent the least time in the hospital and 
had the best overall functioning at follow-up I. The 
moderate to heavy users at follow-up I had the best 
concurrent social functioning. Additionally, the mild 
users at follow-up I had better overall functioning at 
follow-up II as compared to the abstainers. 
The most striking aspect of these results is that in 
all cases where there was a significant effect, contrary 
to the hypotheses, substance users fared better than 
nonusers. In most cases, the mild users had the best 
outcomes, with the exception of social functioning, in 
which moderate to heavy users had the best outcomes. In 
the overall context of the whole sample, however, it is 
important to bear in mind that both the users and the 
nonusers continued to have some difficulties in 
functioning and some rehospitalizations in the follow-up 
period. Thus, neither the users nor the abstainers 
epitomized ideal mental health. 
It is also noteworthy that the results for the whole 
sample were probably influenced by the f indinqs of one of 
the largest groups, the nonpsychotic depressives. 
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Another interesting aspect of these findings for the 
whole sample is that the substance users had poorer 
premorbid adjustment than the nonusers. Therefore, the 
associations between substance use and better functioning 
and outcome were obtained despite the fact that the 
substance using patients had poorer initial adjustment. 
Given that poor premorbid adjustment has been shown to be 
a powerful predictor of subsequent poor outcome 
(Westermeyer & Harrow, 1986), the odds were stacked 
against these patients functioning better than the 
nonusers. Thus, on the basis of their premorbid 
adjustment, these patients would not have been expected to 
do as well as the nonusers. Given this, the finding that 
the users actually had better post-hospital functioning 
than the nonusers is all the more compelling, and suggests 
that there is either something about the kind of people 
who use substances, or something about substance use 
itself that is associated with better functioning. 
There were 
Depressives 
three primary findings for the 
depressives. 
multivariate 
First, there was an almost significant 
effect indicating that higher levels of 
substance use at follow-up I were associated with better 
social functioning, and less time in the hospital over the 
previous year at the first follow-up. In the area of 
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social functioning there were significant differences 
between all of the levels of substance use, with the 
moderate to heavy users having the best social functioning 
(with most meeting with friends at least once a week), 
followed by the mild users (with most meeting with friends 
at least once a week) , and the abstainers (with most 
meeting with friends two to three times per month). For 
rehospitalization, the mild users spent the least time in 
the hospital (with most not being rehospitalized), 
followed by the moderate to heavy users (with most being 
rehospitalized less than three months), and the abstainers 
(with most being rehospitalized less than three months). 
The second finding was that higher levels of 
substance use at follow-up I was associated with better 
concurrent overall functioning for the nonpsychotic 
depressives. There were significant differences between 
the abstainers and the mild users, with the mild users 
having better overall functioning than the abstainers. 
Mean scores were in the moderately impaired range. 
The third finding was that higher levels of substance 
use at follow-up I predicted better overall functioning at 
follow-up II for the depressives. There were significant 
differences between the mild users and the abstainers, 
with the mild users at follow-up I having better overall 
functioning at follow-up II (with most in the good-
moderate range of functioning), as compared to the 
187 
abstainers (most of whom were in the moderate range of 
functioning). 
In summary, for the depressives, moderate to heavy 
levels substance use at follow-up I were associated with 
the best concurrent social functioning. Mild levels of 
use at follow-up I were associated with spending the least 
time in the hospital at follow-up I, and with the best 
overall functioning at follow-up I. Furthermore, mild 
levels of substance use at follow-up I predicted better 
overall functioning at follow-up II. 
Again, as for the sample as a whole, the most 
striking finding is that, contrary to the hypotheses, 
substance use was actually associated with better outcome 
for the depressives. 
Furthermore, for the depressives, as was the case for 
the sample as a whole, the substance users had poorer 
premorbid adjustment than the nonusers. Therefore, the 
depressed substance users had better outcomes despite the 
fact that their previous adjustment had been poorer than 
that of the depressed nonusers. 
Schizophrenics 
There were three primary findings for the 
schizophrenics. First, the highest level of substance use 
at the index hospitalization predicted worse overall 
functioning at follow-up I. 
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There were significant 
differences between all of the levels of substance use, 
with the heavy users having the worst overall functioning 
followed by the mild users, the abstainers, and the 
moderate users. Thus, there appeared to be a nonlinear 
relation between substance use and overall outcome for the 
schizophrenics. The heavy users had poor functioning in 
almost all areas, while the abstainers, mild, and moderate 
users had moderate impairments in functioning. 
Second, there was an almost significant multivariate 
trend indicating that higher levels of substance use at 
follow-up I were associated with concurrent detriments in 
symptomatology for the schizophrenics. An examination of 
the univariate results indicated that there were no 
significant effects for depression, psychosis, or thought 
disorder. Thus, there was a general exacerbation in 
symptoms among substance using schizophrenics, but no 
specific symptom alone showed a sufficient degree of 
severity to reach statistical significance. 
Third, of the eight schizophrenic patients who 
committed suicide in the post-hospital period, six of them 
had been substance users. Within the schizophrenic group 
alone there was not a significant relation between 
differences in level of substance use and suicidality. 
However, in an analysis of all of the psychotic patients, 
which included the schizophrenics, the psychotic patients 
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who committed suicide used higher levels of substances 
than those who did not commit suicide. 
Thus, the findings for the heavy using schizophrenics 
are markedly different than the findings for the sample as 
a whole, and for the nonpsychotic depressives. Consistent 
with the hypotheses, for the schizophrenics, substance use 
was associated with detriments in functioning. 
Specifically, heavy use at the index hospitalization 
predicted poor overall outcome at the first follow-up. 
Additionally there was a trend indicating that higher 
levels of substance use at the first follow-up were 
associated with more severe concurrent symptomatology. 
Furthermore, for the psychotic patients, including the 
schizophrenics, the patients who committed suicide had 
significantly higher levels of substance use (in the 
moderate to severe range) than the patients who did not 
commit suicide (in the mild to moderate range). 
Other Nonpsychotics and Other Psychotics 
There were no significant findings for the other 
nonpsychotic patients (nonpsychotic patients without 
depressive disorders) or for the other psychotic patients 
(psychotic patients who are not schizophrenic) • One 
explanation for the lack of findings in these two groups 
may be that each of the groups was extremely 
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heterogeneous. The other nonpsychotic group contained 
patients with numerous diagnoses including, but not 
limited to, eating disorders, mania, antisocial 
personality disorder, borderline personality disorder, and 
panic disorder. The other psychotic group consisted 
mostly of patients with psychotic affective disorders, 
including schizoaffectives, bipolar disorders, major 
depressives, and manics. It is possible that different 
findings might be obtained for certain subgroupings of 
these psychotic and nonpsychotic patients, such as 
patients with manic disorders and patients with character 
disorders. For instance, Reich, et al. (1974) found that 
excessive alcohol use in manic patients differentiated the 
hospitalized patients from the never hospitalized 
patients. Other studies (e.g., Cohen & Klein, 1974) have 
found that patients with character disorders who are heavy 
drug users have poor post-hospital adjustment. 
On the Relation Between Substance Use and 
Better Outcome for the Depressives and 
the Sample as a Whole 
There are at least four straightforward 
interpretations of the data for the depressives. The 
first is that psychiatric patients who use substances tend 
to have better coping mechanisms or more ego strength, and 
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therefore they have better outcomes than nonusers. The 
second interpretation is that certain kinds of psychiatric 
patients who use substances have better coping mechanisms, 
or more ego strength and adaptability, and therefore have 
better outcomes. Both of these accounts suggest that 
there is something about these people, rather than about 
substance use per se that is associated with better 
outcomes. 
The third interpretation is that drugs and/or 
alcohol facilitate better functioning in psychiatric 
patients. The fourth interpretation is that drugs and/or 
alcohol facilitate better functioning in some kinds of 
psychiatric patients. These latter two accounts are 
consistent with the self-medication theory (cf., McLellan 
& Druley, 1977; Wurmser, 1978) of substance use. This 
theory suggests that disturbed individuals use certain 
substances because the pharmacological properties of these 
substances are likely to alleviate certain symptoms. For 
instance, depressives may use certain kinds of illicit 
substances in an attempt to medicate their dysphoria and 
lethargy. 
There are also several other possible interpretations 
of the data involving more complex interactions between 
certain kinds of psychiatric patients and certain kinds of 
substances. These data lend some support for the second 
and fourth interpretations, since different patterns of 
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findings emerged for the depressives and the 
schizophrenics. That is, these data suggest that certain 
kinds of substance using psychiatric patients (ie., 
depressives) are more adaptable, flexible people who 
perhaps have better coping mechanisms, and/or that 
substances help certain kinds of psychiatric patients 
(ie., depressives) to function better (self-medication 
theory). 
In either case, the evidence of a relationship 
between substance use and better functioning for the 
depressives occurred primarily for concurrent functioning 
at the first follow-up. If these patients were attempting 
to medicate some of their symptoms, this strategy may be 
initially somewhat successful in helping them to function. 
However, this tactic may not be as successf'Ul over the 
whole course of an individual's life. More research is 
needed to investigate the question of whether the better 
outcomes seen for the substance using depressives continue 
over the course of their illnesses·. 
In interpreting these findings, it is also noteworthy 
that mild use generally entails occasional or experimental 
patterns of use involving significantly fewer drugs in 
smaller amounts and for shorter durations than would be 
the case for substance abuse or dependence. In all 
instances in which there were significant findings for the 
sample as a whole or for the depressives, with the 
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exception of social functioning, mild rather than moderate 
to heavy use was related to better outcome as compared to 
no use. 
Previous studies have indicated that the vast 
majority of young adults in this country engage in 
recreational use of alcohol and marijuana (e.g., Johnston, 
O'Malley, & Bachman, 1986; Miller, et al, 1983). In most 
cases this alcohol and drug use does not engender 
subsequent abuse or dependence. Moreover, a number of 
researchers have suggested that substance use among 
adolescents and young adults may reflect age-appropriate 
experimentation. For instance, Newcomb and Bentler (1988) 
have proposed that 
one defining feature of adolescence is a quest for 
establishment of independence and autonomous identity 
and functioning. This may involve experimentation 
with a wide range of behaviors, attitudes, and 
activities before choosing adirection and way of life 
to call one's own. This process of testing attitudes 
and behavior may include drug use. In fact, 
experimental use of various drugs, both licit and 
illicit, may be considered a normative behavior among 
United States teenagers in terms of prevalence, and 
from a developmental task perspective. (p. 214, cited 
in Shedler & Block, 1990, p.613) 
Recent empirical evidence suggesting a link between 
mild drug use and psychological health among adolescents 
has been garnered by Shedler and Block (1990) . Subjects 
for the Shedler and Block study were 101 18-year olds 
participating in longitudinal study of ego and cognitive 
development. The subjects were initially recruited at age 
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3 from a normal sample of nursery school children, and 
were given extensive batteries of psychological tests at 
ages 3, 4, 5, 7, 11, 14, and 18. At age 18 each of the 
subjects was asked about their drug use, in addition to 
many other topics, in individual interviews. Subjects 
were divided into three categories of drug use: 
abstainers, experimenters, and frequent users. Shedler 
and Block conducted a series of analyses in which they 
used the experimenters as the comparison group. That is, 
in their analyses they compared the frequent users to the 
experimenters, and the abstainers to the experimenters. 
They found that at age 18, the frequent users were more 
alienated, had less impulse control, and were more 
distressed as compared to the experimenters. The 
abstainers were more anxious, emotionally constricted, and 
lacking in social skills as compared to the experimenters. 
Thus, the adolescents who engaged in mild experimental 
drug use at age 18 were more psychologically healthy, from 
a number of vantage points, than either the frequent users 
or the abstainers. 
As is the case among normative samples of adolescents 
and young adults, substance use among young adult 
psychiatric patients appears to be the norm rather than 
the exception. Furthermore, just as there is evidence 
that mild levels of use are related to psychological 
health for normal adolescents, mild levels of use may be 
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indicative of enhanced adaptive functioning in some young 
adult psychiatric patients, particularly nonpsychotic 
depressed patients. Alternatively, it may be that 
substance use itself is associated with better functioning 
for the depressives, perhaps because of mood altering or 
relaxation effects. 
The finding that moderate to heavy levels of 
substance use in depressives and in the sample as a whole 
are related to better social functioning than mild use or 
no use is somewhat puzzling, but not entirely 
counterintuitive. The puzzling aspect is that many of the 
individuals who were moderate to heavy substance users 
would have met the DSMIII-R criteria for substance abuse 
or dependence. In general, when one thinks about the 
effects of severe, habitual alcohol and drug abuse, one 
thinks of consequent deficits rather than strengths. 
Indeed, the current conception of the diagnostic 
distinction between use, abuse, and dependence according 
to DSMIII-R criteria hinges on the extent to which the 
substance use results in deficits in functioning, 
including social functioning. This differs from previous 
formulations which relied more on assessments of physical 
symptoms, such as withdrawal and blackouts in making 
differentiations between use, abuse, and dependence. 
However, among young adults, including young adult 
psychiatric patients, substance use may often occur in the 
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context of social peer interactions. It has been well 
documented that many people who have been psychiatrically 
hospitalized feel stigmatized by their status as former 
psychiatric inpatients. Subsequent hospitalizations, if 
they occur, only add to this sense of social alienation. 
Often when young people are discharged from psychiatric 
hospitals, one of the most difficult dilemmas they face is 
whether and how they will be able to regain or, in some 
cases, initiate, social networks. Many may view drugs 
and alcohol as a means of alleviating social awkwardness 
and facilitating interaction with peers. 
In the few published studies in which patients have 
been asked for their reasons for using substances, many 
have cited social factors (Bergman & Harris, 1985: Test et 
al., 1989). Consequently, when psychiatric patients are 
interviewed in the post-hospital period and asked about 
their social lives, patients who frequently use drugs and 
alcohol may feel more optimistic about their social 
interactions than do patients who use substances 
infrequently or never. 
There may, however, be some disparities between these 
patients self-perceptions of their social functioning and 
the perceptions of others. Indeed it may be that the 
substance using depressed patients have a tendency to 
overestimate their social involvement. In this regard it 
is also noteworthy that the measure of social functioning 
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employed in the present research focuses on the amount of 
social contacts that an individual has, rather than the 
quality of these contacts. Therefore, a person could 
conceivably have very conflictual or superficial 
relationships with numerous people on a frequent basis and 
score "high" on social functioning, as assessed in the 
present study. Thus, while the present findings indicate 
that the moderate to heavy users have more social contacts 
than mild users or abstainers, further research is needed 
to elucidate the quality and character of these 
relationships. 
On the Relation Between Substance Use and Poor Outcome 
for the Schizophrenics 
In stark contrast to the findings for the 
depressives, and for the sample as a whole, for the 
schizophrenics, higher levels of substance use at the 
index hospitalization were related to severe impairments 
in overall outcome at the first follow-up. There was also 
some evidence indicating that higher levels of substance 
use at follow-up I were linked to more severe concurrent 
symptomatology. Furthermore, higher levels of substance 
use at the index hospitalization were associated with 
subsequent death by suicide. Therefore these findings 
provide substantial evidence that heavy levels of 
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substance use have highly destructive consequences for 
schizophrenic patients. 
These findings are particularly worrisome in light of 
the fact that approximately one-third of the 
schizophrenics showed evidence of sustained substance use 
at all three of the assessment periods, spanning 
approximately five years in the early course of their 
illnesses. Thus, despite the fact that substance use is 
potentially devastating for these patients, a substantial 
portion of them have enduring, rather than transient 
episodes of drug use. 
There are four potential interpretations of the data 
for the schizophrenics. The first is that substance using 
psychiatric patients are more disturbed patients, with 
poorer coping mechanisms, than nonusing psychiatric 
patients. The second interpretation is that certain kinds 
of substance using psychiatric patients (i.e., 
schizophrenics) are more disturbed patients, with poorer 
coping mechanisms than nonusing psychiatric patients with 
similar diagnoses. The third interpretation is that 
substance use itself causes impairments in functioning for 
psychiatric patients. The fourth interpretation is that 
substance 
certain 
use causes 
kinds of 
schizophrenics). 
impairments in 
psychiatric 
functioning for 
patients (ie., 
Again, these data lend support for two of the 
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aforementioned interpretations. Substance using 
schizophrenics may be more disturbed than their nonusing 
counterparts, and/ or drugs and alcohol may have 
particularly harmful effects for schizophrenic patients. 
Other interpretations involving more complex interactions 
of certain kinds of schizophrenic patients with certain 
kinds of drugs are also possible. 
Zubin and Spring's (1977) vulnerability theory of 
schizophrenia suggests a possible conceptual framework for 
these findings. From the vantage point of vulnerability 
theory, substance use may serve as a stressor that 
interferes with the schizophrenic's coping ability, 
resulting in a breakdown of coping activities. This, in 
turn, leads to difficulties in functioning and 
exacerbations in symptomatology and suicide potential. 
This theory is most consistent with the interpretation 
that there is something about substance use per se that is 
detrimental to schizophrenic patients in particular. 
In describing the course of illness in 
schizophrenics, Harrow and his colleagues (Harrow, Carone 
& Westermeyer, 1985; Marengo & Harrow, 1984) have proposed 
a modification of Zubin and Spring's formulation. 
According to this modified view, schizophrenics are 
vulnerable to a disorder that is severe and sustained, 
rather than episodic as Zubin and Spring initially 
suggested. The present findings suggest that substance 
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use, particularly persistent, heavy use, is a factor that 
contributes to the enduring nature of deficits in 
functioning for some schizophrenic patients. 
Toward a Diagnosis-Specific Understanding of the Impact 
of Substance Use on Psychiatric Patients 
The disparate findings on the effects of substance 
use for the depressives, as compared to the 
schizophrenics, suggests that substance use in psychiatric 
patients has diagnosis-specific effects, or effects linked 
to specific types of psychopathology. Therefore, contrary 
to the hypotheses of the present study, and contrary to 
clinical theory (Alterman, 1985; Bergman & Harris, 1985; 
Brown et al., 1989), as well as clinical lore, substance 
use is not associated uniformly with poorer functioning 
and outcome for all psychiatric patients. Rather, the 
present study indicates that substance use has highly 
detrimental, potentially lethal consequences for 
schizophrenic patients, whereas it is associated with 
better functioning in some areas for nonpsychotic 
depressed patients. 
several factors may be involved in these diagnosis-
specific findings. One possibility is that there may be 
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important differences between psychotic versus non 
psychotic patients in their reactions to, or interactions 
with, substance use. Perhaps the neurochemical substrate 
underlying psychotic disorders is adversely affected by 
the psychopharmacological properties of certain kinds of 
illicit substances. No such untoward biological 
interactions may be present for depressives. 
Alternatively, psychotic individuals may be a 
particularly psychologically vulnerable group. Perhaps 
these individuals have poorer tolerance for the thoughts 
and feelings that might be engendered in the course of 
obtaining and using substances. Such individuals might 
also react negatively to the emotional and physical 
sequelae of substance use. Depressed patients, who 
presumably have a wider range of higher level 
psychological defenses, might be less emotionally fragile 
in the face of the thoughts and feelings stimulated by 
substance use. For instance, many people feel some degree 
of guilt when they use psychoactive substances, 
particularly illicit ones. Depressed individuals, who are 
able to rationalize their drug use (particularly mild use) 
might say to themselves that they feel guilty that they 
used drugs, but that they needed to do something to relax, 
and besides, all of their friends were doing it too. A 
psychotic individual, on the other hand, in response to 
feeling guilty about drug use, might think that severe 
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retribution from Satan was inevitable, which might then 
produce strong feelings of fear and agitation. 
Premorbid functioning and Gender in Users versus 
Nonusers 
Consistent with numerous previous reports (e.g., 
Bowers & Swigar, 1987; Drake et al., 1989; Hasin et al., 
1985; Hensala et al., 1967), in the present study, 
substance use was more prevalent among the male patients 
than the female patients. In this study, however, when 
this finding was examined within each of the diagnostic 
groups, it was observed that this finding held for the 
psychotic patients, but not the nonpsychotic patients. 
Thus, among the nonpsychotic depressives, there were just 
as many female substance users as male substance users. 
However, consistent with the prediction, but contrary 
to reports by Bowers (1977) and Breakey, et al. (1974), 
for the sample as a whole, and specifically for the 
depressives, substance use at the acute phase was related 
to worse premorbid functioning. 
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Premorbid Functioning and Gender as Mediators of the 
Relation between Substance Use and outcome 
This study also explored the possibility that in 
cases in which substance use was related to outcome, this 
relation might be mediated by premorbid functioning and/or 
gender differences. Indeed, there were five analyses in 
which there initially appeared to be a significant 
relation between substance use and outcome that was no 
longer significant when the variance due to gender and 
premorbid functioning was removed. 
In four out of the five cases, the analyses were for 
the whole sample. In all cases, the initial multivariate 
analysis had shown a significant association between 
substance use and poor functioning or outcome. The 
subsequent analyses, in which the variance due premorbid 
functioning and gender were removed, were no longer 
significant. In each case, premorbid functioning was a 
significant covariate. This suggests that for these 
analyses of the whole sample, poor initial premorbid 
functioning was associated with subsequent poor 
functioning and outcome, such that the relation between 
substance use and outcome was obscured. 
In the one remaining case, which involved an analysis 
for the other psychotic group, despite the fact that there 
was not a significant multivariate effect for the 
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covariates, the effect for substance use was no longer 
significant when the variance due to the covariates was 
removed. In this case, despite the fact that the 
relationship between the covariates and the dependent 
variable was not statistically significant, there was a 
still some positive association between premorbid 
functioning and outcome. Therefore, in this case, some of 
the variance in outcome was attributable to variance in 
substance use as well as premorbid functioning. The net 
result was that there was no longer a clear-cut 
association between substance use and outcome. 
Suicide 
In the sample as a whole, higher levels of substance 
use differentiated between patients who committed suicide 
and those who did not, with the patients who died by 
suicide having moderate to heavy use. This finding is in 
accord with previous observations that substance use in 
conjunction with psychiatric illness creates a tremendous 
risk for suicide (e.g., Kesselman et al., 1982). There 
was also a stronger link between substance use and suicide 
for the male patients, as compared to the female patients, 
particularly for male patients who were heavy users. 
Moreover, there was a significant relation between 
higher levels of substance use and suicide for the 
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psychotic patients, but not for the nonpsychotic patients. 
Therefore, in the early phase of their illnesses, 
substance use is particularly risky, and potentially 
lethal for psychotic patients. This finding should be 
considered in light of other research (Westermeyer & 
Harrow, 1989) indicating that psychotic patients are, in 
general, more likely to commit suicide than nonpsychotic 
patients. 
Limitations of the Present Study 
One of the main limitations of the present 
study is that it relied on patient self-reports of drug 
and alcohol use, with the consequent risk that patients 
may have under-represented their substance use. However, 
there have been numerous studies suggesting that patients' 
self-reports about their extent of drug and alcohol use 
tend to be relatively accurate (Ball, 1972; Bernadt, 
Mumford, & Murray, 1984; Cox & .Longwell, 1974; Guze, 
Tuason, Steward, & Picken, 1962; Sobell, Maisto, Sobell, 
& Cooper, 1979),. Nevertheless, in some cases it might 
have been advantageous to have collateral sources of 
information, such as reports from family members, and/or 
laboratory screenings of drug and alcohol content in blood 
or urine samples. 
Additionally, the assessments of substance use at 
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the index hospitalization were based on retrospective 
ratings of chart notes, diagnostic summaries, and other 
information collected at the time of hospitalization. 
During the 1970's when patients were first assessed for 
this study, drug and alcohol use among psychiatric 
patients was not recognized as a particularly widespread 
phenomenon. Consequently, some of the clinicians were not 
very rigorous in their assessments of the drug and alcohol 
consumption of patients who were presenting for treatment 
with other psychiatric symptoms. Indeed, 78 subjects from 
the larger Chicago Follow-up Study sample were omitted 
from the present study because of ambiguous or nonexistent 
information on drug and alcohol use. In other cases in 
which there was information on drug and alcohol use, this 
information was somewhat vague and 
Nevertheless, in the majority of cases, 
inquire about substance use, and 
imprecise. 
clinicians did 
reported this 
information in the interviews and diagnostic summaries at 
the index hospitalization. Consequently, it was possible 
to make reliable judgments about the extent of substance 
use of the patients in this sample, although there was 
some imprecision in the ratings of substance use. 
A second limitation of the present study relates to 
the use of the Strauss-Carpenter measures of work 
functioning, social functioning, and rehospitalization in 
the post-hospital period. The measures of social and work 
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functioning are quantitative rather than qualitative 
measures of adjustment in these areas. 
findings for social functioning have 
discussed in light of this distinction. 
The unexpected 
already been 
With regard to 
work functioning, it is possible that there might have 
been some significant effects obtained if more qualitative 
features of work functioning had been assessed. However, 
in practice, these measures, particularly the measure of 
work functioning, have been used widely, and shown to 
correlate with a number of other important variables, both 
in the current research program and in other research 
programs. Thus, there is substantial evidence of the 
construct validity of these measures. 
The measure of rehospitalization is particularly 
problematic in that a rating of "4", the best rating, 
corresponds to no rehospitalizations in the previous year 
before follow-up, while a rating of "3" corresponds to 
being hospitalized less than three months in the past 
year, a rating of "2" corresponds to being hospitalized 
three to six months in the past year, a rating of "l" 
corresponds to being hospitalized over six months, and a 
rating of "O" corresponds to being hospitalized more than 
nine months. One difficulty is that there might be a very 
large difference between a person who receives a rating of 
11 4 11 versus a person who receives a rating of "3" • For 
instance, according to conventional notions of what it 
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means to be doing well when a person has returned to the 
community after having had a psychiatric hospitalization, 
few people would think that a person who needed to return 
to the hospital six different times, adding up to over two 
months of rehospitalization in the past year, was having 
a good outcome. 
Therefore it is possible that the present study did 
not find more frequent rates of rehospitalization 
associated with higher levels of drug and alcohol 
consumption, as has been documented in a number of other 
studies, (Alterman et al., 1982; Bergman« Harris, 1985; 
Cohen & Klein, 1974; Drake et al., 1989; Tsuang et al., 
1982) because the Strauss-Carpenter measure of 
rehospitalization assesses length of time in the hospital, 
rather than number or rehospitalizations. 
A third limitation of the present study is that it is 
difficult, with the data available, to make distinctions 
between psychotic symptoms of short duration (e.g., less 
than six months), versus those of longer duration. 
Previous studies by Tsuang and his colleagues (Perkins, et 
al, 1986; Tsuang et al., 1982) have obtained differences 
in premorbid functioning, rehospitalization, work 
functioning, and overall outcome between patients who are 
substance users with short-lived psychotic SY1I1ptoms versus 
substance users who have more enduring psychotic symptoms. 
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Treatment Implications 
As Alterman (1985) has noted, there is little known 
about the ways in which patients with psychiatric 
illnesses who use or abuse drugs and alcohol respond to 
treatment. The general assumption is that substance users 
fare more poorly in many types of treatment than do 
patients without substance use complications. Although the 
present study did not specifically assess kinds of 
treatment or treatment outcomes, the study does lend 
itself to some speculations in this area. First, treating 
clinicians should be aware of the tremendous suicide 
potential associated with drug and alcohol use in middle 
class, psychotic, male patients. Whether this is a 
characteristic of the type of patients who use substances, 
or a direct effect of substance use, or some interaction, 
is an issue which remains to be explored. 
Second, clinicians who treat young adult 
schizophrenics might consider informing these patients 
about some of the negative consequences associated with 
drug and alcohol use, particularly, moderate to heavy 
levels of use. Patients could be informed that there is 
some evidence indicating that patients similar to them who 
used drugs and alcohol had much more trouble in many areas 
of life, and more persistent symptoms, than other patients 
who did not use drugs and alcohol. 
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Young adult 
schizophrenic patients are often very disturbed by their 
illness, and very fearful about their future prospects in 
life. Consequently, they may be very receptive to 
information about behaviors they have control over (i.e., 
reducing or eliminating drug and alcohol consumption) that 
could help them to improve their chances of functioning 
better and having fewer symptoms. 
Treatment recommendations for the young adult 
depressed patients are less straightforward. While the 
present findings do not suggest that drug and alcohol use 
should be recommended for these patients, they do suggest 
that mild levels of substance use are not necessarily 
detrimental to them. Rather, young adult depressed 
patients may react to mild levels of drug and alcohol use 
in a manner comparable to that of normative samples of 
young adults. The present findings are consistent with 
previously published reports of substance use in 
adolescents and young adults (Newcomb & Bentler; Shedler 
& Block, 1990) which indicate that mild use of substances 
may be related to aspects of psychological health rather 
than only to psychological distress and rnaladaptation. 
APPENDIX 
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Table 36 
Mean Rehospitalization Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Premorbid Functioning 
Rehospitalization at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Pre morbid Prernorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 44 2.98 56 3.21 54 3.20 38 2.84 
Low 45 3.64 42 3.86 57 3.74 27 3.74 
Mod-Heavy 30 3.30 30 3.40 31 3.39 25 3.32 
Depressives 
None 9 3.33 21 2.90 24 3.21 6 2.33 
Low 12 3.67 21 3.81 29 3.76 2 3.50 
Mod-Heavy 4 3.25 11 3.55 8 3. 13 6 4.00 
Other Nonpsychotics 
None 4 3.75 8 3.00 6 2.83 5 3.80 
Low 8 3.75 5 4.00 6 4.00 7 3.71 
Mod-Heavy 4 3.25 6 3.83 3 3.67 6 3.50 
Schizophrenics 
None 17 2.47 11 3.55 10 3.30 16 2.50 
Low 13 3.62 4 4.00 8 3.75 8 3.63 
Mod-Heavy 8 2.88 3 3.00 4 3.75 7 2.43 
Other Psychotics 
None 14 3.14 16 3.50 14 3.29 11 3.18 
Low 12 3.58 12 3.83 14 3.57 10 3.90 
Mod-Heavy 14 3.57 10 3. 10 16 3.38 6 3.50 
NQY.. Higher scores represent better functioning. 
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Table 37 
Mean Social Functioning Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Premorbid Functioning 
Social Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 44 2.43 56 2.77 54 2.83 38 2.39 
Low 45 3.29 42 3.55 57 3.39 27 3.52 
Mod-Heavy 30 3.63 30 3.63 31 3.45 25 3.84 
Depressives 
None 9 2.67 21 3.00 24 2.92 6 2.83 
Low 12 3.67 21 3.71 29 3.66 2 4.00 
Mod-Heavy 4 3.50 11 3.91 8 3.75 6 4.00 
Other Nonpsychotics 
None 4 3.00 8 3.25 6 3.50 5 2.80 
Low 8 2.75 5 3.80 6 3.00 7 3.29 
Mod-Heavy 4 3.75 6 4.00 3 3.67 6 4.00 
Schizophrenics 
None 17 2.00 11 2.55 10 2.40 16 1. 94 
Low 13 3.15 4 2.75 8 3.25 8 3.13 
Mod-Heavy 8 3.50 3 2.67 4 2.74 7 3.57 
Other Psychotics 
None 14 2.64 16 2.38 14 2.71 11 2.64 
Low 12 3.42 12 3.42 14 3.07 10 3.90 
Mod-Heavy 14 3.71 10 3.40 16 3.44 6 3.83 
Note. Higher scores represent better functioning. 
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Table 38 
Mean Work Functioning Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Premorbid Functioning 
Work Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 44 1. 82 56 2.32 54 2.48 38 1.55 
Low 45 2.51 42 3.02 57 2.96 27 2.33 
Mod-Heavy 30 2.43 30 2.93 ·31 3. 19 25 2.12 
Depressives 
None 9 2.67 21 2.43 24 2.75 6 1. 50 
Low 12 3.50 21 3. 14 29 3. 17 2 4.00 
Mod-Heavy 4 2.50 11 3.73 8 3.38 6 3.33 
Other Nonpsychotics 
None 4 2.25 8 2.50 6 2. 83 5 2.20 
Low 8 2.38 5 2.00 6 2.33 7 2.14 
Mod-Heavy 4 2.00 6 3.00 3 3.00 6 2.67 
Schizophrenics 
None 17 1. 29 11 1. 73 10 1. 90 16 1. 13 
Low 13 2.00 4 3.00 8 2.75 8 2.00 
Mod-Heavy 8 1. 50 3 1. 33 4 3.00 7 .57 
Other Psychotics 
None 14 1. 79 16 2.50 14 2.29 11 1. 91 
Low 12 2.17 12 3.25 14 2.93 10 2.40 
Mod-Heavy 14 3.07 10 2.50 16 3.19 6 2.17 
Note. Higher scores represent better functioning. 
215 
Table 39 
Mean Depressive Symptom Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Prernorbid Functioning 
Depressive Symptoms at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 37 3.01 50 4.07 51 3.79 36 3.38 
Low 42 3.88 39 3.38 56 3.71 25 3.50 
Mod-Heavy 26 3.40 24 3.98 29 4.00 21 3.24 
Depressives 
None 6 3.42 21 4.31 23 4.11 4 4.13 
Low 12 4.00 18 3.86 28 3.93 2 3.75 
Mod-Heavy 3 3.67 8 3.63 8 3.56 3 3.83 
Other Nonpsychotics 
None 3 2.17 8 4.25 6 4.17 5 3.10 
Low 8 3.25 5 3.40 6 3.58 7 3.07 
Mod-Heavy 4 3.75 5 3.80 3 4.83 6 3.25 
Schizophrenics 
None 15 2.83 9 3.67 9 3.44 15 2.97 
Low 11 4.00 4 2.88 8 3.56 7 3.86 
Mod-Heavy 8 3.06 3 4.67 4 4.25 7 3.07 
Other Psychotics 
None 13 3.23 12 3.83 13 3.31 12 3.75 
Low 11 4.09 12 2.83 14 3.39 9 3.50 
Mod-Heavy 11 3.45 8 4.19 14 4.00 5 3.10 
Note. Lower scores represent less symptomatology. 
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Table 40 
Mean Psychotic Symptom Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Premorbid Functioning 
Psychotic Symptoms at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M} N (M) N (M) 
Whole Sample 
None 37 1. 92 50 1. 72 51 1. 65 36 2.03 
Low 42 1. 76 39 1. 41 56 1. 46 25 1. 88 
Mod-Heavy 26 1. 62 24 1. 71 29 1. 62 21 1. 71 
Depressives 
None 23 1. 52 4 1. 75 6 1. 67 21 1. 52 
Low 28 1. 36 2 2.00 12 1. 42 18 1. 39 
Mod-Heavy 8 1. 50 3 1. 67 3 1. 67 8 1. 50 
Other Nonpsychotics 
None 6 1. 33 5 1. 40 3 1.00 8 1.50 
Low 6 1. 50 7 1. 57 8 1.63 5 1. 40 
Mod-Heavy 3 1. 67 6 1. 50 4 1.50 5 1. 60 
Schizophrenics 
None 9 1. 67 15 2.20 15 2. 13 9 1. 78 
Low 8 1. 63 7 2.71 11 2. 18 4 2.00 
Mod-Heavy 4 1. 75 7 1. 86 8 1.63 3 2.33 
Other Psychotics 
None 13 2.00 12 2.17 13 2.00 12 2.17 
Low 14 1. 57 9 1. 44 11 1.82 12 1. 25 
Mod-Heavy 14 1. 64 5 1. 80 11 1.64 8 1. 75 
Note. Lower scores represent less symptomatology. 
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Table 41 
Mean Thought Disorder Scores at Follow-up I as a Function of 
Concurrent Substance Use and Gender and Prernorbid Functioning 
Thought Disorder at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 37 2.92 50 2.34 51 2.35 36 2.92 
Low 42 2.50 39 2.08 56 2.21 25 2.48 
Mod-Heavy 26 2.58 24 3.13 29 2.86 21 2.81 
Depressives 
None 6 2.50 21 1. 86 23 2.13 4 1. 25 
Low 12 2.00 18 2.33 28 2.18 2 2.50 
Mod-Heavy 3 3.33 8 2.50 8 2.88 3 2.33 
Other Nonpsychotics 
None 3 2.00 8 2.13 6 2.00 5 2.20 
Low 8 2.25 5 2.20 6 2.17 7 2.29 
Mod-Heavy 4 2.00 5 3.40 3 3.67 6 2.33 
Schizophrenics 
None 15 3.33 9 3.11 9 2.89 15 3.47 
Low 11 2.55 4 2.00 8 2. 13 7 2.71 
Mod-Heavy 8 3.00 3 4.oo· 4 2.75 7 3.57 
Other Psychotics 
None 13 2.85 12 2.75 13 2.54 12 3.08 
Low 11 3.18 12 1. 67 14 2.36 9 2.44 
Mod-Heavy 11 2.27 8 3.25 14 2.71 5 2.60 
Note. Lower scores represent less symptomatology. 
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Table 42 
Mean Overall Functioning Scores at Follow-up I as a Function 
of Concurrent Substance Use and Gender and Premorbid 
Functioning 
Overall Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 37 5.19 50 4.76 51 4.53 36 5.53 
Low 42 4.17 39 3.00 56 3.52 25 3.80 
Mod-Heavy 26 4.58 24 3.75 29 3.66 21 4.90 
Depressives 
None 6 3.67 21 5.00 23 4.70 4 4.75 
Low 12 3.00 18 2.89 28 2.86 2 4.00 
Mod-Heavy 3 4.33 8 3.38 8 3.50 3 4.00 
Other Nonpsychotics 
None 3 3.00 8 4.13 6 4.00 5 3.60 
Low 8 3.50 5 3.40 6 3.50 7 3.43 
Mod-Heavy 4 3.50 5 3.00 3 4.33 6 2.67 
Schizophrenics 
None 15 6.40 9 5.00 9 4.56 15 6.67 
Low 11 4.73 4 4.00 8 4.25 7 4.86 
Mod-Heavy 8 5.75 3 5.67 4 4.00 7 6.71 
Other Psychotics 
None 13 5.00 12 4.58 13 4.46 12 5.17 
Low 11 5.36 12 2.67 14 4.43 9 3.22 
Mod-Heavy 11 4.18 8 3.88 14 3.50 5 5.60 
~- Lower scores represent better overall functioning. 
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Table 43 
Mean Rehospitalization Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Rehospitalization at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N {M) N {M) N (M) N {M) 
Whole Sample 
None 27 3.70 58 3.53 58 3.52 23 3.74 
Low 26 3.23 22 3.32 33 3.30 15 3.20 
Moderate 32 3.25 21 3.43 26 3.62 23 2.91 
Heavy 35 3.11 27 3.48 26 3.35 29 3.14 
Depressives 
None 8 3.75 26 3.38 30 3.43 2 4.00 
Low 8 3.38 7 3.29 14 3.29 1 4.00 
Moderate 4 3.00 11 3.09 9 3.56 5 2.00 
Heavy 5 3.60 9 3.89 8 3.75 6 3.83 
Other Nonpsychotics 
None 5 4.00 7 3.57 8 3.63 4 4.00 
Low 2 4.00 5 3.00 3 2.33 4 4.00 
Moderate 6 3.67 3 4.00 4 4.00 5 3.60 
Heavy 3 2.67 4 3.75 0 0.00 5 3.20 
Schizophrenics 
None 6 3.50 9 3.44 5 3.60 9 3.33 
Low 9 2.56 3 4.00 6 3.67 6 2.17 
Moderate 11 3.64 1 4.00 5 4.00 6 3.33 
Heavy 12 2.33 5 3.40 6 3.00 10 2.30 
Other Psychotics 
None 8 3.63 16 3.81 15 3.60 8 4.00 
Low 7 3.71 7 3.29 10 3.40 4 3.75 
Moderate 11 2.73 6 3.67 8 3.25 7 2.71 
Heavy 15 3.67 9 3.00 12 3.25 8 3.63 
Note. Higher scores represent better functioning. 
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Table 44 
Mean Social Functioning Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Prernorbid Functioning 
Social Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 27 3.07 58 2.93 58 2.90 23 3.26 
Low 26 3.12 22 3.55 33 3.42 15 3.07 
Moderate 32 3.06 21 3.52 ·26 3.65 23 2.74 
Heavy 35 3.03 27 3.37 26 3.12 29 3.38 
Depressives 
None 8 3.88 26 3.19 30 3.30 2 4.00 
Low 8 2.75 7 3.86 14 3.21 1 4.00 
Moderate 4 3.00 11 3.55 9 3.78 5 2.60 
Heavy 5 3.40 9 3.89 8 3.50 6 4.00 
Other Nonpsychotics 
None 5 2.80 7 3.57 8 2.88 4 4.00 
Low 2 2.50 5 4.00 3 4.00 4 3.25 
Moderate 6 3.17 3 3.67 4 3.75 5 3.00 
Heavy 3 3.67 4 3.25 0 0.00 5 3.40 
Schizophrenics 
None 6 2.50 9 2.22 5 1. 80 9 2.56 
Low 9 2.89 3 2.67 6 3.33 6 2.33 
Moderate 11 3.00 1 4.00 5 3.40 6 2.67 
Heavy 12 2.42 5 3.00 6 2.50 10 2.80 
Other Psychotics 
None 8 2.88 16 2.63 15 2.47 8 3.50 
Low 7 4.00 7 3.29 10 3.60 4 3.75 
Moderate 11 3.09 6 3.33 8 3.63 7 2.71 
Heavy 15 3.27 9 3. 11 12 3.17 8 3.63 
Note. Higher scores represent better functioning. 
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Table 45 
Mean Work Functioning Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Work Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Pre morbid Premorbid 
at Index 
N {M) N (M) N (M) N {M) 
Whole Sample 
None 27 2.74 58 2.86 58 2.79 23 2.74 
Low 26 2.42 22 2.50 33 2.76 15 1. 80 
Moderate 32 2.13 21 2.76 26 2.08 23 1.43 
Heavy 35 1. 83 27 2.44 26 2.77 29 1. 79 
Depressives 
None 8 3.50 26 2.88 30 2.93 2 3.50 
Low 8 2.88 7 3.57 14 3.14 1 4.00 
Moderate 4 2.25 11 2.36 9 3.00 5 .80 
Heavy 5 3.20 9 3.56 8 3.25 6 3.67 
Other Nonpsychotics 
None 5 2.80 7 3.14 8 2.88 4 3.25 
Low 2 1.50 5 1. 60 3 1. 33 4 1. 75 
Moderate 6 2.33 3 3.00 4 3.25 5 2.00 
Heavy 3 1. 67 4 2.25 0 0.00 5 2.40 
Schizophrenics 
None 6 2.00 9 1. 56 5 1.00 9 2.00 
Low 9 1. 78 3 2.67 6 3.00 6 1. 00 
Moderate 11 2.27 1 1. 00 5 3.40 6 1. 33 
Heavy 12 .58 5 2.40 6 2. 17 10 .60 
Other Psychotics 
None 8 2.50 16 3.44 15 3.07 8 3.13 
Low 7 3.00 7 2.00 10 2.50 4 2.50 
Moderate 11 1. 82 6 3.67 8 2.88 7 1. 57 
Heavy 15 2.40 9 1. 44 12 2.75 8 1.50 
~. Higher scores represent better functioning. 
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Table 46 
Mean Depressive Symptom Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Depressive Symptoms at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 23 3.57 53 3.89 56 3.86 20 3.60 
Low 26 3.33 22 3.57 32 3.72 16 2.88 
Moderate 29 3.24 18 3.58 26 3.63 21 3.05 
Heavy 28 3.75 20 4.10 23 4.00 25 3.80 
Depressives 
None 8 3.69 24 4.27 30 4. 12 2 4.25 
Low 7 3.79 7 4.07 13 4.00 1 3.00 
Moderate 2 3.75 10 3.65 9 3.72 3 3.50 
Heavy 4 4.00 6 3.58 7 3.43 3 4.50 
Other Nonpsychotics 
None 5 3.50 7 3.64 8 3.63 4 3.50 
Low 2 2.75 5 3.70 3 4.83 4 2.38 
Moderate 6 2.83 3 4.50 4 4.38 5 2.60 
Heavy 2 3.75 3 4. 17 0 0.00 5 4.00 
Schizophrenics 
None 3 3.50 8 3.56 4 3.25 7 3.71 
Low 9 3.39 3 2.67 6 3.42 6 3.00 
Moderate 11 3.09 0 0.00 5 3.40 6 2.83 
Heavy 11 3.27 5 4.40 6 4. 33 10 3.20 
Other Psychotics 
None 7 3.50 14 3.54 14 3.61 7 3.36 
Low 8 3.00 7 3.36 10 3.20 5 3.10 
Moderate 10 3.55 5 2.90 8 3.31 7 3.36 
Heavy 11 4.14 6 4.33 10 4.20 7 4.21 
Note. Lower scores represent less symptomatology. 
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Table 47 
Mean Psychotic Symptom Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Psychotic Symptoms at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 23 1. 61 53 1. 58 56 1.52 20 1. 80 
Low 26 1. 81 22 1. 73 32 1.81 16 1. 69 
Moderate 29 1. 72 18 1. 33 26 1.38 21 1. 81 
Heavy 28 2.00 20 1. 80 23 1.61 25 2.20 
Depressives 
None 8 1. 50 24 1. 38 30 1.37 2 2.00 
Low 7 1. 86 7 1. 86 13 1.92 1 1. 00 
Moderate 2 1. 00 10 1. 30 9 1.22 3 1. 33 
Heavy 4 1. 25 6 1. 67 7 1.14 3 2.33 
Other Nonpsychotics 
None 5 1. 00 7 1. 29 8 1.13 4 1.25 
Low 2 1. 50 5 1. 80 3 2.33 4 1. 25 
Moderate 6 1. 57 3 1. 33 4 1.50 5 1. 60 
Heavy 2 2.00 3 1. 67 0 0.00 5 1. 80 
Schizophrenics 
None 3 2.67 8 2.13 4 2.00 7 2.43 
Low 9 1. 78 3 1. 67 6 1.50 6 2.00 
Moderate 11 1. 91 0 0.00 5 1.40 6 2.33 
Heavy 11 2.18 5 1. 80 6 1.83 10 2.20 
Other Psychotics 
None 7 1. 71 14 1. 79 14 1.93 7 1. 43 
Low 8 1. 88 7 1. 57 10 1.10 5 1.80 
Moderate 10 1. 70 5 1. 40 8 1.50 7 1. 71 
Heavy 11 2.09 6 2.00 10 1.80 7 2.43 
Note. Lower scores represent less symptomatology. 
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Table 48 
Mean Thought Disorder Scores at Follow-up I as a Function of 
Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Psychotic.Symptoms at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 23 2.57 53 2.36 56 2.29 20 2.80 
Low 26 2.69 22 2.00 32 2.34 16 2.44 
Moderate 29 2.38 18 2.56 26 2.50 21 2.38 
Heavy 28 3.00 20 2.90 26 2.50 21 2.38 
Depressives 
None 8 2.00 24 2.08 30 2. 10 2 1.50 
Low 7 2.57 7 2.00 13 2.38 1 1.00 
Moderate 2 2.00 10 2.50 9 2.67 3 1. 67 
Heavy 4 2.75 6 2.00 7 2. 14 3 2.67 
Other Nonpsychotics 
None 5 2.40 7 2.00 8 2. 13 4 2.25 
Low 2 2.00 5 2.40 3 3.00 4 1. 75 
Moderate 6 2.17 3 2.67 4 2.50 5 2.20 
Heavy 2 1. 50 3 3.67 0 0.00 5 2.80 
Schizophrenics 
None 3 2.67 8 3.13 4 2. 75 7 3.14 
Low 9 3.22 3 2.33 6 2.33 6 3.67 
Moderate 11 2.18 0 0.00 5 2.00 6 2.33 
Heavy 11 3.73 5 3.20 6 3.17 10 3.80 
Other Psychotics 
None 7 3.29 14 2.57 14 2.64 7 3.14 
Low 8 2.38 7 1. 57 10 2.10 5 1.80 
Moderate 10 2.80 5 2.60 8 2.63 7 2.86 
Heavy 11 2.64 6 3.17 10 2.70 7 3.00 
Note. Lower scores represent less symptomatology. 
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Table 49 
Mean Overall Functioning Scores at Follow-up I as a Function 
of Substance Use at Index Hospitalization and Gender and 
Premorbid Functioning 
Overall Functioning at Follow-up I 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Index 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 23 4.00 53 3.85 56 3.96 20 3.70 
Low 26 4.88 22 3.86 32 4.41 16 4.44 
Moderate 29 4.14 18 3.72 26 3. 19 21 4.95 
Heavy 28 5.50 20 4.45 23 4. 13 25 5.92 
Depressives 
None 8 2.75 24 3.88 30 3.73 2 1. 50 
Low 7 4.86 7 3.43 13 4.38 1 1.00 
Moderate 2 1. 50 10 4.50 9 3.33 3 6.00 
Heavy 4 3.00 6 3.67 7 2.43 3 5.67 
Other Nonpsychotics 
None 5 3.00 7 3.00 8 3.50 4 2.00 
Low 2 5.00 5 5.60 3 6.67 4 4.50 
Moderate 6 2.83 3 2.33 4 2.50 5 2.80 
Heavy 2 4.50 3 3.00 0 0.00 5 3.60 
Schizophrenics 
None 3 6.67 8 5.00 4 5.25 7 5.57 
Low 9 5.67 3 3.33 6 4.00 6 6.17 
Moderate 11 4.09 0 0.00 5 2.20 6 5.67 
Heavy 11 7.09 5 5.60 6 5.83 10 7.10 
Other Psychotics 
None 7 5.00 14 3.57 14 4.36 7 3.43 
Low 8 4.00 7 3.29 10 4.00 5 3.00 
Moderate 10 5.50 5 3.00 8 4. 00 7 5.43 
Heavy 11 5.00 6 5.00 10 4.30 7 6.00 
Note. Lower scores represent better overall functioning. 
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Table 50 
Mean Rehospitalization Scores at Follow-up II as a Function of 
Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Rehospitalization at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N (M) N {M) N (M) N {M) 
Whole Sample 
None 40 3.13 51 3.75 54 3.50 37 3.43 
Low 42 3.81 40 3.73 57 3.81 25 3.68 
Mod-Heavy 29 3.66 27 3.63 31 3.71 25 3.56 
Depressives 
None 9 3.33 21 3.57 24 3.50 6 3.50 
Low 12 4.00 19 3.74 29 3.90 2 3.00 
Mod-Heavy 4 4.00 10 4.00 8 4.00 6 4.00 
Other Nonpsychotics 
None 3 4.00 8 4.00 6 4.00 5 4.00 
Low 8 3.63 5 4.00 6 4.00 7 3.57 
Mod-Heavy 4 4.00 5 4.00 3 4.00 6 4.00 
Schizophrenics 
None 15 2.87 9 4.00 10 3.40 14 3.21 
Low 11 3.82 4 4.00 8 4.00 7 3.71 
Mod-Heavy 8 3.00 3 3.33 4 3.75 7 2.71 
Other Psychotics 
None 13 3.08 13 3.69 14 3.36 12 3.42 
Low 11 3.73 12 3.50 14 3.43 9 3.89 
Mod-Heavy 16 3.50 6 3.67 
Note. Higher scores represent better functioning. 
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Table 51 
Mean Social Functioning Scores at Follow-ug II as a Function 
of Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Social Functioning at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N {M) N (M) N (M) N {M) 
Whole Sample 
None 40 2.73 51 3.37 54 3.13 37 3.03 
Low 42 3.50 40 3.50 57 3.46 25 3.60 
Mod-Heavy 29 3.38 27 3.22 31 3.23 25 3.40 
Depressives 
None 9 2.33 21 3.24 24 2.96 6 3.00 
Low 12 3.33 19 3.79 29 3.59 2 4.00 
Mod-Heavy 4 4.00 10 3.90 8 3.88 6 4.00 
Other Nonpsychotics 
None 3 3.67 8 3.88 6 4.00 5 3.60 
Low 8 3.50 5 4.00 6 3.83 7 3.57 
Mod-Heavy 4 3.50 5 2.60 3 2.00 6 3.50 
Schizophrenics 
None 15 2.40 9 3.11 10 3.00 14 2.43 
Low 11 3.64 4 2.75 8 3.25 7 3.57 
Mod-Heavy 8 2.75 3 2.67 4 2.75 7 2.71 
Other Psychotics 
None 13 3.15 13 3.46 14 3. 14 12 3.50 
Low 11 3.55 12 3.08 14 3. 14 9 3.56 
Mod-Heavy 13 3.54 9 3.00 16 3.25 6 3.50 
Note. Higher scores represent better functioning. 
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Table 52 
Mean Work Functioning Scores at Follow-up II as a Function of 
Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Work Functioning at Follow-up II 
Level of Use 
Within Each Male Female Low High 
Diagnostic Group Premorbid Premorbid 
at Follow-up I 
N {M) N (M) N (M) N (M) 
Whole Sample 
None 40 2.00 51 2.98 54 3.00 37 1. 89 
Low 42 3.00 40 3.20 57 3.32 25 2.60 
Mod-Heavy 29 2.52 27 3.07 31 3.03 25 2.48 
Depressives 
None 9 2.22 21 3.14 24 3 . 1 7 6 1. 67 
Low 12 3.50 19 3.21 29 3.41 2 2.00 
Mod-Heavy 4 2.75 10 3.90 8 3.38 6 3.83 
Other Nonpsychotics 
None 3 3.00 8 3.38 6 3.67 5 2.80 
Low 8 2.63 5 3.80 6 3.67 7 2.57 
Mod-Heavy 3 2.75 5 3.40 3 3.33 6 3.00 
Schizophrenics 
None 15 1. 73 9 2.33 10 2.30 14 1. 71 
Low 11 2.55 4 2.25 8 2.75 7 2.14 
Mod-Heavy 8 1. 75 3 1. 33 4 2.75 7 1.00 
Other Psychotics 
None 13 1. 92 13 2.92 14 2.93 12 1. 83 
Low 11 3.18 12 3.25 14 3.29 9 3. 11 
Mod-Heavy 13 2.85 9 2.56 16 2.88 6 2.33 
NQ:t..e.. Higher scores represent better functioning. 
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Table 53 
Mean Depressive Symptom Scores at Follow-up II as a Function 
of Substance Use at Follow-up I and Gender and Prernorbid 
Functioning 
Depressive Symptoms at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Prernorbid Pre morbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 33 3.06 40 3.41 44 3.35 29 3.10 
Low 35 3.44 31 3.27 45 3.48 21 3.12 
Mod-Heavy 28 3.14 20 3.73 28 3.57 20 3.13 
Depressives 
None 7 4.00 16 3.78 20 3.90 3 3.50 
Low 10 3.30 14 3.54 22 3.43 2 3.50 
Mod-Heavy 4 3.25 6 2.75 7 2.64 3 3.67 
Other Nonpsychotics 
None 3 2.33 7 3.36 5 3.20 5 2.90 
Low 7 3.00 5 3.20 5 3.60 7 2.71 
Mod-Heavy 4 2.50 4 4.63 3 4.83 5 2.80 
Schizophrenics 
None 13 2.85 8 3.25 8 3.00 13 3.00 
Low 9 3.50 3 2.83 6 3.42 6 3.25 
Mod-Heavy 7 3.00 2 4.00 3 3.50 6 3.08 
Other Psychotics 
None 10 2.90 9 2.94 11 2.68 8 3.25 
Low 9 3.89 9 3.06 12 3.54 6 3.33 
Mod-Heavy 13 3.38 8 3.94 15 3.77 6 3.17 
Note. Lower scores represent less symptomatology. 
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Table 54 
Mean Psychotic Symptom Scores at Follow-up II as a Function of 
Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Psychotic Symptoms at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Prernorbid Prernorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 33 1. 33 40 1. 33 44 1. 18 29 1. 55 
Low 35 1. 47 31 1. 29 45 1. 29 21 1. 76 
Mod-Heavy 28 1. 54 20 1. 55 28 1. 61 20 1.45 
Depressives 
None 7 1. 29 16 1. 25 20 1.20 3 1. 67 
Low 10 1. 50 14 1. 14 22 1.23 2 2.00 
Mod-Heavy 4 1.50 6 1. 17 7 1.29 3 1. 33 
Other Nonpsychotics 
None 3 1. 00 7 1.14 5 1.00 5 1. 20 
Low 7 1. 43 5 1. 20 5 1.40 7 1. 29 
Mod-Heavy 4 1.00 4 1. 50 3 1.67 5 1. 00 
Schizophrenics 
None 13 1. 31 8 1. 75 8 1.25 13 1. 62 
Low 9 1. 89 3 2.33 6 1.33 6 2.67 
Mod-Heavy 7 1. 86 2 2.00 3 1.67 6 2.00 
Other Psychotics 
None 10 1. 50 9 1. 22 11 1.18 8 1. 63 
Low 9 1. 44 9 1. 22 12 l. 33 6 1. 33 
Mod-Heavy 13 1. 54 8 1. 75 15 1. 73 6 1. 33 
Note. Lower scores represent less symptomatolo9y. 
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Table 55 
Mean Thought Disorder Scores at Follow-up II as a Function of 
Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Thought Disorder at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Pre morbid Premorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 33 2.45 40 2.15 44 2.20 29 2.41 
Low 35 2.51 31 2.06 45 2 .16 21 2.62 
Mod-Heavy 28 2.39 20 2.15 28 2 .18 20 2.45 
Depressives 
None 7 2.86 16 2.00 20 2 .15 3 3.00 
Low 10 1. 50 14 2. 14 22 l. 77 2 3.00 
Mod-Heavy 4 1.50 6 1.33 7 1.29 3 1. 67 
Other Nonpsychotics 
None 3 1. 00 7 1. 71 5 1.80 5 1.20 
Low 7 2.71 5 1.20 5 l. 60 7 2.43 
Mod-Heavy 4 2.50 4 1.25 3 l. 67 5 2.00 
Schizophrenics 
None 13 2.92 8 3. 13 8 2.63 13 3.23 
Low 9 2.78 3 2.67 6 3.00 6 2.50 
Mod-Heavy 7 3.86 2 3.50 3 3.67 6 3.83 
Other Psychotics 
None 10 2.00 9 1. 89 11 2.18 8 1. 63 
Low 9 3.22 9 2.22 12 2.67 6 2.83 
Mod-Heavy 13 1. 85 8 2.88 15 2.40 6 1. 83 
Note. Lower scores represent less symptomatology. 
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Table 56 
Mean Overall Functioning Scores at Follow-up II as a Function 
of Substance Use at Follow-up I and Gender and Premorbid 
Functioning 
Overall Functioning at Follow-up II 
Level of Use 
Within Each Male Female High Low 
Diagnostic Group Pre morbid Prernorbid 
at Follow-up I 
N (M) N (M) N (M) N (M) 
Whole Sample 
None 33 4.24 40 3.38 ·44 3.25 29 4.55 
Low 35 3.09 31 2.90 45 2. 80 21 3.43 
Mod-Heavy 28 3.50 20 3.90 28 3.75 20 3.55 
Depressives 
None 7 3.57 16 3.88 20 3.50 3 5.67 
Low 10 2.40 14 2.64 22 2.36 2 4.50 
Mod-Heavy 4 3.25 6 1. 83 7 2.29 3 2.67 
Other Nonpsychotics 
None 3 1. 33 7 2.00 5 1. 40 5 2.20 
Low 7 2.86 5 2.00 5 2.40 7 2.57 
Mod-Heavy 4 1. 75 4 3.75 3 4.67 5 1.60 
Schizophrenics 
None 13 5.38 8 3.63 8 3.63 13 5.38 
Low 9 3.89 3 4.67 6 3.33 6 4.83 
Mod-Heavy 7 5.29 2 4.00 3 3.33 6 5.83 
Other Psychotics 
None 10 4.10 9 3.33 11 3.36 8 4.25 
Low 9 3.22 9 3.22 12 3.50 6 2.67 
Mod-Heavy 13 3.15 8 5.50 15 4.33 6 3.33 
Note. Higher scores represent better functioning. 
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